Companies Investors Start

Transcription

Companies
Start-up
projects
Investors
Rhône-Alpes’Gateway to Innovative Business in Life Sciences
70 000 jobs in Life Sciences - 600 Life Sciences companies -10 company creations per year
More than e 1 billon of private investment in vaccines and diagnostics
Supported by:
In partnership with:
Contents
c o m pa n i e s
PA G E >
S ta r t-up projects
PA G E >
157
169
investors
PA G E >
index
PA G E >
2
11
201
Grain (Grenoble-Alpes-Incubation) is a public incubator whose aim is to
convert mature research projects into innovative start-ups.
These companies, closely linked to public research, integrate technology in such a way as to convert it into a significant competitive advantage both for their development and their client’s welfare.
Figures
GRAIN was established in 1999. By the end of 2009, more than 100
young start-ups have benne launched after being incubated at GRAIN, raising more than 75 Me frome venture capital over the years and making
an approximate consolidated gross income of 63 Me for 2009 with 665
highly qualified jobs.
Know-How
Within 18 months, GRAIN provides a personal and team coaching and
up to 300 training hours a year. The projects leaders are encouraged to
optimize:
- The building of a motivated and talented team;
- The production of an effective business plan,
- The choice between growth strategies.
To doing so, a sharp focus is put on:
- Questioning the applications and opportunities of the technology,
- Surveying the potential market,
- Consolidating the competitive positioning of the start up,
- Launching its first commercial campaign.
Objectives
GRAIN particularly encourages the creation of the new companies with
high-growth potential, helping them integrate into the regional economic
system. The clear aim is that these companies will generate a sustainable
economic activity resulting in a significant source of the new jobs for qualified people, and the development of new export markets.
GRAIN
31, rue Gustave Eiffel - F-38000 GRENOBLE
+33 (0)4 76 61 38 00
www.grain-incubation.com
Companies
Start-up
projects
Investors
Companies
Companies
index
12
ADNucleis
13
Dextérité Surgical 57
Magnisense 110
ADOCIA 14
Drive 58
Mellitech 112
Advanced Accelerator
Applications 16
Ecrins Therapeutics 59
Merial 113
17
EDAP TMS 60
Metabolys 114
Advicenne Edelris 61
115
Aguettant 18
Movea 19
Elicityl 62
Nano-H 116
Alaxia 20
ERYtech Pharma 63
NatX-ray 117
Alizé Pharma 21
ESRF 65
NETRIS Pharma
118
AltraBio Estenity R&D
66
119
Alvedia 22
Nocosium 23
Ethera 67
Noraker 120
Amoéba 24
Eurofins Optimed 68
Novadiscovery 121
ANaBior Eveon 69
122
Antagene 25
Novocib 26
EyeTechCare 71
Novotec 123
Antialis 27
Flamel Technologies 73
Orega Biotech 124
AXO Science Ayawane 28
Fluoptics 75
Bactup 29
Fondation Mérieux 76
Becton dickinson 30
GCS-Etoile 77
Bio Elpida 31
Geneuro 78
Genostar 80
genOway 82
Genzyme Polyclonals Gifrer Barbezat Glycode 86
HLA-G Technologies 87
iDD biotech 89
Roche Diagnostics 138
139
Phatophy 125
Powder Systems LimiteD
(PSL) 127
Poxel 129
Prediction BioSciences 130
Presbeasy 132
84
Promise Advanced
Proteomics
133
85
PX’Therapeutics 134
RCTs 136
ReproXX 137
Bioclinica 33
Bioclinome 34
Biomatech Namsa 35
BioMérieux 36
Biomnis 37
Biom’up 38
Biotem 39
Calixar 40
ILL 91
Sanofi Pasteur Centre d’Immunologie
Pierre Fabre Imaxio 92
Shimadzu 141
41
ImmunID 93
Singulex
142
Cirma 42
Indicia 95
SmartINST 143
Clean Air Technologies 43
InfYnity Biomarkers 97
Sofradim 144
Clininfo 44
Innate Pharma 98
Spygen 145
Compétence Biotech 46
Institut Merieux 99
Stragen Services 146
Conidia 47
IntuiSKin
100
SynapCell 147
CoSMo 48
jlm lab 101
Synthelis 148
Kendle 102
Top Industrie 149
150
CreaCell 49
CTI-Lyon 50
Khorionyx 104
Transgene Cylergie-Cofely
52
K-PLAN 106
Vaxeal 152
Cynbiose 53
Visoon 154
107
Vivalis 155
Voxcan 156
Cytoo 54
La cosmétique alpine
avancée
DAMSI 55
Latoxan
108
Dendritics 56
LC2 109
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Activities
Diagnostics / Analysis method.
Application fields: Animal health, Human health, Infectious
diseases, Allergology, Orphan diseases, Genetic / Rare
diseases, Nutrition / Food.
Activities
Company activities
Engineering of PCR kits from the creation to the marketing
R&D specialized in rapid diagnosis kits for Food Sanitary
Quality, Animal Health, Human Health Genotyping applied
to products traceability.
Company key features
General company information
Multi-targets analysis kits «open system» strategy (kits can be
used on every PCR platforms). Practicability and cost of kits.
Company name: ADNucleis
Address: 30, chemin des Mouilles
Zip code: F-69290
City: Grezieu la Varenne
Website: www.adnucleis.com
Founded in: 03/04/2007
Number of employees: 7
Turnover: 350 000 Ke (in 2010)
Main activity: Manufacturer of rapid diagnosis kits through
Recent news
Subsidiary of a group: No
Prize winner for innovative start-up: No
Innovative company (FCPI): Yes
Other status: Yes
Skills and know-how
Funding
Products / Services / Technologies
RT PCR Genotyping
Looking for funding: Yes
Nature of funding searches: Pathogens project amount
1,000 M euros AFNOR certification for 4 kits dedicated
to the detection of pathogens in Food Safety.
Public funding obtained: Feder 140,000 euros
Stock exchange listing: No
3 AFNOR certified kits (Salmonella spp, E.coli O157H7,
Cronobacter sakazakii) 1 kit in the final stage of AFNOR
certification (Listeria monocytogenes): certification planned
in March 2011 Equality of certified kits with main competitor
25 kits validated internally for Food Safety 32 kits validated
internally for Animal Health. H1N1 external validation is
in process 4 kits for environmental analyses: legionella 30 kits
validated in Human Health.
Conception of kits. Extraction of nucleic acids. Amplification of
genes. Genotyping Sequencing.
Pipeline product 1
Preclinical: AFNOR kits.
Pipeline product 2
Preclinical: Other kits in Food Safety.
Pipeline product 3
Preclinical: Animal Health kits.
Company contact
Company services
CEO contact detail
First name: Michel
Last name: Franck
Position: CEO
Email: [email protected]
Phone: +33 (0)6 60 96 01 41
Conception of kits Extraction of nucleic acids Amplification
of genes Genotyping Sequencing.
Company technologies
Quantitative PCR sequencers.
Partnership
opportunities / Licensing
Company segmentation
Business model
Product developer - Biopharmaceuticals, Product developer Pharmaceuticals, Product developer - Other health, Laboratory
equipment supplier.
Value chain
Research, Manufacturing, Marketing / Distribution.
Collaboration framework
Reinforcement of capital (491K today, for increase 2000K euros)
Innovative project («Pathogens») in process with Oséo-Feder
(financed at the end of 2008) Financing request for «Bedside»
project in process.
Partnership opportunities
PRTechnology Analyses. laboratories. Agro-industries.
Manufacturers of materials for laboratories. Academies
for some R&D sectors.
Out-licencing opportunity
Yes if export. Possible contracts pending (Eastern Europe,
North America, North Africa).
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
13
Business model
Product developer - Biopharmaceuticals, Other.
Value chain
Research, Preclinical, Clinical.
Activities
Drug delivery, Other.
Application fields
Human health, Metabolic diseases.
Activities
Company activities
Company name: ADOCIA
Address: 115, avenue Lacassagne
Zip code: 69003
City: Lyon
Website: www.adocia.com
Main activity: Adocia is a French biotech, specialized
in regenerative medicine and treatment of chronic diseases.
Incubator: No
Other status: Yes (European PME)
Adocia is specialised in tissue regeneration and treatment
of chronic diseases. The company develops its proprietary
innovative technology BioChaperoneTM for the formulation
of growth factors for regenerative medicine and also
for therapeutic proteins such as human insulin
and monoclonal antibodies.
BioChaperoneTM is a new family of polymers, “bioinspired”
by heparin, which have the property to protect and increase
the efficacy of therapeutic proteins, with which they form
specific molecular complexes. Various BioChaperoneTM have
been tailored made for each protein studied, and have resulted
in more than 20 patents being filed, covering products
and applications of this system.
Recent news
Funding
Looking for funding: No
Private funding obtained: 1.8 million euros raised at the
company’s inception. 12 million euros raised in November
2007. 14 million euros raised in January 2010.
Public funding obtained: Loan from Oseo of 2.250.000 €
granted in Sept 2006 (Osteoporosis project). Loan from Oseo
of 420,000 € and grant from Feder of 420.000 €
(Insulin project) granted in Sept 2009.
Adocia has closed its second financial round of 14 M€
on 5 January 2010. These additional funds will permit Adocia
to finance its clinical program on wound healing and bone
repair.
Skills and know-how
Adocia can rely on a team composed of 17 PhD and a skilled
management. Adocia’s core activity covers the chemistry
of polymers up to preclinical studies of therapeutic protein
formulations.Adocia benefits from a strong pluridisciplinary
expertise in R&D, in chemistry, analysis, formulations,
biologics.
Company contacts
CEO contact detail
First name: Gérard
Last name: Soula
Position: CEO & President
Phone: +33 (0)4 72 61 06 10
Other contact
First name: Olivier
Last name: Soula
Position: R&D Director
Phone: +33 (0)4 72 61 06 10
Fax: +33 (0)4 72 36 39 67
14
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Pipeline product 1
Therapeutic area: Chronic wounds
Therapeutic indication: Diabetic Foot Ulcer
Preclinical:
Phase 1: BC PDGF-BB
Phase 2: BC PDGF-BB.
Pipeline product 2
Therapeutic area: Bone repair
Therapeutic indication: Spinal fusion
Preclinical: BC BMP-2.
Pipeline product 3
Therapeutic area: Diabet
Therapeutic indication: Treatment of postprandial glycemy
Preclinical: BC human Insulin.
Company services
Adocia do not propose any service.
BioChaperoneTM is a new family of polymers, “bioinspired”
by heparin, which have the property to protect and increase
the efficacy of therapeutic proteins, with which they form
specific molecular complexes. Various BioChaperoneTM have
been tailored made for each protein studied, and have lead
to more than 20 patents being filed, covering products and
applications of this system. Adocia applies its technology
BioChaperone™ to regenerative medicine field by focusing
on growth factors already approved and commercialized:
PDGF-BB for chround wounds and Bone Morphogenic
Proteins (BMPs) for spinal fusion and bone repair (non-union
fractures, cartilage regeneration, osteoporosis). BioChaperone
is also applied for subcut therapeutic monoclonal antibodies
formulations.
Partnership
Adocia has 5 collaborations on going (confidentialundisclosed). Adocia aims to licence its various projects
to medtech/biopharma companies.
Adocia’s technology BioChaperone offers therapeutic
indications for the following medical needs:
– Diabetic foot ulcers
– Venous ulcers
– Osteoporosis
– Degenerative disc disease
– Non-union fractures
– Human Insulin
– Monoclonal Antibodies
Adocia’s business model consists of rapidly generating
convincing “Proofs of Concept” for its products (Phase IIa
or animal models when relevant) and to license its products
to leading companies in the field.
In-licencing opportunity
Non applicable.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
15
Company contacts
CEO contact detail
First name: Stefano
Last name: Buono
Position: President & CEO
Phone: +33 (0)4 50 99 30 70
Other contact
First name: Heinz
Last name: Maeusli
Position: CFO
Phone: +33 (0)4 50 99 30 70
Business model
Product developer - Pharmaceuticals.
Value chain
Research, Manufacturing.
Activities
Company name: Advanced Accelerator Applications
Address: 20, rue Diesel
Zip code: 01630
City: Saint Genis Pouilly
Website: www.adacap.com
Turnover: 27 M Euros (in 2010)
Main activity: Advanced Accelerator Applications (AAA), is
a European Pharmaceutical Group founded in 2002 by Italian
academics as a spin-off of the “European Organization
for Nuclear Research” (CERN), Geneva, Switzerland),
to develop innovative diagnostic and therapeutic applications
and products. AAA main focus is on products addressing
Molecular Imaging and Therapy for the personalized treatment
of serious diseases (the so-called Personalized Medicine).
AAA first commercial product is Gluscan® (FDG
or FluoroDeoxyGlucose), a diagnostic short-lived (i.e. with
a 10-hour shelf life) radiotracer used for Positron Emission
Tomography (PET). PET is a state-of-the-art diagnostic
technique that is today mainly used in clinical oncology,
cardiology and neurology. With 10 production facilities and
R&D laboratories and more than 130 employees in 5 countries
(France, Italy, Switzerland, Spain and United States), AAA is
a truly “private public company” with over 75 private
and institutional shareholders.
Innovative company (FCPI): No
Other status: Yes
Funding
R&D PROJECT funded
accredited BY LYONBIOPOLE
Theranean: Therapy through Neutron-Activated Nanopar-
ticles
Funding: FUI (AAP7 2009)
Role in the project: Leader
16
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Diagnostics / Analysis method, Drug discovery, Other.
Application fields
Human health.
Activities
Company activities
AAA developed a unique platform for the research, development,
production and distribution of radiopharmaceuticals and
molecules designed for molecular diagnostics and therapy.
Thanks to its comprehensive approach, AAA is able to produce
and deliver both commercial drugs and research products for
clinical or pre-clinical studies. Moreover, it can provide partner
organizations with support for clinical studies, technology for
setting up industrial production of PET radiopharmaceuticals,
consultancy and people training.
AAA laboratories have a Good Manufacturing Practice (GMP)
qualification to the manufacturing of Investigational Medical
Products (IMP).
Recent news
AAA has received GMP approval for the manufacture of Lutate,
a radioactively labelled peptide that can be used to treat
metastatic Gastro Entero Pancreatic Neuro Endocrine Tumors
(GEP-NETs). The approval by the Italian Pharmaceutical
Regulatory Authority will enable AAA to manufacture Lutate
at its facility in Colleretto Giacosa, near Turin, Italy, making
it the first industrial facility in the world approved to produce
radio-labelled peptides for molecular nuclear therapy.
Skills and know-how
AAA has developed a unique know-how in building
radiopharmaceutical laboratories to be used, at the same
time, for industrial scale production and state-of-the-art R&D
activities.
Our laboratory concept has been tested in every-day production
for more than 6 years now and proven to be entirely reliable
and effective. AAA laboratories are modular and scalable, fully
expandable and easy to upgrade to the latest technology and
know-how to meet future market developments and customer
expectations.
This know-how can be transferred to AAA partners,
interested in setting up their own industrial production
of PET radiopharmaceuticals. AAA has already completed
such technology transfers in the past and is willing to do
so in the future. On-site consulting by AAA personnel, sharing
of all relevant documentation, and extensive training
of partners’ employees in our facilities are key to assure
the successful know-how transfer.
Company name: ADVICENNE
Address: Espace Innovation 3, 442, rue Georges Besse
Zip code: 30035 Cedex 1
City: Nîmes
Website: www.advicenne.com
Main activity: Advicenne Pharma is a pharmaceutical
company devoted to paediatric produts. The company focus
is on development and marketing of paediatric products
adressed to neurological diseases and nephrological disorders.
Advicenne Pharma aim is to build and market products from a
paediatric portfolio adressed to unmet medical needs.
Advicenne Pharma development strategy is based on a short
term (2 years) business model. The aim is to market paediatric
drugs generating sales as soon as 2012.
This model is based on:
• Importation of drugs able to benefit from the status of
compassionate access «Autorisation Temporaire d’Utilisation»
(ATU) for paediatric use in France,
• Market in Europe in house products first under
compassionate access then under Puma status or Orphan
drug status,
• Paediatric formulation in short time frame and at minimal
cost.
Other status: Yes
Funding
CEO contact detail
First name: Luc André
Last name: Granier
Position: CEO and Medical Director
Phone: +33 (0)6 19 20 29 50
Other contact
First name: Marie Laure
Last name: Pellotier
Position: CFO
Phone: +33 (0)6 31 92 15 51
Fax: +33 (0)4 66 21 23 35
s c i e n c e s
d i r e c t o r y
Business model
Value chain
Research, Manufacturing, Preclinical, Clinical.
Activities
Other.
Application fields
Pediatrics, Human health, Orphan diseases, Genetic / Rare
diseases, CNS related diseases.
Activities
Company activities
Neurology
ADV 6208
Is an innovative liquid formulation of a molecule. ADV 6208
is perfectly adapted to oral administration in case of child
epilepsy emergency as Status Epilepticus.
ADV 6209
Is a similar formulation: oral administation adressed to
anaesthesia and conscious sedation.
Nephrology
ADV 7103
Is a paediatric formulation (micro-tabs) adressed to a
nephrological genetical disease. ADV 7103 is a tasteless drug,
able to cover a 8-12 hours period. ADV 7103 will benefit from
an orphan status.
Products / Serv ices / Technologies
Company contacts
l i f e
2 0 1 1
Pipeline product 1
Preclinical: realized
Phase 1: to be launched
Phase 3: not necessary.
Pipeline product 2
Pipeline product 3
17
Business model
Value chain
Activities
Drug discovery, Medical device, Other.
Application fields
Animal health, Human health, Infectious diseases, Nutrition /
Food, Other.
Activities
Company name: Aguettant
Address: 1 rue alexander fleming
Zip code: 69007
City: Lyon
Website: www.aguettant.com
Main activity: AGUETTANT designs and improves solutions
and injectable drugs for patients and health care professionals,
from hospital to the home.
Subsidiary of a group: Yes (Groupe Aguettant)
Company activities
AGUETTANT is an independent family owned pharmaceutical
company with more than 100 years of experience. The company
is a pioneer in the injectable drugs market with 350 references.
A key player in the sectors of:
– Anaesthetics,
– Injectable morphine,
– Cardiology,
– Infectious diseases,
– Parenteral micro-nutrition (trace elements),
– Parkinsonian acute treatment,
– Small volume infusion,
– Irrigation and rinsing.
Recent news
Aguettant develops a range of emergency drugs in plastic
prefilled syringes.
R&D PROJECT funded
Accredited BY LYONBIOPOLE
POLYBIO: Innovative plastics for a better packaging
of pharmaceutical products
Company contacts
CEO contact detail
First name: Michel
Last name: Fasne
Position: President
Phone: +33 (0)4 78 61 51 41
Other contact
First name: Eric
Last name: Debuyser
Position: Director Development
Phone: +33 (0)4 78 61 51 41
Fax: +33 (0)4 78 61 09 35
18
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Skills and know-how
Experienced product development and regulatory affairs teams.
Company technologies: The filling of glass or plastic
containers as, ampoules, vials, bottles or syringes, in aseptic
or no aseptic conditions.
Partnership
– Disposable auto-injector pens,
– Plastic prefilled syringes,
– Innovative infusion bags with integrated rinsing,
– Reconstitution medical devices,
– Injectable generic + pharmaceutical dossiers.
Objective: extend Aguettant products’ portfolio by acquiring:
– Niche products for hospital use (pharmaceuticals
or disposable small medical devices),
– Co-development partners,
– Generics + files for hospital.
Activities
Company activities
Company name: Alaxia
Address: 3-11, rue de la Perlerie
Zip code: 69120
City: Vaulx en Velin
Website: www.alaxia-pharma.eu
Main activity: Alaxia, a young innovative company (JEI and
FCPI qualified) develops airway medicinal products for orphan
diseases.
Other status: Yes (JEI, SME)
Funding
Alaxia, a young innovative company (JEI and FCPI qualified)
developping airway solutions for respiratory diseases. Recently,
its Meveol product, 1st product exiting the pipeline, has been
recognised Orphan medicinal product for cystic fibrosis, CF,
condition by EMEA. Meveol is both an antimicrobial and anti
inflammatory product , targeting to kills bacteria, including
superbugs and to compensate innate lung defense system.
www.alaxia-pharma.eu Cystic Fibrosis (Mucoviscidose) an
orphan disease affecting 100,000 patients in US and EU.
- Products and process are protected
by several patents and ODD - ALAXIA staff important knowledge
on antimicrobial API - A new therapeutic approach answering
clinicians and patients request taking into account antibiotic
microbial resistances, biofilm protection mode… - Efficacy on
MRSA, BCC - Top level European scientific/medical committee.
Recent news
Meveol Orphan medicinal status granted in EU, July 2009 SME
status in September 2009 Meveol, Orphan drug status granted
in US, Nov 2009 www.alaxia-pharma.eu.
Skills and know-how
AMP (antimicrobials proteins) aerosols and aerosoltherapy with
our partners Based on our peroxidase plate form, we are able
to produce various kind of antimicrobials active compounds (eg
OSCN, OI…) &/or antiinflammatory products.
Company contacts
CEO contact detail
First name: Philippe
Last name: Bordeau
Position: CEO
Phone: +33 (0)4 72 81 09 26
Other contact
First name: Maria
Last name: Ahmed Chavarino
Position: Head of regulatory affairs
Phone: +33 (0)4 72 81 09 26
Fax: +33 (0)4 78 41 17 79
Pipeline product 1
Therapeutic area: Respiratory
Therapeutic indication: Infectious
Preclinical: Meveol.
Pipeline product 2
Therapeutic area: Medical device
Preclinical: Eol.
Pipeline product 3
Therapeutic area: Respiratory
Therapeutic indication: COPD
Company technologies: Our technologies are based on our
peroxidase plateform.
Business model
Product developer - Biopharmaceuticals, Product developer Pharmaceuticals, Product developer - Other health.
Value chain
Research, Other.
Treatment of respiratory diseases (URTI or LRTI), COPD.
Activities
Drug discovery, Other.
Research program on , URTI, LRTI, COPD.
Application fields
Pediatrics, Human health, Infectious diseases, Orphan
diseases, Genetic / Rare diseases.
l i f e
s c i e n c e s
Partnership
d i r e c t o r y
2 0 1 1
No orphan diseases, eg Pneumonia, COPD, Nausocomial
diseases.
19
Business model
Product developer - Biopharmaceuticals, Product developer Pharmaceuticals.
Value chain
Company name: Alizé Pharma
Address: 15, chemin du Saquin, Bat. G
Zip code: 69130
City: Écully
Founded in: 2007
Main activity: The Alizé Pharma Group is specialized
in the development of innovative biopharmaceuticals
for the treatment of metabolic diseases and cancer.
Other status: Yes (JEI)
R&D PROJECT FUNDED
ACCREDITED BY LYONBIOPOLE
ASPAREC: Development of a new RECombinant L-ASPAraginase with long acting properties
Company contacts
CEO contact detail
First name: Thierry
Last name: Abribat
Position: President
Phone: +33 (0)4 72 18 94 28
Other contact
First name: Valérie
Last name: Wesley
Position: Direction Assistant
Phone: +33 (0)4 72 18 94 28
Fax: +33 (0)4 78 33 36 29
Activities
Clinical trials, Preclinical trials, Drug discovery, Other.
Application fields
Human health, Infectious diseases, Orphan diseases, Genetic /
Rare diseases, Metabolic diseases, Cancer.
Activities
Company activities
The Alizé Pharma Group is composed of privately-held
biopharmaceutical companies specialized in the development
of innovative therapeutics for the treatment of metabolic
diseases and cancer. The group acquires R&D programs
from public or private laboratories, selecting them according to
strict criteria, with particular reference to medical need
and innovation. It then handles preclinical and clinical
development and establishes partnerships with the
pharmaceutical industry via co-development or out-licensing
agreements. The first of the two entities of the Group, Alizé
Pharma SAS, is dedicated to AZP-01, a program based
on unacylated ghrelin agonists, a new therapeutic class
for the treatment of Type II diabetes. Unacylated ghrelin
and its analogs have the potential not only to control
the disease but also to have a positive impact on other
cardiovascular risk factors such as obesity, dyslipidemia
and impaired vascular remodeling. The parent molecule
and its analogs are protected by four patent families
worldwide. The second entity is Alizé Pharma II SAS. It is
focused on the development of Asparec® (AZP-02), a new,
long-acting recombinant L-asparaginase with reduced
immunogenicity for the treatment of acute lymphoblastic
leukemia, and currently at the preclinical stage. Founded
in April 2007, the Alizé Pharma group is based in Ecully, near
Lyon, France. Its management is made up of a team of drug
development experts and a board of directors offering wide
international experience. Since its inception, Alizé Pharma
has raised Eur 4.8 M from private and institutional investors.
Recent news
2007: acquisition of the Unacylated Ghrelin (AZP-01) program
from Erasmus MC (Rotterdam) and University of Turin.
2008: acquisition of the Asparec program (AZP-02) from EUSA
Pharma Inc.
2009: Fund raising of Eur 3,0 M (for a total of Eur 4,8 M raised
since inception).
2010: Research collaboration and license option agreement
with Eli Lilly & Co. (US).
20
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Service provider - Scientific.
Value chain
Activities
Diagnostics / Analysis method, Bioinformatics / Modeling,
Other.
Company name: AltraBio
Address: 24, rue Baldassini, porte B
Zip code: 69007
City: Lyon
Website: www.altrabio.com
Turnover: 730 000 Euros (in 2009)
Main activity: Biotechnology.
Incubator: Yes (CREALYS)
Funding
Nature of funding searches: Please contact us
for more details.
Company contacts
CEO contact detail
First name: Laurent
Last name: Buffat
Position: CEO
Phone: +33 (0)4 26 84 69 63
Other contact
First name: Christel
Last name: Paris-Bicking
Position: Partnerships and Strategic
Development Manager
Phone: +33 (0)4 26 84 69 63
Fax: +33 (0)4 72 70 92 42
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Application fields
Animal health, Human health, Immunology, Inflammatory
diseases, Infectious diseases, Autoimmune diseases,
Orphan diseases, Genetic / Rare diseases, Metabolic diseases,
CNS related diseases, Cancer, Dermocosmetics, Other.
Activities
Company activities
AltraBio delivers comprehensive solutions in exploration,
mining and integrative analysis of life science data.
By exploiting the full potential of experimental results, AltraBio
helps optimize the preclinical and clinical development
of candidate compounds. AltraBio interprets the results
in the context of current biomedical knowledge and formulates
hypotheses for the mechanisms of action underlying
the observations. AltraBio provides data analysis services
ranging from basic research applications such as gene
expression profiling through clinical trial data analysis
and audit.
The analysis and interpretation team is made of highly
skilled professionals with transversal, double expertise
in medecine and bio-informatics/mathematics, who are not
only able to provide quick and efficient statistical analysis,
but also to understand the end customers’ own questioning
and sometimes help redesign the research studies. The staff
is also multicultural, with members fluent in many foreign
languages, which is an advantage in international research
programs.
Recent news
AltraBio agreed to participate in the Bio-Informatics platform
of the «IRT Infectiologie» (Regional Excellence Research
Program, with focus on infectious diseases).
Skills and know-how
AltraBio works in close cooperation with Europe’s best
micro-array and next generation sequencing platforms.
It focuses on developing further «tailor made»expertise
in data analysis & management, at the highest possible level
of interpretation, and as close as possible to the researcher’s
own questioning. In this aim, the team also developed its own
tools for detecting potential errors in the transmitted biological
data, and in designing «easiest to read», customer friendly,
analysis reports.
21
Business model
Company name: Alvedia
Address: 60, avenue Rockefeller
Zip code: 69008
City: Lyon - France
Website: www.alvediavet.com
Main activity: Alvedia is specialized in the immuno-
Service provider - Scientific, Product developer Pharmaceuticals, Product developer - Other health, Laboratory
equipment supplier.
Prize winner for innovative start-up: Yes
Other status: Yes
Diagnostics / Analysis method, Other.
Funding
Activities
hematology veterinary field.
d i r e c t o r y
Activities
Application fields
Animal health, Immunology, Infectious diseases.
Skills and know-how
Veterinary immuno-hematology.
Other contact
First name: Elisabeth
Last name: Louis
Position: Product Manager
Phone: +33 (0)4 78 38 02 39
Fax: +33 (0)4 78 93 95 63
s c i e n c e s
Research and developpement of innovative products for blood
typing, blood transfusion, crossmatching, infectious desease.
Transfusion scientific supports for the veterinary profession.
Alvedia provides worldwide blood typing Quick Test for cats
and dogs.
CEO contact detail
First name: Alice
Last name: Rigal
Position: General Manager
Phone: +33 (0)6 33 41 17 02
l i f e
Value chain
Company activities
Company contacts
22
2 0 1 1
Company name: Amoéba
Zip code: 69008
City: Lyon
Website: www.amoeba-biocide.com
Main activity: Amoéba is an innovative company which
develops, manufactures and markets biological products
and services of disruptive treatment for legionella
and for amoebae in water. Our solutions open a new way
of biological treatment of the legionella and amoebae risk
for the industrials companies.
Our biological offer is a measured and sure answer
to a biological problem allowing a cost cutting with
an environmental approach anticipating the future law.
Prize winner for innovative start-up: Yes (Emerging 2010)
Other status: Yes (JEI and CIR)
Funding
Public funding obtained: CREALYS € 30 K, Rhône Alpes
region € 30 K, French ministry € 40 K
Business model
Other.
Value chain
Other.
Activities
Other.
Application fields
Other.
Activities
Company activities
We market a solution in the form of products associated with
a service to protect the cooling tower of industrials companies
from the world against the bacteriological risks. Our solution
is a biological agent which eliminates Legionella and Biofilm
present in water from the wet cooling tower.
The product will be presented in concentrated liquid form
which will be injected directly into the water network.
The service consists in injecting the amoebae in the water
network of the cooling tower and guarantee throughout
the year the threshold of the desire concentration of our Ameba
to eliminate 100% Legionella and to avoid the Biofouling.
In addition of our product and service, our knowledge allows us
to be an European leader for the analysis and the numeration
of the amoebae in industrial water.
Company contacts
CEO contact detail
First name: Fabrice
Last name: Plasson
Phone: +33 (0)4 26 69 16 00
Other contact
First name: Jacques
Last name: Bodennec
Phone: +33 (0)4 72 43 11 71
Fax: +33 (0)4 72 43 11 72
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
23
Business model
Company name: ANaBior
Address: 58, route du Rivet
Zip code: 38330
City: Saint-Ismier - France
Main activity: ANaBior is dedicated to the development
of an innovative technology platform that features specific
bioresorbable nanoparticles as vector systems for veterinary
and human pharmaceutical applications .
Incubator: No
Other status: No
Funding
R&D PROJECTS FUNDED
PARSYNVAC: Design of a synthetic and biodegradable
nanoparticulate vaccine vehicle
Funding: ANR (2005 RIB)
Role in the project: Partner
ANABIO: Biodegradable nanoparticles of poly lactic
Acid as adjuvant for subunit vaccines
Funding: ANR (2008 Biotecs)
Company contacts
s c i e n c e s
d i r e c t o r y
Research, Manufacturing, Preclinical.
Activities
Vaccine, Nanotechnology, Drug delivery, Other.
Application fields
Animal health, Human health.
Activities
Company activities
ANaBior develops its proprietary integrated manufacturing
process, from the specific bioresorbable PLA (Poly-lactic acid)
polymer production to the synthesis of reproducible batches
of very homogeneous nanoparticles with strong colloïdal
stability . For research purposes, ANaBior is able to provide
PLA nanoparticles upon request. In collaboration with scientific
experts, ANaBior is also focused on the development
of an innovative antigen formulation process into
the nanoparticles in order to design a new synthetic
vaccination vector and stabilizing agent.
– Full R&D and production existing infrastructure.
– Validated manufacturing process.
– Established proof of concept.
– Preclinical and long term data in several animal models.
– Close collaboration with worldwild recognised research
partners.
Skills and know-how
– Strong know-how on manufacturing of PLA polymers
and nanoparticles and on final formulation of the active
product.
– Successful technology transfer experience.
– Multidisciplinary and highly experienced scientific,
management and production team.
– Specific polymerisation and purification process
for bioresorbable polymers synthesis.
– One-step, surfactant free PLA nanoparticles elaboration.
– Solvent free protein formulation.
Other contact
First name: Jacqueline
Last name: Huet
Phone: +33 (0)4 76 52 51 60
Fax: +33 (0)4 76 52 49 62
l i f e
Value chain
CEO contact detail
First name: Yves
Last name: De Backer
Position: CEO
Phone: +33 (0)6 07 74 60 74
24
Partnership
ANaBior is looking for strategic partners in order to co-develop
innovative nanocarrier-based systems.
2 0 1 1
Business model
Company name: Antagene
Address: 2 allée des Séquoias
Zip code: 69578
City: Limonest
Website: www.antagene.com
Turnover: 8 K Euros (in 2010)
Main activity: Biotech company in animal health and genetics.
Prize winner for innovative start-up: Yes (2001
Service provider - Scientific, Product developer - Other health.
Other status: Yes (JEI, CIR)
Activities
(Creation-Development))
Value chain
Activities
Application fields
Animal health, Orphan diseases, Genetic / Rare diseases,
Cancer.
Company activities
Development and commercialization of DNA tests for animals
(dog, cat).
Funding
Nature of funding searches: We are looking for funding
our reseach programs in animal genomics, genetic disorders
in dog and cat as model for human diseases.
Private funding obtained: € 1,4 M venture-capital between
2003 and 2009
Public funding obtained: € 540 K between 2007 and 2011
Biomarks (EuroTransbio 2007-2009) LUPA (FP7 2008-2011)
Research programs in genetic disorders in dog and cat,
homologous to human diseases.
Skills and know-how
Animal genomics Molecular genetics Dog/cat spontaneous
models.
Company contacts
Company services
DNA tests for genetic diseases in dog and cat Research
services in comparative genomics (human-animal).
CEO contact detail
First name: Guillaume
Last name: Queney
Position: President
Phone: +33 (0)4 37 49 90 03
Whole-genome scan - DNA chip - Sequencing - Microsatellites/
SNP genotyping.
Other contact
First name: Anne
Last name: Thomas
Position: Director of R&D
Phone: +33 (0)4 37 49 87 04
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
25
Activities
Company activities
Company name: Antialis
Address: 18, rue du souvenir
Zip code: 69009
City: Lyon
Main activity: Pharmaceutical.
Incubator: No
Other status: No
Development of new medical indications of old molecules
in allergy and cancer.
Funding
Private funding obtained: € 0.5 M
Preclinical: ANTIALIS 1.
Research.
Recent news
POC in cancer.
Skills and know-how
Clinical, research and business in Pharmaceutical field.
Pipeline product 1
Pipeline product 2
Preclinical: ANTIALIS 2.
Company contact
CEO contact detail
First name: Gaetan
Last name: Terrasse
Position: CEO
Phone: +33 (0)6 64 90 06 54
Partnership
CNRS Neker IGR Paris.
Cancer and allergy.
Allergy and cancer.
Business model
Value chain
Activities
Drug discovery.
Application fields
Human health, Immunology, Allergology, Cancer.
26
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Cancer.
Company name: AXO Science
Address: Parc d’activité GVIO, 2, place de l’Europe, Bât. A,
Zip code: 38070
City: Saint Quentin Fallavier
Website: www.axoscience.com
Main activity: AXO Science, headed by a group of founders
from marketing/commercial and scientific background,
is specialized in the development of high-throughput
and multiparametric analysis tools dedicated
to the characterisation of biological samples.
The company offers complete solutions for diagnostic tools
development, both for research projects and products
industrialisation. As the gold Standard in high-throughput
microarray technologies, spotting facilities are mandatory
for all your future diagnostic projects. Here, Axo Science is
a valuable partner, bringing all its know-how and technological
services to your R&D projects.
Other status: No
Company contacts
Business model
Service provider - Scientific,
Product developer - Other health.
Value chain
Research, Clinical.
Activities
Diagnostics / Analysis method, Instrumentation, Clinical trials,
Medical device.
Application fields
Animal health, Human health, Immunology, Infectious
diseases, Autoimmune diseases, Allergology, Genetic / Rare
diseases.
Activities
Company activities
– Microarray spotting services (high quality control, surface
chemistry)
– R&D activity in the field of multiparameter high-throughput
assays for blood group genotyping and human serology
– Consulting services:
• High throughput assays development
• Test efficiency improvements
• Diagnostic solutions.
CEO contact detail
First name: Cédric
Last name: Louis
Position: President
Phone: +33 (0)4 72 43 13 69
Other contact
First name: Christophe
Last name: Marquette
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
27
Activities
Company activities
Development of veterinary care products.
Research & development of biomaterials for tissue
and osteoarticular repair.
Company name: Ayawane
Address: 60, Avenue Rockefeller
Zip code: 69008
City: Lyon
Website: www.ayawane.com
Main activity: Development of innovative veterinary care
products.
Other status: Yes
Funding
Twenty years experience in biomaterials. Multidiscipilanry
team : Pharmacy, chemistry, biochemistry, and veterinary
medecine. Two equine care products on the market and six
to be launched in 2011.
Recent news
Financial support and certification: CREALYS, Novacite, Réseau
entreprendre, Innotech and Oseo.
Skills and know-how
Research and development of new chemical entities.
Non clinical and clinical assessment.
Tissue and osteoarticular repair.
Pipeline product 1
Therapeutic area: Equine Care
Therapeutic indication: External care
Preclinical: 2009
MA: july 2010.
Pipeline product 2
Therapeutic area: Animal Health
Therapeutic indication: Wound care
Preclinical: ongoing.
Company contact
CEO contact detail
First name: Latifa
Last name: Dahri Correia
Position: CEO
Phone: +33 (0)4 78 09 34 06
Pipeline product 3
Therapeutic area: Animal heath
Therapeutic indication: Viscosupplementation
Preclinical: ongoing
Company services
Business model
Product developer - Pharmaceuticals, Product developer Other health.
Value chain
Activities
Other.
Ayawane is an innovative company that develops and markets
equine veterinary care products. Ekine Care is the first line
marketed by Ayawane.
The technology of Ayawane is based on the design
of biomaterials obtained by functionalization of polymers
that endowed them with biospecific activities.
Partnership
Biotechnologies and pharmaceutical laboratories.
Application fields
Animal health.
Dermatology, ophthalmology, surgery, orthopedy and esthetic.
Out-licencing of the biomaterials for human use.
28
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: Bactup
Address: 27, chemin des Peupliers - BP 74
Zip code: 69573
City: Dardilly cedex
Website: www.bactup.com
Main activity: Bactup offers services on demand
in microbiology. It is located in a pharmaceutical industrial
plant near Lyon (France). Our activites are focused on :
– Secured and confidential storage and management
of collections of micro-organisms of our customers.
– Microbial identification and characterization of microorganisms, based on ISO17025:2005 and BPF/GMP guidelines.
– Production of master cells banks and working cells banks
of micro-organisms, with calibration, according to BPF/GMP
guidelines.
– R&D on demand in microbiology.
– Consulting and training on demand in microbiology.
– EasyBactup software dedicated to the management
of collections of micro-organisms.
Funding
Company contacts
CEO contact detail
First name: Raphaël
Last name: Lavenir
Position: CEO
Phone: +33 (0)9 62 23 09 72
Business model
Service provider - CRO, Service provider - Non Scientific,
Service provider - CMO, Service provider - Scientific, Other.
Value chain
Research, Other.
Activities
Diagnostics / Analysis method, Biobank.
Application fields
Animal health, Human health, Infectious diseases, Nutrition /
Food, Other.
Activities
Company activities
Bactup offers services on demand in microbiology. It is located
in a pharmaceutical industrial plant near Lyon (France).
Our activites are focused on:
– Secured and confidential storage and management
of collections of micro-organisms of our customers.
We use freeze-drying and freezing (-20°C to -150°C) processes.
– Microbial identification and characterization
of micro-organisms, based on ISO17025:2005 and BPF/GMP
guidelines. We have biochemical (Vitek 2 and API) and
molecular (PCR-sequencing) tools.
– Production of master cells banks and working cells banks
of micro-organisms, with calibration, according to BPF/GMP
guidelines. We can perform freeze-drying process in vials
or ampoules, or Freezing process in cryovials.
– R&D on demand in microbiology. Here, we develop new
processes to perform scientific essays according to our
customer’s requests.
– Consulting and training on demand in microbiology.
We can operate in our customer’s plant to perform more
efficient training and consulting.
– EasyBactup software dedicated to the management
of collections of micro-organisms.
Other contact
First name: Ludovic
Last name: Champier
Phone: +33 (0)9 62 23 09 72
Fax: +33 (0)4 78 64 92 39
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
29
Company contact
CEO contact detail
First name: Christian
Last name: Seux
Position: CEO
Phone: +33 (0)4 76 68 36 36
Company name: BD
Address: 11, rue Aristide Bergès - BP4
Zip code: 38801
City: Le Pont de Claix Cedex
Website: www.bd.com/fr
Turnover: 813 582 466 e (in 2010)
Main activity: BD, a leading global medical technology
company that makes and sells medical devices, instrumented
systems and regents, is dedicated to improving people’s
health throughout the world. The company serves healthcare
institutions, life science researchers, clinical laboratories,
industry and the general public.
Subsidiary of a group: Yes (BD Corporate US)
Business model
Product developer - Pharmaceuticals, Laboratory equipment
supplier, Other.
Value chain
Funding
Research, Manufacturing, Preclinical,
Marketing / Distribution, Clinical, Other.
Activities
R&D PROJECTS FUNDED
MICROVAX: Skin immunology and vaccination
TBDERMATEST: Development of a novel skin test using
the HBHA antigen for the diagnosis of latent M. tuberculosis
infection
EXPANDID: Extending the scope of application of intradermal
vaccination
30
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Diagnostics / Analysis method, Instrumentation,
Biomanufacturing, Clinical trials, Preclinical trials,
Drug discovery, Medical device, Other.
Application fields
Human health, Other.
Activities
Company activities
BD is focused on improving drug therapy, enhancing the quality
and speed of diagnosing infectious disease, and advancing
research and discovery of new drugs and vaccines.
Business model
Service provider - CMO, Product developer Biopharmaceuticals, Service provider - Scientific, Product
developer - Pharmaceuticals.
Value chain
Activities
Vaccine, Cell therapy, Biomanufacturing, Clinical trials,
Biobank, Other.
Application fields
Company name: Bio Elpida
Address: 27, chemin des Peupliers
Zip code: 69572
City: Dardilly
Website: www.bio-elpida.com
Turnover: 0.5 M e (in 2009)
Main activity: Bio Elpida is a Biotechnology Contract
Manufacturing Company located in Lyon - France - with strong
experience on innovative cell therapy products (Advanced
Therapy Medicinal Product as define by the EMEA) based on
cell culture and immunology approaches.
Our team of experts can conduct your project all the way
from early proof of concept studies to pre-clinical and clinical
phases. This includes:
– R&D feasibility,
– Pharmaceutical development,
– Manufacturing of clinical and small scale marketing batches,
– Immuno-testing,
– Additional support such as bulk purification, fill and finish,
formulation, training, regulatory files, analytical development…
For any project, you will be assigned a project manager who
will work with you as a partner giving you regular updates and
making sure that our top priority is the achievement of your
goals, following current regulation (ICH, cGMP, CFR 21).
Subsidiary of a group: No (Immodulon)
Other status: No
Funding
Company contacts
CEO contact detail
First name: Benoît
Last name: Pinteur
Position: CEO
Phone: +33 (0)4 78 47 94 58
Other contact
First name: Gilles
Last name: Devillers
Position: Head of Business Development
Phone: +33 (0)6 42 98 40 16
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Human health, Immunology, Inflammatory diseases, Infectious
diseases, Autoimmune diseases, Allergology, Orphan diseases,
Cancer.
Activities
Company activities
Bio Elpida is a Biotechnology Contract Manufacturing Company
located in Lyon - France - with strong experience on innovative
cell therapy products (Advanced Therapy Medicinal Product
as define by the EMEA) based on cell culture and immunology
approaches.
Our team of experts can conduct your project all the way
from early proof of concept studies to pre-clinical and clinical
phases. This includes:
– R&D feasibility,
– Pharmaceutical development
– Manufacturing of clinical and small scale marketing batches,
– Immuno-testing
formulation, training, regulatory files, analytical development…
For any project, you will be assigned a project manager who
will work with you as a partner giving you regular updates and
making sure that our top priority is the achievement of your
goals, following current regulation (ICH, cGMP, CFR 21).
Working with Bio Elpida means more than services. Reaching
your goals, timelines and budget is the minimum to expect
from a service company. At Bio Elpida, the project managers
and the expert teams ensure that you benefit from our
extensive knowledge and experience. We operate as an
extension of your company and take your problems as ours.
Hence, from a simple piece of contract service to the most
complex issue in cell culture, Bio Elpida endeavours to provide
you with the highest quality work possible within the following
range of cell culture and cell therapy services:
– R&D and feasibility
– Pharmaceutical development
– Manufacturing of clinical and small scale marketing batches
with single use technology
– Immuno-testing
formulation, analytical development and regulatory services
Bio Elpida partners with our clients to develop client-specific,
custom protocols to meet each unique need in cell therapy, cell
culture and immunotherapy projects.
Recent news
Bio Elpida has recently released its web site. You are invited
to visit it and learn more about how we can contribute to you
cell therapy development success at www.bio-elpida.com.
Skills and know-how
Bio Elpida is a biotechnology service company focused on the
development and manufacturing
of cell culture and innovative cell therapy.
The company’s expertise covers the pharmaceutical
Research & Development, from proof of concept to late
stage clinical trial, including the process development and
feasibility, analytical method validation, product testing, GMP
manufacturing and release.
31
Optimisation
Once the technology transfer would have been performed
according to plan, our scientists lead by the project manager
will strive to optimise the existing process in order to increase
yield, decrease time and cost of production.
Scale-Up
Our core competencies apply in:
– Cell banking: Master Cell Bank and Working Cell Bank
– Cell culture: eukaryotic cell culture as well as prokaryotic
cell culture
– Cell isolation from human samples
– Innovative cell therapy: autologous anticancer cell therapy,
regenerative stem cells approach…
– Immunotherapy: immunomodulator and other bioproducts
– Immunoassays: flow Cytometry, characterisation, etc.
With an optimised cell culture process, the manufacturing staff
will scale the process up to the desired clinical batch size.
Analytical Method
Company services
R&D and feasibility
During this preliminary phase, under a CDA, you will present
and define your project to Bio Elpida including: your objective,
the deliverables, the description of the technology… Bio Elpida
will provide you with a specific proposal including a complete
presentation of the company and our capability.
Proof of Concept Evaluation
Following the presentation, Bio Elpida will evaluate with your
collaboration, the preliminary results you had obtained. Bio
Elpida will propose you technical solutions to adapt your
project according to your expectations, taking into account the
industrialisation requirements and complying with regulatory.
Bio Elpida will provide you with a «master services agreement»
covering services to be delivered to manage your project
including a schedule for the specific R&D and feasibility steps.
Research & Development
This phase is dedicated to test the different solutions imagined
during the evaluation and proposed in the development
program. After this R&D step, the best solution will be
proposed according to the parameters defined
in the development program.
Feasibility Study
The aim of this step is to confirm the solution selected during
the R&D step according to a defined protocol. The results
of this study are registered in a formal report that anticipates
the pharmaceutical development procedures.
During this preliminary phase, under a CDA, you will present
and define your project to Bio Elpida including: your objective,
the deliverables, the description of the technology… Bio Elpida
will provide you with a specific proposal including a complete
presentation of the company and our capability.
Pharmaceutical Development
Thanks to Bio Elpida’s expertise ranging from tissue
acquisition to process scale-up and design, media
optimisation,
immuno-assay development and validation, our staff is
prepared to collaborate, guide you and work with you all
the way to your success.
Technology transfer
Prior to any development work, the dedicated project manager
and staff will work as closely as possible with our partners
to transfer information and verify existing methodologies,
creating a defined baseline against which process
improvements are measured.
l i f e
s c i e n c e s
d i r e c t o r y
At Bio Elpida, we recommend to our partners taking
the Single-Use approach. Not only it represents the preferred
option to Regulatory Bodies, but it is also less complex
to scale up. Hence, Bio Elpida proposes to use SUB (Single
Use Bioreactor) or Biowave type of bioreactor and we propose
different production means such as perfusion by ultra filtration,
continuous centrifugation or simply by batch.
Together with the process development, the analytical methods
attached to our partner’s process will be transferred, created or
modified as required and agreed.
Manufacturing
Following the development stage of your pharmaceutical
products, Bio Elpida follows strict procedures to ensure clinical
batch production: Validation:
• GMP
• Stability
• Clinical batch
Testing Bio Elpida focuses on Human bio-analysis and immunotesting of cell based therapies and proposes immuno-testing as
well as other analytical tests.
Immuno-Testing
Program Development
32
Single-Use Approach
2 0 1 1
Bio Elpida provides existing and novel immuno-assay designs
and methods for immuno testing:
– Flow cytometry for known antibodies and antibodies
development,
– Immuno-histology,
– ELISA for cytokines:
IL-1, IL-4, IL-10, IL-12p40, EPO IL-2, IL-5, TNF alpha, IL-12p70,
EGFR, IL-3, IL-6, VEGF, IL-8, etc.
Support
Further to its core services, Bio Elpida also provides additional
services to support your cell based product:
– Aseptic Fill & Finish for vials and pre-filled syringes
– Formulation of wet and dry formats such as sterile liquid,
lyophilisation, spray drying…
– Regulation IMPD
– Training
– Drug Analytical Development
– Bulk Purification.
When required by scale or specificity, we can expand
our existing support capabilities by working with very close
network of organisations. In all cases, we retain full control and
responsibilities of any piece of work given to Bio Elpida.
Partnership
Bio Elpida would be delighted to participate and contribute
to a collaborative framework you would lead in the cell therapy,
cell culture, or immunology fields.
Should you have a partnership in mind, we would be happy
to know more about it and initiate corresponding discussions.
Company name: Bioclinica SAS
Address: Bioparc - 60, avenue Rockefeller
Zip code: 69008
City: Lyon
Turnover: 1 622 Ke (in 2009)
Main activity: BioClinica is a global clinical trials service
organization, providing medical image management
and eClinical services. This includes electronic data capture
and clinical data management solutions to pharmaceutical,
biotechnology and medical device companies and other
organizations, such as contract research organizations (CROs)
engaged in clinical trials.
Subsidiary of a group: Yes (BIOCLINICA Inc.)
Other status: Yes
Funding
Business model
Service provider - CRO.
Value chain
Research.
Activities
Other.
Application fields
Human health, Geriatrics, CNS related diseases, Cancer.
Activities
Company activities
BioClinica is a global clinical trials service organization,
providing medical image management and eClinical services.
This includes electronic data capture and clinical data
management solutions to pharmaceutical, biotechnology and
medical device companies and other organizations, such as
contract research organizations (CROs) engaged in clinical
trials.
Company contact
CEO contact detail
First name: Chahin
Last name: Pachai
Position: Executive Director
Phone: +33 (0)4 26 23 05 05
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
33
BIOCLINOME
Business model
Value chain
Activities
Company name: Bioclinome
Address: 563, chemin Champ Jaillet
Zip code: 38190
City: Bernin
Website: www.bioclinome.com
Main activity: Information technology for personalized
Drug discovery.
Application fields
Human health, Geriatrics, Immunology, Autoimmune diseases,
Allergology, Metabolic diseases, Cancer,
Nutrition / Food, Dermocosmetics.
Activities
Company activities
health care.
Incubator: Yes (Grain)
Bioclinome proposes bioprofile technology software
for medical practitioners to help personalized medical
diagnosis, by means of an extremely rigourous
analyse system of patient data: clinical, lab’s analysis,
genomic,proteomic,epigenomic, actimetric or daily habits.
Funding
For the hospital physiciens or medical research centers the
biologic profile will allow to distinguish clearly two resembling
categories of the same disease. This approch will allow
to diagnose different types of cancer, cardiovascular diseases,
diabets or other degeneratives diseases such
that a personalized therapy could be proposed to the patient.
Other status: Yes
Nature of funding searches: Bank loans.
Company contact
CEO contact detail
First name: Adriana
Last name: Climescu
Position: CEO
Phone: +33 (0)4 76 08 02 81
The physicien may follow the evolution of the bioprofile on time
and the status of his patient health stady. Our approch enables
to consider in the centre of the clinical process the patient
instead of the disease, according to the personalized medicine
principle.
Bioclinome proposes also services for pharmaceutical
compagnies in relationship with the developement of new
target molecules. Bioclinome realises «in silico» analysis
to improve the predictability of fail or succes for a molecule.
Innovative technology based on new mathematical concepts
derived intrinsecaly from the nature of patient biological data.
Recent news
Hiring researchers and engineers.
Skills and know-how
- Biomarkers discovery
- Proposition to the hospitals of personalized treatment
approaches for cancer patients
- Design and validation of clinical and pharmaceutical trails
- Omics data mining Multiple databases inferences.
34
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: Biomatech Namsa
Address: Zi de L’Islon
Zip code: 38670
City: Chasse sur Rhône
Website: www.biomatech.fr
Turnover: 11 M e (in 2009)
Main activity: Medical devices and biotechnology products
evaluation. Biocompatibility studies. Microbiology.
RD outsourcing. Clinical research.
Incubator: No
Subsidiary of a group: Yes (Namsa)
Other status: Yes
Funding
Service provider - CRO, Product developer Biopharmaceuticals, Service provider - Scientific, Product
developer - Other health.
Value chain
Activities
Cell therapy, Models (animal - cellular…), Clinical trials,
Preclinical trials, Nanotechnology, Medical device, Drug
delivery, Other.
Application fields
Activities
Medical devices and biotechnology products evaluation.
Biocompatibility studies. Microbiology. RD outsourcing.
Clinical research.
Company contacts
Customized services and fast turnover rates.
CEO contact detail
First name: Jean-Pierre
Last name: Boutrand
Position: Managing Director
Phone: +33 (0)4 78 07 92 34
Company services
Medical devices and biotechnology products evaluation.
Biocompatibility studies. Microbiology. RD outsourcing.
Clinical research.
Other contact
First name: Hugues
Last name: Danjou
Position: Project Manager
Phone: +33 (0)6 85 11 18 31
Fax: +33 (0)4 72 24 08 12
s c i e n c e s
Business model
Company activities
l i f e
d i r e c t o r y
2 0 1 1
35
Business model
Product developer - Other health, Laboratory equipment
supplier.
Company name: bioMérieux
Address: 376, chemin de l’Orme
Zip code: 69280
City: Marcy l’Étoile - France
Number of employees: 6 300
Turnover: 1 357 M Euros (in 2010)
Main activity: In vitro diagnostics.
Other status: No
Funding
Stock exchange listing: bioMérieux is listed on the NYSE
Euronext Paris market since July 6, 2004.
R&D PROJECTS FUNDED
GAP Healthcare shield solutions against avian flu and flu
pandemics
Funding: FUI (2005)
DEMINAP: Use of toll-like receptors (TLRs) in order to detect
inapparent microorganisms and their ligands for diagnostic
and therapeutic applications
COVADIS: innovative nanoporous sensors to detect volatile
organic compounds (VOC) for applications responding to two
major needs in human health
ADNA: Advanced diagnostics for new therapeutic approaches
Funding: OSEO (ISI 2007)
Value chain
Activities
Application fields
Human health, Immunology, Infectious diseases, Allergology,
Cancer, Nutrition / Food.
Activities
Company activities
A world leader in the field of in vitro diagnostics for over
45 years, bioMérieux is present in more than 150 countries
through 39 subsidiaries and a large network of distributors.
In 2010, revenues reached €1,357 million with 87% of sales
outside of France. bioMérieux provides diagnostic solutions
(reagents, instruments, software) which determine the source
of disease and contamination to improve patient health and
ensure consumer safety. Its products are used for diagnosing
infectious diseases and providing high medical value results
for cancer screening and monitoring and cardiovascular
emergencies. They are also used for detecting microorganisms
in agri-food and biopharmaceutical products. bioMérieux is
listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN:
FR0010096479). Other information can be found
at www.biomerieux.com.
– Over 45 years experience in IVD, drawing on a century
of expertise in infectious diseases
– Leader in microbiology analysis worldwide
– The pioneer and number 1 in industrial microbiology
for the food, cosmetics and biopharmaceutical industries
– R&D investment above industry average (number 1 among
top ten IVD companies), representing 12% of sales each year,
and a substantial commitment over the long term
– Only company in the industry with extensive skills
in microbiology, molecular biology and immunoassays
– Installed base of approx. 60,000 instruments worldwide
Recent news
bioMérieux’slatestnewson:www.biomerieux.com/servlet/srt/bio/
portail/dynPage?lang=en&node=press_releases_2
Company contacts
CEO contact detail
First name: Stephane
Last name: Bancel
Position: Chief Executive Officer
Phone: +33 (0)4 78 87 20 00
Other contact
First name: Gianluigi
Last name: Moroni
Position: Business Development Manager
for the European Region
Phone: +33 (0)4 78 87 20 00
36
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
bioMérieux is one of the few companies mastering
the complete range of technologies essential for in vitro
diagnostics:
– Microbiology
– Immunoassays
– Molecular biology
We have a long and successful tradition of integrating
the 3 detection technologies into fully automated systems,
comprised of instruments, software and reagents. Systems
are constantly evolving and must integrate an increasing
number of parameters.
Activities
Company activities
Company name: Biomnis
Address: 17/19, avenue Tony Garnier
Zip code: 69007
City: Lyon
Website: www.biomnis.com
Main activity: Reference laboratory for specialised medical
diagnostic.
Other status: No
Company contact
CEO contact detail
First name: Pierre-Yves
Last name: Guiavarch
Position: CEO
Phone: +33 (0)4 72 80 10 51
Business model
Specialised Medical Pathology. Most of Biomnis’ activities focus
on specialised testing based on advanced technologies
in all the fields. Screening and titers are performed with
the help of the most up to date and sophisticated techniques.
Biomnis has his own division for clinical trials. Substantial
experience has been acquired in running clinical studies
for the pharmaceutical industry, an activity that is based
on the expertise of 45 pathologists with access to stateof-the-art equipment. Biomnis also has an independent
laboratory for genetic fingerprinting. Genetic fingerprinting
is used in forensic medicine to identify or exculpate suspects,
and also in paternity cases. Biomnis has a specialised
fingerprinting laboratory with all the equipment
and accreditations necessary to perform such tests.
Legal experts from the fingerprinting laboratory are consulted
in a variety of different fields, including evidence samples
analyses (exhibits), profiles for the Criminal Registry,
mitochondrial DNA sequencing and paternity tests.
Two specialised multidisciplinary centres (in Paris
and Lyon) covering all the disciplines of medical testing
45 pathologists – over 1,000 employees in France
20,000 patient records registered every day 40,000 tests
per day. Over 2,500 parameters available.
An affiliated transport company to ensure the collection and
temperature-controlled transportation of samples:
TSE Express Medical (25 logistic agencies spread throughout
France, 450 employees, 380 vehicles) 2 international
premises: Claymon in Dublin, leader in private medical
pathology in Ireland; and a laboratory in Dubai based in Dubai
Healthcare City The trust of the most established Contract
Research Organisations for clinical trial tests, and of the
major companies specialising in in vitro diagnosis for the
development and validation of new reagents and instruments
Governmental accreditations for regulated procedures Cofrac
accreditation of both sites as per the EN ISO/IEC 17025
standard (No. 1-1100 and No. 1-1973, Tests, Scope available on
www.cofrac.fr ).
Value chain
Research, Manufacturing, Clinical.
Activities
Diagnostics / Analysis method, Clinical trials, Biobank, Other.
Application fields
Human health, Immunology, infectious diseases, Autoimmune
diseases, Allergology, Orphan diseases, Genetic / Rare diseases,
Metabolicdiseases,CNSrelateddiseases,Cancer,Nutrition/Food.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
As part of his development of new diagnostics tests,
automatised techniques, oncomarkers, assay methods,
Biomnis is looking for partnership opportunities.
37
Company name: Biom’up
Address: 8, allée Joliot Curie - M7
Zip code: 69800
City: Saint Priest
Website: www.biomup.com
Main activity: Since 2005, Biom’Up SAS designs, develops,
manufactures and markets innovative medical devices based
on biopolymers like collagen. Collagen is a unique biopolymer.
It is biocompatible, absorbable and it gathers incredible
polymorphism and biological properties. R&D and production
services are based on our site of Saint Priest, near Lyon,
France. Our energy is focused on the development of innovative
and performing products, to bring confort, safety for patients
and to simplify the surgical procedures.
Incubator: Yes
Company contact
CEO contact detail
First name: Sylvain
Last name: Picot
Position: CEO
Phone: +33 (0)4 86 57 36 10
38
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Activities
Biomanufacturing.
Application fields
Pediatrics, Human health, Geriatrics.
Activities
Company activities
Expert in absorbable biopolymers like collagen for biomedical
applications, Biom’Up develops and manufactures implantable
medical devices to enhance human reconstruction.
Business model
Service provider - CRO, Service provider - CMO, Service
provider - Scientific.
Value chain
Research, Manufacturing, Preclinical,
Marketing / Distribution.
Activities
Diagnostics / Analysis method, Vaccine, Cell therapy,
Biomanufacturing, Models (animal - cellular - …), Biobank,
Drug discovery, Drug delivery, Other.
Company name: Biotem
Address: 250, route de Charavines
Zip code: 38140
City: Le Rivier d’Apprieu
Website: www.biotem.fr
Main activity
Expert in immunotechnologies, BIOTEM proposes the
development of monoclonal antibodies from the hybridoma
generation stages up to antibody production at any scale,
antisera production, antibody purification and modification,
immunoassay development and customised studies.
For more than 30 years, BIOTEM has developed a unique
expertise and a large panel of cutting edge proprietary
technologies. For most projects BIOTEM is proud to propose
contracts with guaranteed results.
Other status: Yes (ISO 9001v2008, CIR)
Funding
Application fields
Allergology, Orphan diseases, Genetic / Rare diseases,
Metabolic diseases, CNS related diseases, Cancer, Nutrition /
Food, Dermocosmetics, Other.
Activities
Company activities
Expert in immunotechnologies, BIOTEM is a contract research
organisation that complies with ISO 9001 quality standards.
Since its establishment in 1980, the company has been
the privileged partner of prestigious industrial and academic
laboratories for their research, development, diagnostics
and therapeutics projects.
Our services include the development of monoclonal antibodies
from the hybridoma generation stages up to in vitro or in vivo
antibody production at any scale, antisera production, antibody
purification and modification, immunoassay development
and customised studies.
Based on a high level of expertise and exclusive technologies,
BIOTEM implements the most relevant strategies for each
project and is pledged to achieve the results outlined
in the contract.
Know-how and 30 years experience - Exclusive technologies Results guaranteed (by contract) - Quality system accreditation
(ISO 9001) - Success rate (since 2005): 94,7%.
Company contact
CEO contact detail
First name: Clarence
Last name: Deffaud
Position: CEO / CSO
Phone: +33 (0)4 76 65 10 91
Recent news
Founded in 1980, BIOTEM is the first French CMO to have
proposed the production of customised monoclonal antibodies.
Today, BIOTEM actively continues its development and confirms
its position as a leader in the field of monoclonal antibodies..
Company services
– Human monoclonal antibodies development
– Generation of murine hybridoma
Genetic, substractive, in vitro immunizations, etc.
R.A.D: Rapid Antibody Development
– In vitro and in vivo production: bioreactors, CELLine,
production on nude mice, balb/c, etc.
– Antibody purification and modification
– Immunoassays design
– Polyclonal serum production and purification.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
39
Company name: Calixar SAS
Address: c/o IBCP 7, passage du Vercors
Zip code: 69367
City: Lyon
Website: www.calixar.com
Main activity: Production of integral and functional membrane
Business model
Product developer - Biopharmaceuticals, Service provider Scientific, Product developer - Pharmaceuticals.
Value chain
Activities
proteins / antigens in solution without denaturation Global
service : Protein design / Expression / Extraction and
Purification / Structural and functional Tests / Scale-up
Specific services : Crystallization tests / 3D Structure
determination.
Other status: Yes
Diagnostics / Analysis method, Vaccine, Biomanufacturing,
Drug discovery, Nanotechnology.
Funding
Activities
Application fields
Metabolic diseases, CNS related diseases, Cancer,
Dermocosmetics.
Company activities
Company contact
CEO contact detail
First name: Emmanuel
Last name: Dejean
Phone: +33 (0)6 84 04 95 34
Calixar has developped a new innovative and patented
technology for extraction of membrane proteins and antigens
without denaturation. The technology is based on a multi-step
extraction strategy and uses a specific serie of home-made
non denaturing detergents. Calixar offers its services
to industries (pharma, biopharma, biotech) and academic
teams which want to work on the right therapeutic or antigenic
targets and which want to master the production
of their target. The technology can be applied from gene
or from biological samples.
Non denaturing extraction technology All expression systems
compatible No refolding step Structural and functional control
of the target / antigen Global service from gene to protein
up to the structure Full-lenght/integral membrane protein
production in solution.
Recent news
Novacité Label in 2011 Lyon Science Transfer Prize 2010.
Skills and know-how
Biochemistry of proteins in particular membrane proteins
Molecular Biology Cellular Biology Crystallization of proteins
Organic chemistry.
40
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: Centre d’Immunologie Pierre Fabre
Address: 5, avenue Napoléon III
Zip code: 74160
City: Saint-Julien en Genevois
Website: www.cipf.com
Main activity: Research in cancer biotherapy.
Subsidiary of a group: Yes (Pierre Fabre Laboratories)
R&D PROJECTS FUNDED
OPTIMABS: Optimization of monoclonal antibodies drugability
by emergent analytical and structural methods: from lead to
clinical candidate.
Company contacts
CEO contact detail
First name: Nathalie
Last name: Corvaia
Phone: +33 (0)4 50 35 35 55
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Product developer - Biopharmaceuticals.
Value chain
Research.
Activities
Biomanufacturing, Drug discovery.
Application fields
Human health, Immunology, Cancer.
Activities
Company activities
A Centre of excellence in biotechnology, the Centre of
Immunology Pierre Fabre (CIPF) develops research programs
for cancer immunotherapy, in particular the identification
of therapeutic monoclonal antibodies. Since its inauguration
in 1990, the CIPF has acquired its renown through
the production of recombinant proteins and bacterial
biomasses. Research teams that were originally working
on vaccines have focused since 2003 on discovery
and characterisation of monoclonal antibodies in oncology.
The Research and Industrial Biotechnology departments
combine their specific know-how and expertise to identify
antibodies, specify their therapeutic properties and produce
them at industrial scale. Cancer immunotherapy has a key role
in antitumor therapy. The CIPF is at the cutting edge within
the industry and has now entered the ranks of the world’s top
R&D centres dedicated to antibody biotherapies.
41
Business model
Value chain
Research, Preclinical.
Activities
Diagnostics / Analysis method, Instrumentation.
Company name: cirma
Address: 1, avenue Bourgelat
Zip code: 69280
City: Marcy l’Etoile
Website: www.irm-animaux.fr
Turnover: 50171 Euros (in 2009)
Main activity: Design of new methods and instruments
for animal’s MRI
Background: The development of MRI in France is in two main
directions:
– clinical imaging at 1.5T and 3T,
– and pre-clinical studies on animals at very high field at 7 T
to 9.4 T. All these MRI systems are very expensive both
in acquisition and running costs. We propose new innovative
methods and instruments to take advantage of low field
permanent magnet MRI dedicated to medium size animal
studies. This low field system allows to drastically reducing
the costs without compromising image quality thanks to our
specific designs.
cirma is:
– available to veterinary practitioners to support their
diagnoses of animal from mice to anesthetized horses,
– able to perform preclinical longitudinal studies for health
industry,
– used to train veterinary students and others to practice MRI.
Other status: Yes
Funding
Public funding obtained: Rhone Alpes region 60 000 euros
in 2008 Faisabilty study OSEO 50 000 euros in 2008-2009 Cifre
ANRT 2009.
Company contacts
s c i e n c e s
d i r e c t o r y
Activities
Company activities
Although it is often thought that «bigger is better» low field
MRI have many advantages for veterinary medicine compared
to midfield or high-field MRI units. Advantages of low-field MRI
units include their larger gantry size and so the possibility to
image animals of various sizes like mice, rats, cats, dogs, ewes,
goats, pigs… So, “big” animal model like pigs can be used for
pre clinical studies (for example cardiovascular studies) with
lower purchasing and operating costs compared to a high field
MRI unit. A reduced image quality is often associated with low
field MRI: cirma expertise, with dedicated imaging protocols,
innovative radiofrequency coils design and new contrast agents,
considerably reduces the gap in image quality.
cirma is a start-up issued from Creatis (I. Magnin) a well
recognized research laboratory, among the leaders in medical
imaging.
cirma has a strong scientific expertise: all the permanent staff
is PhD.
cirma is located at the heart of the VetAgro-Sup campus
and has strong links with animal specialists.
cirma is a small company and Customer Service is the small
business advantage.
Company services
cirma believes in “one medicine”, and develops efficient
solutions for animal’s MRI:
– for diagnostic purposes on pets to help veterinary practitioner
– for longitudinal studies on important cohorts of animals
in preclinical studies.
Partnership
Other contact
First name: Hervé
Last name: Saint-Jalmes
Position: Research and development director
l i f e
Animal health, Metabolic diseases.
Engineering of MRI kits comprising optimized radiofrequency
coils and dedicated imaging protocols.
Keywords:
Open MRI, animal imaging, preclinical studies, radiofrequency
coils, imaging protocols.
CEO contact detail
First name: Marie José
Last name: Seurin
Position: CEO
Phone: +33 (0)4 78 87 56 53
42
Application fields
2 0 1 1
cirma is looking for partners
to apply its breakthrough technology and methods.
The know-how of cirma could be transferred to veterinary
practitioners wanting to develop animal’s MRI. cirma
methodology is also available to realize preclinical studies
at low cost, related to all medical specialties.
Company name: Clean Air Technologies
Address: 1, route du Dôme
Zip code: 69630
City: Chaponost
Website: www.catsas.com
Main activity
Established in 1998, Clean Air Technologies LTD is at the
forefront of Bio-containment and contamination control.
With a company ethos of Teamwork, Quality and Integrity we
seek to uphold our market position as a company synonymous
with professional, pragmatic, cost-effective, engineered
solutions to airborne contamination control issues.
Offering full support to Bio-containment & Cleanroom
operators on all levels, from conception of design through
to upgrading of existing facilities, Clean Air Technologies
have a full comprehension of the regulatory constraints
and standards.
In the 12 years of operation we have developed a loyal client
base throughout the pharmaceutical, Bio-containment
and Biotechnology industries.
Clean Air Technologies SAS was created to bring this depth
of experience and knowledge tied in with the business model
designed to reflect the needs of a regulated market to France.
Incubator: No
Subsidiary of a group: Yes (Sterigene / Clean Air Technologies)
Other status: No
Funding
d i r e c t o r y
Value chain
Activities
Other.
Application fields
Animal health, Pediatrics, Human health, Geriatrics,
Immunology, Inflammatory diseases, Infectious diseases,
Autoimmune diseases, Allergology, Orphan diseases,
Genetic / Rare diseases, Metabolic diseases, CNS related
diseases, Cancer, Nutrition / Food, Dermocosmetics.
Activities
Company activities
Established in 1998, Clean Air Technologies LTD is at the
forefront of Bio-containment and contamination control. With
a company ethos of Teamwork, Quality and Integrity we seek
to uphold our market position as a company synonymous with
professional, pragmatic, cost-effective, engineered solutions
to airborne contamination control issues.
Offering full support to Bio-containment & Cleanroom
operators on all levels, from conception of design through
to upgrading of existing facilities, Clean Air Technologies
have a full comprehension of the regulatory constraints
and standards.
In the 12 years of operation we have developed a loyal client
base throughout the pharmaceutical, Bio-containment
and Biotechnology industries.
Recent news
CEO contact detail
First name: John
Last name: Mumford
Position: Commercial Manager
Phone: +33 (0)6 01 59 12 17
s c i e n c e s
Business model
Clean Air Technologies SAS was created to bring this depth
of experience and knowledge tied in with the business model
designed to reflect the needs of a regulated market to France.
Company contact
l i f e
2 0 1 1
A Joint Venture has recently been signed which has led
to the creation of Clean Air Technologies SAS.
43
clininfo
Company name: Clininfo SA
Address: Entrée n°7 - 99, rue de Gerland
Zip code: 69007
City: Lyon
Website: www.clininfo.fr
Main activity
We apply a rigorous approach and proven methodologies
developed from our university clinical origins and through our
partnership with the C.R.O (Clinical Research Organization).
This rigour has ensured reliable data management for the past
20 years for some of the largest controlled studies ever done.
We put our adaptable expertise at your service to address
your particular needs.
Our scalable system can be adapted to your study, small or
large, and put into place quickly to manage data from several
dozen to tens of thousands of patients. This adaptability and
flexibility are reflected in our products as well as in the proven
skills of our team. Our systems are designed for interactivity
with you—our client.
Incubator: Yes (EZUS)
Other status: No
Business model
Service provider - CRO, Other.
Value chain
Research, Clinical, Other.
Activities
Diagnostics / Analysis method, Clinical trials, Preclinical trials,
Other.
Application fields
Autoimmune diseases, Allergology, Orphan diseases,
diseases, Cancer, Nutrition / Food, Dermocosmetics, Other.
Activities
Company activities
Our multilingual electronic case report form (eCRF) is built
on more than two decades of experience with databases
dedicated to clinical trials. The robustness of the concepts
and the data structures we use were validated by several dozen
studies, following phase IV tests in oncology (both hospital
and specialist). The integrated procedures in production,
development, test and maintenance were thoroughly audited
and fully documented in compliance with CFR 21, Part 11.
Adaptability, flexibility, and security of our products are our
strengths.
Our Data Management (DM) software, at your disposal, is
in conformance with the requirements of FDA 21, CFR Part 11.
It’s robust, reliable, and adaptable to your requirements.
Company contacts
Recent news
Funding
Our products were developed with the Clinical Pharmacology
Service at the University of Lyon, and so we have managed
many diverse projects:
– for more than 20 years
– at 20 client sites
– through 460 studies
– including 731,000 patients
– with 240 million variables
– through more than 14 on site audits
CEO contact detail
First name: Patrick
Last name: Chevarier
Position: C.E.O.
Phone: +33 (0)4 78 61 44 26
Other contact
First name: Myriam
Last name: Gherbia
Position: Personal Assistant
Phone: +33 (0)4 78 61 44 20
Fax: +33 (0)4 78 58 31 67
44
l i f e
s c i e n c e s
d i r e c t o r y
Skills and know-how
All of our experts are available to provide the training of your
choice for all of our services, at your site, in French or English.
You have the opportunity to benefit from their technical skills
and solid practical experience in their respective fields.
2 0 1 1
clininfo
Company services
Several quality levels are available at your request:
– simple data entry
– double entry, with or without adjudication
– double entry with double entry / difference checking
Initially integrated within a traditional CRO, our data entry
group has more than 15 years of experience. We have more
than 100 clinical trials, epidemiological records and studies
in diversified fields: oncology, cardiology, epidemiology,
psychiatry, diabetes, rheumatology, pediatrics, and economics
of health care.
We are also ready to work with you to develop any other
application in the medical field.
We dedicate part of our activity to developing new systems
in response to Requests for Proposals or for custom
systems. In this way, we have developed recording systems
for data collection on PCs, decentralized and autonomous
randomisation, clean monitoring, management
of correspondents, management of fees, and management
of bibliographies. We are available to study any situation where
specific data processing solutions are needed.
With our Data Management solutions, you need no longer
worry about technical difficulties. Trust your data to us remotely.
We offer two types of contracts for information management:
– Proportional fee, for individual study (for example, by the
number of characters entered, by the number of controlled
variables, by the number of edits and corrections, by the
number of randomised patients, etc.)
– Base cost fee, with the same types of invoicing as above, a
monthly minimum use, and some customisation for individual
studies.
Simplicity of use and high functionality are two strengths of our
data management solutions.
The different platforms (vocal server, modem, Internet,
telephone, fax) can be used interchangeably, because
they access the same database used for questionnaire
management and visit monitoring.
The following randomisation schemas are available:
– screening period
– factorial design
– cross-over, witness case studies, static randomisation
(stratification, permuted block), dynamic randomisation
(minimization)
– management of provisioning on all levels (tests, country,
regions, coordinators, centres).
Our standard service, available 24/7, is especially designed
for two applications:
– centralized randomisation
– self-evaluation (quality of life, evaluation of pain indicated by
the patient).
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
45
Business model
Company name: Compétence Biotech
Address: Lyonbiopole Business Center
Other.
Zip code: 69007
City: Lyon
Main activity: Competence biotech pools the competencies
Other.
321, avenue Jean Jaurès
defined by the biotech sector. Depending on the needs
expressed, the employees are recruited in partnership with
the biotech companies concerned. Factually, Quality Assurance
and Regulatory skills are most in demand.
Incubator: No
Other status: No
CEO contact detail
First name: Sylvie
Last name: Tournand
Position: Director
Phone: +33 (0)6 17 17 26 33
Other contact
First name: Thomas
Last name: Chuzel
l i f e
s c i e n c e s
d i r e c t o r y
Value chain
Activities
Other.
Application fields
Other.
Activities
Company activities
Competence Biotech pools the competencies defined
by the biotech sector. Depending on the needs expressed,
the employees are recruited in partnership with the biotech
companies concerned. Factually, Quality Assurance
and Regulatory skills are most in demand.
Company contacts
46
2 0 1 1
Proven skills: employees are senior. They provide a solid
experience, operational skills and strategic decision support.
Safety: a charter anticipates potential conflicts of interest,
in the interests of companies and employees. Sustainability:
the Competence Biotech employee is integrated
in the company’s team with no limited time.
Company name: Conidia
Address: 10, rue Raphaël Dubois
Zip code: 69622
City: Villeurbanne
Website: www.conidia.fr
Main activity: R&D in microbiology (in particular on mould
type micro-organisms).
Business model
Value chain
Research.
Activities
Other.
Application fields
Other.
Prize winner for innovative start-up: Yes (Novad’or 2009)
Activities
Company activities
CONIDIA is working on moulds in different activity
fields (pharmaceutical, phytosanitary, agro-alimentary,
microbiological air quality…). We propose services
of indentification by microscopy and molecular biology
and we have a research team to treat specific moulds
problematics.
Company contacts
Recent news
Funding
CEO contact detail
First name: Sébastien
Last name: Vacher
Position: CEO
Phone: +33 (0)4 72 43 10 43
Rewarded in 2009 by the Novad’or prize from the CCI of Lyon.
Other contact
First name: Catalina
Last name: Hernandez Fernandez
Phone: +33 (0)4 72 43 10 43
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
47
Company name: CoSMo
Address: 102, rue Montgolfier
Zip code: 69006
City: Lyon
Website: www.thecosmocompany.com
Turnover: 750000 (in 2011)
Other status: Yes
Funding
Company contacts
CEO contact detail
First name: Eric
Last name: Boix
Position: CEO
Phone: +33 (0)6 47 88 61 55
Other contact
First name: Hugues
Last name: de Bantel
Phone: +33 (0)6 22 42 95 67
48
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Research.
Activities
Diagnostics / Analysis method, Biomanufacturing, Clinical
trials, Preclinical trials, Bioinformatics / Modeling, Drug
discovery, Nanotechnology, Medical device, Drug delivery,
Other.
Application fields
Animal health, Human health, Immunology, Infectiology,
Aautoimmune diseases, Allergology, Orphan diseases,
Genetic / Rare diseases, CNS related diseases, Cancer,
Nutrition / Food, Dermocosmetics, Other.
Company name: CreaCell
Address: biopolis 5 avenue Grand Sablon
Zip code: 38700
City: La Tronche
Website: www.creacell.com
Main activity: CreaCell’s activity includes two domains:
development of «cardiac» Ion Channel Cell Lines for safety
pharmacology and Cell Culture Services for drug discovery.
Prize winner for innovative start-up: Yes (Emergence 2002)
Other status: No
Funding
Business model
Service provider - CRO, Product developer - Other health.
Value chain
Activities
Models (animal - cellular - …), Drug discovery.
Application fields
Food.
Activities
Company activities
Development and marketing of «cardiac» Ion Channel Cell
Lines for safety pharmacology is our first activity. The second
is Mammalian Cell Culture Services for drug discovery,
performed in our P2 laboratory. For eight years, our products
and services for mammalian cell-based research have been
distributing worldwide (North America - Europe - Asia)
to support R&D efforts of our customers.
Company contacts
CEO contact detail
First name: Pierre-Yves
Last name: Perche
Position: CEO
Phone: +33 (0)4 76 63 75 89
Other contact
Last name: Perche
Position: Marketing manager
Phone: +33 (0)4 76 63 75 89
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
49
Company name: CTI-Lyon / Cell Therapy Research Institute
Address: Parc technologique de Lyon St Priest
97, Allée Alexandre Borodine Cèdre 1
Zip code: 69800
City: St Priest
Website: www.cticell.org
Main activity: CTI-LYON studies adult and neonatal stem cell
populations to investigate biological systems regulating cell
proliferation and differentiation into endodermal, mesodermal
and ectodermal lineages. CTI-LYON developed and validated
a range of technologies enabling 2D and 3-dimensional tissue
engineering using bioreactors, biomaterials and clinical-grade
growth factors. CTI-LYON’s research applications include
bioassay development, drug screening platforms, biomedical
device, cGMP bioprocessing and clinical applications.
CTI-LYON runs pre-clinical and clinical programmes to enable
cell therapy applications for diabetes, stroke, cerebral palsy,
hematoimmunological diseases, cranio-facial malformations,
orthopaedic lesions, cancer. CTI-LYON develops 3D bioassays
for molecular screening and toxicology platforms from human
stem cells.
Incubator: No
Other status: Yes (CIR/JEI)
Funding
Company contacts
CEO contact detail
First name: Colin
Last name: McGuckin
Position: President
Phone: +33 (0)4 26 03 01 30
Other contact
First name: Nico
Last name: Forraz
Position: Vice-President
Phone: +33 (0)6 78 90 38 50
50
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Service provider - CRO, Service provider - CMO, Product
developer - Biopharmaceuticals, Service provider - Scientific.
Value chain
Activities
Diagnostics / Analysis method, Cell therapy,
Biomanufacturing, Models (animal - cellular - …), Biobank,
Preclinical trials, Drug discovery.
Application fields
Pediatrics, Human health, Immunology, Autoimmune
diseases, Genetic / Rare diseases, CNS related diseases,
Cancer.
Activities
Company activities
CTI-Lyon developed and validated a range of technologies
enabling 2D and 3-dimensional tissue engineering using
bioreactors, biomaterials and clinical-grade growth
factors. CTI-Lyon’s research applications include bioassay
development, drug screening platforms, biomedical device,
cGMP bioprocessing and clinical applications. CTI-Lyon runs
pre-clinical and clinical programmes to enable cell therapy
applications for diabetes, stroke, cerebral palsy, hematoimmunological diseases, cranio-facial malformations,
orthopaedic lesions, cancer. CTI-Lyon expertise grew from
haematology and oncology research and patient based therapy
including bone marrow disorders where stem cells fail to
grow. Using Cord Blood and Bone Marrow, we use normal
and abnormal stem cell populations to understand control
mechanisms including cytokine and transcriptional pathways.
This led us to investigate human “adult” and cord blood stem
cells for haematology-oncology transplantation. The noninvasive nature of collection umbilical cord and cord blood
offer a distinct advantage over any other sources of adult and
embryonic stem cells. Umbilical cord and cord blood cells can
be characterized and cryopreserved bio-banks worldwide.
With over 130 million children born each year, neonatal is
an abundant stem cell source from all genetic and ethnic
background.
Our research has shown that cells from all three germ layers
can be produced from umbilical cord, cord blood and bone
marrow stem cells. We have developed routine protocols for
isolation of defined cell populations from extremely immature
stem cell compartments, through to more mature progenitor
cells, which have allowed defined tissue engineering and
regenerative procedures to be advanced. The most significant
development of our work has been the development of a
protocol for the production of karyotypically normal Cord
Blood-derived Embryonic – like stem cells (CBE’s), which
have the ability to form embryoid body – like structures
and to express the majority of Embryonic Stem Cell markers.
It is also possible to subculture these cells for ex vivo
expansion for over 12 weeks, whilst maintaining their
immaturity. This research, published in 2005, is the first
production of a clone of embryonic – like cells from
a non-embryonic tissue.
We further demonstrated the pluripotent nature of umbilical
cord and cord blood stem cells that can be differentiated
into endodermal, mesodermal and ectodermal tissues
including neural, endothelial, hepatic, and pancreatic tissues.
Conventional cell culture methods employ 2D dimensional
culture systems to propagate cells in vitro. Although this
approach is useful to understand key biological features like
the cell cycle, growth factor stimulation, proliferation rates and
signal transduction, the large scale clinical grade ex-vivo tissue
and organ expansion generation calls for 3-dimensional Tissue
Bio-engineering. Our preliminary work with bioreactors has
demonstrated that they allow continuous rotation, expansion
and endogenous extracellular matrix production in a shear
stress-free environment favouring development into functional
3-D tissues. A key finding in this was our ability to expand,
maintain and differentiate CBE’s into hepatic and neural
progenitors in 3-dimensions with and without supporting bioscaffolds.
CTI-Lyon host a team of 15 international researchers
with extensive expertise in stem cell biology and cord blood
bio-processing as well as stem cell cultures and tissue
engineering.
Skills and know-how
Our group technical expertise includes 3-dimensional
tissue engineering and bioreactor systems, flow cytometry,
molecular biology, microarray, proteomics, laser-scanning
confocal microscopy, bioprocessing using adult (bone marrow,
adipose tissues, cornea) and neonatal stem cells (umbilical
cord, cord blood, placenta) as universal vectors for tissue
engineering, drug screening, cell therapy and regenerative
medicine research.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
51
Business model
Company name: Cylergie-Cofely’s Research & Development
Other.
Address: L’orée d’Ecully, chemin de la Forestière
Zip code: 69130
City: Écully
Website: www.cofely-gdfsuez.com
Founded in: 1988
Main activity: Research and development for the Cofely
Value chain
Center
activities: management and maintenance of energy production
installations.
Subsidiary of a group: No (GDFSuez)
Other status: Yes
Funding
R&D PROJECT FUNDED
COLLECTAIR: Development of an air sampling device
dedicated to bioaerosol analysis for healthcare center
Company contacts
CEO contact detail
First name: Jean
Last name: Roland
Position: Administrator
Phone: +33 (0)1 41 20 10 00
Other contact
First name: Patrick
Last name: Haenel
Position: Manager
Phone: +33 (0)4 72 86 09 80
Fax: +33 (0)4 78 43 30 59
52
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Other.
Activities
Other.
Application fields
Activities
Company activities
Research and technical support (marketing,assistance
expertise, lobbying, training) on following subjects:
– District Heating (& Cooling ) Networks
– Energy Management
– Metrology, Automation, Remote Systems, Indicators
– Renewable Energies, New Energy Technologies
– Environnement, Health, Comfort.
Activities
Company activities
Cynbiose is a new company meeting the needs of public
and private companies involved in drug development
and biomedical research.
Where as larger CROs already propose standard regulatory
studies, Cynbiose is one of the rare European private
companies with expertise in primatology, which carries
out exploratory studies with the aim to reduce time
of drug development. Cynbiose allows private and academic
researchers to access NHP models with support to face high
level of constraints due to the use of this sensitive animal
model (regulatory, sanitary, technical, ethical and economical
aspects).
Company name: Cynbiose
Zip code: 69280
Main activity: Cynbiose is a preclinical assesment platform
dedicated to the use of Non Human Primates (NHP) models
for biomedical research.
Incubator: No
Other status: Yes
Funding
Company contact
CEO contact detail
First name: Hugues
Last name: Contamin
Position: CEO
Phone: +33 (0)6 62 74 35 66
Business model
Service provider - CRO, Service provider - Scientific.
Activities
Vaccine, Models (animal - cellular - …), Preclinical trials, Drug
discovery, Drug delivery, Other.
Application fields
Pediatrics, Human health, Geriatrics, Immunology,
Inflammatory diseases, Infectious diseases, Autoimmune
diseases, Orphan diseases, Metabolic diseases, CNS related
diseases, Cancer.
s c i e n c e s
d i r e c t o r y
Cynbiose is also supported by different scientific experts
for the development of innovative protocols on NHP.
Cynbiose is also member of the world-class competitiveness
cluster “Lyonbiopole”, to set-up scientific collaborations
with national and international companies.
– Animal facility with a high capacity (100 animals of different
reliable NHP species) - biosafety level 1 and 2
– Expertise
– Flexibility and Reactivity
– Strategic Partners
– Innovative Models developed in partnership
– Science, Quality and Animal Welfare.
Recent news
Research and development programs in progress since 2009:
“Bioavailibility of new pharmacological approaches to study
neurodegenerative diseases”: partnership with CNRS (Institut
des Maladies Neurodégénératives de Bordeaux) and Motac
SA.
“Development of non-human primate models for preclinical
assessment of innovative osteoarthritis treatments”:
partnership with Voxcan SARL and Bone Therapeutics SA;
Grant Eurostars. Perspectives: GLP and AAALAC authorized in
2011.
Skills and know-how
Value chain
l i f e
Cynbiose collaborates with strategic partners dedicated
to the use of NHP in research:
– the testing facilities are located at the Institut Claude
Bourgelat at the National Veterinary School of Lyon (VetAgeo
Sup, Marcy l’étoile),
– Bioprim (Bazièges, France) is the only one private company
in France dedicated to the import and quarantine of NHP
for research with high sanitary controls,
– breeding colonies supply the NHP with high quality
standards.
2 0 1 1
– Expertise in NHP models from import, quarantine, housing,
ethical, sanitary, technical and veterinary aspects
to the development of protocols and data analyses.
– Development of innovative models in immunology,
neuroscience, infectious and metabolic diseases implying
the use of innovative technologies for non invasive approaches
(imaging, telemetry, video-monitoring).
– Focused on ethics with the development of an Animal Welfare
program (AAALAC accreditation expected in 2011).
53
Business model
Value chain
Manufacturing.
Activities
Other.
Application fields
Human health, Inflammatory diseases, Infectious diseases,
Autoimmune diseases, Orphan diseases, Metabolic diseases,
CNS related diseases, Cancer, Dermocosmetics.
Activities
Company activities
Cytoo focuses on innovative products for the life science
research market with an emphasis in cell based assays,
high content analysis and cell screening.
Company name: Cytoo SA
Address: 7, parvis Louis Néel
Zip code: 38040
City: Grenoble
Website: www.cytoo.com
Main activity: We develop, manufacture, and distribute
products that make cellular analysis robust and reliable
by drastically decreasing cell variability.
Our new micropattern-based products are designed to meet
the needs of all clients whatever their research goals in cell
biology research, cell based assays and cell screening for drug
discovery.
(Creation Development 2008)
Funding
Private funding obtained: June 2008: €1M July 2009: € 3.2 M
Cytoo was incorporated in France in June 2008 and
established its premises at the heart of Grenoble’s micro and
nanotechnology innovation center MINATEC after closing a
seed round of 1 M€ with CEA Investissement, Rhone Alpes
Creation and private investors. That same year, Cytoo was
rewarded at both the Startup competition of the French
Ministry for Research and the «Tremplin Entreprises»
of the French Senate.
Recent news
In July 2009, Cytoo raised € 3.2 M (US$ 4.8 M) in a VC round
with AURIGA Partners and previous private investors
and in September opened a US subsidiary in Massachusetts.
In January 2010, Cytoo’s headcount scores 15 including
8 PhDs.
Skills and know-how
Cytoo’s technology is a revolutionary discovery of the Institut
Curie in Paris, based on the exquisite control of the cell’s
microenvironment and offering an entirely new way of looking
at cellular behavior. Specific designs of adhesive micropatterns
not only control the shape and location of individual cells,
but also control internal cell organization down
to the position of the organelles. Cytoo’s manufacture is based
on microelectronic processes such as photolithography.
Company contact
Cytoochip: micropatterned glass chips for cell analysis in the
research market
Cytooplate: micropatterned microplates for High Content
Analysis in cell screening.
CEO contact detail
First name: François
Last name: Chatelain
Position: President and CEO
Phone: +33 (0)4 38 88 47 05
Partnership
Looking for partners in projects
for FP7, EUREKA, ANR, IMI.
OEM with Life Science Tools companies, cell based assay kit
providers, etc.
54
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Company name: DAMsi
Address: World Trade Center Cité Internationale
Other.
Zip code: 69006
City: Lyon
Website: www.damsi.fr
Main activity: Automated & integrated solutions to secure
Marketing / Distribution, Other.
15, quai Charles de Gaulle
and monitor the medicines distribution circuit.
Incubator: No
Other status: No
Value chain
Activities
Drug delivery, Other.
Application fields
Human health, Geriatrics, Other.
Activities
Company activities
Consulting, Research & Development, Software editor,
Integration. French distributor of Japanase Tosho Inc., world
leader in medicines dispensing machines. French distributor
of English Stripfoil systems, automatic deblistering systems.
Company contacts
CEO contact detail
First name: Claire
Last name: Tredez
Phone: +33 (0)4 26 68 38 00
Other contact
First name: Stéphane
Last name: Mellet
Position: Director / Partner
Phone: +33 (0)4 26 68 38 00
Fax: +33 (0)4 72 40 57 08
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
55
Company name: Dendritics
Zip code: 69008
City: Lyon
Website: www.dendritics.net
Main activity: Dendritics develops and markets monoclonal
antibodies targeting the dendritic cells and their microenvironment, thus providing tools for research and diagnostic.
Dendritics also proposes on-demand generation of monoclonal
antibodies. Dendritics develops innovative tools and processes
intended for the scientific community.
Other status: Yes
Funding
Company contacts
CEO contact detail
First name: Jean-Jacques
Last name: Pin
Position: Head and Founder
Phone: +33 (0)6 89 01 11 81
Other contact
First name: Diane
Last name: Razanajaona-Doll
Phone: +33 (0)4 72 71 74 03
Fax: +33 (0)4 78 00 14 36
l i f e
s c i e n c e s
d i r e c t o r y
Business model
Service provider - Scientific, Product developer - Other health,
Other.
Value chain
Research, Manufacturing, Preclinical, Marketing / Distribution,
Clinical, Other.
Activities
Diagnostics / Analysis method, Models (animal - cellular - …),
Application fields
Allergology, Orphan diseases, Cancer, Other.
Activities
Company activities
Generation and marketing of murine monoclonal antibodies
Generation of murine monoclonal antibodies on-demand
Development of innovative processes intented for the scientific
community.
56
2 0 1 1
DExtérité
Surgical
Company name: Dextérité Surgical
Address: 1, rue des Glières
Zip code: 74000
City: Annecy
Main activity: Develop, manufacture and sale innovative
Business model
Value chain
Activities
Medical device.
instruments for laparoscopic surgery.
Application fields
(Création-développement - 2008)
Activities
Human health.
Company activities
Funding
Nature of funding searches: 2nd round of financing planned
for Q4 2011.
Private funding obtained: First round of € 950K closed in
october 2010
Public funding obtained: Prize-winner of the national
competition for innovative start-up: € 300 K
Patients, medical community and health care payers are all
asking for an even faster development of Laparoscopic Surgery.
More than 6 millions patients did benefit from this surgery
last year. Unfortunately, this minimal invasive surgery is much
more difficult to perfrom and requires a long training and high
dexterity. The only existing tool to ease this technique is a very
expensive and cumbersome heavy Robot. Dextérité Surgical is
helping surgeons to perform laparoscopic surgery by providing
them with easy to use and cost effective instruments. The first
of which is an «Hand Held Robot» for laparoscopic surgery that
costs 10 times less than the existing heavy Robot.
Company contact
CEO contact detail
First name: Pascal
Last name: Barrier
Position: CEO
Phone: +33 (0)9 70 44 07 82
Over 70 years of added experience in the Medical Device
industry (EU and US) for 3 of the founders. Agile, and cost
effective to maximize ROI. Innovative products in a fast growing
market.
Recent news
The first clinical use of the «Hand Held Robot» for laparoscopic
surgery is planned for the first half of 2011.
Pipeline product 1
Therapeutic area: Laparoscopic surgery
Partnership
We would be delighted to discuss partnership with companies
developing 3D / enhance vision for laparoscopic surgery.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
57
Business model
Company name: Drive
Address: 14, place Jules Ferry
Zip code: 69006
City: Lyon
Website: www.driveimplants.com
Main activity: Conception, manufacturing and marketing
Other status: No
Activities
Funding
Nature of funding searches: Oseo fundings innovation:
€ 100 K€, I-declik fundings: € 80 K, Bank findings: € 150 K,
Private fundings: €150 K.
Private funding obtained: Individuals findings
Public funding obtained: See above
Recent news
of innovative dental implants range.
Value chain
Research, Manufacturing, Marketing / Distribution, Clinical.
Activities
Medical device, Other.
Application fields
Human health.
Company activities
Dental implants conception, manufacturing and sales.
Innovation, Research and development, High-tech marketing,
International: North Africa and Eatern Europe.
Launching of a very innovating dental implant range
with prosthetical and ancillary.
Skills and know-how
Company contacts
CEO contact detail
Last name: Fromental
Position: CEO
Phone: +33 (0)9 62 30 67 27
Other contact
First name: Ivan
Last name: Blondet
Position: Secrétaire Général
Phone: +33 (0)9 62 30 67 27
30 years experience and expertise in dental implantology,
dental implantology cluster, dental implantology academy,
dental implantology pilot center, dental implantology supply
chain, dental implants manufacturing.
Company services
All services concerning dental implantology specially dental
implants and training units for implantologists.
Patented innovative dental implants.
Partnership
Exploitation licence of patented implantary systems.
Creation of innovative dental implantology companies cluster,
pole of excellency.
58
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Activities
Company activities
Company name: Écrins Therapeutics
Address: BIOPOLIS, 5 avenue du Grand Sablon
Zip code: 38700
City: La Tronche
Website: www.ecrins-therapeutics.com
Main activity: Écrins Therapeutics is a biotechnology company
which focuses on the discovery and development of novel small
molecule drugs that are intended as cancer therapies.
The company aims to develop these potential new drugs
from the preclinical phase to phase 2 clinical proof of concept.
Incubator: Yes (grain)
(2009 -“Emergence”; 2010 - “Création-Développement”)
Other status: Yes (CIR, JEI)
Funding
Nature of funding searches: Founded in 2010 with a vision
to fight cancer, Ecrins Therapeutics is also committed
to delivering value to its shareholders. We are interested
in the investment and/or development partners, who could
speed up the progress of our technology to the market place.
Public funding obtained: Canceropôle CLARA, 2009, € 478 K
MESR/OSEO, «Emergence», 2009, € 26 K
MESR/OSEO, “Création-Développement” , 2010, € 220 K
Drawing on a range of core competencies including
phenotypical and “traditional” high-throughput screening,
microscopy, chemistry R&D, medicinal chemistry, molecular
modeling and animal cancer models, Ecrins Therapeutics
discovers and develops bioactive small molecules.
Original technology; Strong intellectual property; Our lead
clinical candidate shows a strong in vivo activity against human
cancers and is well tolerated by animals.
Recent news
Our lead candidate ET-D5 is an anti-mitotic and anti-vascular
compound. The latter exist in two different classes:
– anti-angiogenic;
– vascular-disrupting agents (VDA). The difference between
them is that while the anti-angiogenic drugs prevent neovessels formation in the growing tumor, the VDA, for example
ET-D5, physically disrupt already established tumor vessels.
The destruction of blood vessels by ET-D5 effectively shuts
down the supply of O2 and nutrients to cancer cells and
provokes a massive intratumoral necrosis. Another mechanism
by which ET-D5 targets cancer cells, is by arresting them
in division (mitotic arrest), followed by cell death. Most
importantly, ET-D5 presents interesting pharmacological
properties, good toxicology profile and is active when
administered per os.
Skills and know-how
Discovery and characterization of bioactive small molecules;
Preclinical developement of anticancer drug candidates.
Pipeline product 1
Therapeutic area: oncology
Therapeutic indication: solid cancers
Preclinical: proof of concept
Company contact
CEO contact detail
First name: Andrei
Last name: Popov
Position: Researcher Inserm
Phone: +33 (0)6 50 63 34 04
Drawing on a range of core competencies including
phenotypical and “traditional” high-throughput screening,
microscopy, chemistry R&D, medicinal chemistry, molecular
modeling and animal cancer models, Ecrins Therapeutics
discovers and develops bioactive small molecules.
Partnership
Business model
We are open to collaboration proposals.
Value chain
Activities
Bioinformatics / Modeling, Drug discovery, Other.
Ecrins Therapeutics seeks outstanding partners in the
pharmaceutical industry
to implement challenging technology programs, essential
to its growth. We would be interested in discussing joint venture
proposals with regards to the following products: ET-D5.
Application fields
diseases, Autoimmune diseases, Orphan diseases, Cancer.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
We are ready to discuss sub-licencing opportunities for our lead
candidate ET-D5.
59
Business model
Value chain
Manufacturing, Marketing / Distribution.
Activities
Medical device, Drug delivery.
Application fields
Human health, Cancer.
Activities
Company activities
Company name: EDAP TMS France
Address: 4, rue du Dauphiné
Zip code: 69120
City: Vaulx-en-Velin
Website: www.edap-tms.com
Main activity: Development and marketing of high-technology,
EDAP TMS France develops and markets Ablatherm, the
most advanced and clinically proven choice for high-intensity
focused ultrasound (HIFU) treatment of localized prostate
cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for
patients with localized prostate cancer (stages T1-T2) who are
not candidates for surgery or who prefer an alternative option,
or for patients who failed radiotherapy treatment. Approved in
Europe as a treatment for prostate cancer, Ablatherm-HIFU
(High Intensity Focused Ultrasound) is currently undergoing
evaluation in a multicenter U.S. Phase II/III clinical trial
under an Investigational Device Exemption granted by the
FDA, the ENLIGHT U.S. clinical study. The Company also
is developing this technology for the potential treatment of
certain other types of tumors. EDAP TMS SA also produces and
commercializes medical equipment for treatment of urinary
tract stones using extra-corporeal shockwave lithotripsy
(ESWL). For more information on the Company, please visit
www.edap-tms.com, www.hifu-planet.com.
minimally invasive medical devices using therapeutic
ultrasound for the treatment of localized prostate cancer
and urinary stones.
Incubator: No
Subsidiary of a group: Yes (EDAP TMS SA (Holding))
Other status: No
Funding
as Japanese approval. Ablatherm-HIFU addressing prostate
cancer under IDE clinical trials in the US. European Launch of
Sonolith i-move compact lithotriptor (CE marking obtained).
Public funding obtained: OSEO: € 300 K / 3 years /2008 ANR:
€ 212 K / 3 years / 2010 OSEO: € 65 K / 3 years /2008
Expert and leader in the development of innovative therapies
using ultrasound (HIFU and shockwaves). trong cooperation
with INSERM and partnerships with local and international
University Hospitals. International distribution network
(Subsidiaries in Germany, Italy, USA, Japan, Malaysia, Korea).
Recent news
€ 510 K FDA (US) approval of Sonolith I-sys lithotriptor as well
Skills and know-how
NASDAQ market in New York since 1997.
Strong knowledge and know-how in the development of
focused therapteutic ultrasound for medical applications
(Strong IP) Expertise in navigating approval processes for
medical devices (FDA, CE marking, Japanese approvals…)
Strong ability to manage clinical trials to validate technologies.
Company contacts
Stock exchange listing: EDAP TMS SA (Holding) is listed on
CEO contact detail
First name: Marc
Last name: Oczachowski
Position: President
Phone: +33 (0)4 72 15 31 50
Other contact
Last name: Blanc
Position: VP Research & Development
Phone: +33 (0)4 72 15 31 50
Fax: +33 (0)4 72 15 31 51
Pipeline product 1
Therapeutic area: Urology: extracorporeal lithotripsy
Therapeutic indication: Urinary stones
MA: Sonolith i-sys & Sonolith i-move lithotriptors
Pipeline product 2
Therapeutic area: Urology
Therapeutic indication: Localized Prostate cancer using HIFU
MA: Ablatherm-HIFU
Pipeline product 3
Therapeutic area: Gastro-enterology
Therapeutic indication: liver metastasis using HIFU
High Intensity Focused ultrasound, Shockwaves, Hardware,
Software.
60
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Research.
Activities
Application fields
diseases, Autoimmune diseases, Orphan diseases, Genetic
/ Rare diseases, Metabolic diseases, CNS related diseases,
Cancer, Dermocosmetics.
Company name: Edelris
Zip code: 69003
City: Lyon
Website: www.edelris.com
Main activity: Founded in early 2005 by a group of senior
managers with extensive drug discovery expertise
from Life-Science organizations, Edelris is a privately-owned
research and services company offering original natural
product-like collections of screening compounds, innovative
fragments for FBDD and efficient hit/lead optimisation
capabilities.
(French Ministery of Research 2004 & 2005)
Other status: Yes
Funding
R&D PROJECT FUNDED
NATHEB: New therapeutic approaches in the treatment of
chronic hepatitis B
Activities
Company activities
Edelris’ Keymical CollectionsTM
Designed to interact highly favourably with biological
systems, these non-exclusive libraries of natural product-like
compounds dramatically increase the potential to find viable
hits with an enhanced probability to lock/unlock biological
targets. At present, Edelris offers more than 15 original
collections comprising 500-1,000 molecules per family
and representing a total of over 9,000 potential hits with an
average purity of 95%. Major Pharmas and Biotech companies
have already recognized the potential of these innovative
compounds. Edelris’ Smart Fragments: Fragment-based Drug
Discovery represents an emerging and valuable tool to enhance
the reliability of the Discovery process, and several companies
have already identified clinical candidates based on this
strategy. Based on its Medchem expertise and using structural
information obtained from crystallographic studies, Edelris is
proposing innovative and soluble 3D fragments highly enriched
in biorelevant motives. Experienced medchem for optimisation
As well as its Keymical Collections and Smart Fragments,
Edelris provides a lead optimisation and fine tuning services
based on the company’s extensive knowledge in drug discovery.
Edelris is well equipped for fine tuning early - or late-stage
drug candidates, and works in close collaboration with
customers ranging from biotech start-ups to major pharmas.
The company operates state-of-the-art laboratory facilities in
Lyon, France.
Recent news
Future goals
Edelris has set itself ambitious objectives for the near future,
including the development and commercialisation of new
Keymical series for 2010-2012 and others services.
Edelris has already attracted several partners from Europe,
Japan and the USA, for both hit-finding activities using the
Keymical Collections and for hit/lead optimisation research.
Skills and know-how
Company contacts
CEO contact detail
First name: Jean-Yves
Last name: Ortholand
Position: CEO
Phone: +33 (0)4 37 56 19 01
Chemical library synthesis; Medicinal chemistry; Total
synthesis of natural products.
Company services
Medicinal chemistry; Chemical library synthesis.
Other contact
First name: Didier
Last name: Roche
Position: Director Strategy & Innovation
Phone: +33 (0)4 37 56 16 60
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Capabilities at Edelris include 700 m2 laboratory facilities
equipped with state of the art chemistry, analytical and robotic
equipment. Bruker ARX 300 NMR; MS coupled analytical
and preparative HPLCs (Waters Micromass ZMD and ZQ
sources); Kuka robot and Gilsons liquid handlers for high speed
chemistry and reliable sample processing; Biotage Flash 40/75
purification systems and Genevac HT4 and HT4X evaporators;
H-cube microreactor; Electronic laboratory notebooks for
secure information and data handling.
61
Company name: Elicityl
Address: 746, avenue Ambroise Croizat
Zip code: 38920
City: Crolles
Website: www.elicityl.com
Main activity: Elicityl’s mission is to supply oligosaccharides
and polysaccharides for biomedical, cosmetic, nutraceutical
and plant health applications. Elicityl develops its competences
for complex sugar production and valorization.
(2000 Emergence - 2001 Développement)
Other status: Yes
R&D PROJECT FUNDED
CARBINFEC: The development of an oligosaccharide library
toward new antiviral therapies
Company contacts
Other contact
First name: Benoît
Last name: Darblade
Position: Healthcare program manager
Phone: +33 (0)4 76 40 71 61
Fax: +33 (0)4 76 45 59 50
l i f e
s c i e n c e s
d i r e c t o r y
Business model
Service provider - CMO, Service provider - Scientific, Product
Value chain
Activities
Biomanufacturing, Other.
Application fields
Animal health, Human health, Nutrition / Food,
Dermocosmetics, Other.
Activities
Company activities
Elicityl is a biotech company focused in complex sugar
engineering and production. Elicityl supplies oligosaccharides
and polysaccharides for biomedical, cosmetic, nutraceutical
and plant health applications. Elicityl proposes two
commercial offers: - OligoTech®: offer of oligosaccharides
and polysaccharides extracted from biomass, produced by
bacterial fermentation and potentially modified thru chemical
functionalization. The OligoTech® offer encompasses Catalogue
of Complex sugars and Customized delivery. - Complex sugars
for plant health: Elicityl commercialises PEL101GV®, an
oligosaccharide extracted from apple which enhances natural
resistance of vineyard to spring frost. PEL101GV® is approved
as a phytopharmaceutical product.
Skills and know-how
CEO contact detail
First name: Joël
Last name: Monnier
Position: President
Phone: +33 (0)4 76 40 71 61
62
2 0 1 1
These offers are based on Elicityl know-how in production,
extraction, purification and fine characterization of complex
sugars obtained thru proprietary industrial production means.
Exclusively, our original technology allows highly purified
oligosaccharides production from the mg to the kg scale.
The OligoTech® offer gives business opportunities using
the untapped variety of complex sugars in compliance with
all aspects of regulation.
Company contacts
CEO contact detail
First name: Pierre-Olivier
Last name: Goineau
Position: CEO
Phone: +33 (0)4 78 74 44 38
Company name: ERYtech Pharma
Address: Bâtiment Adénine, 60, avenue Rockefeller
Zip code: 69008
City: Lyon
Website: www.erytech.com
Main activity: ERYtech Pharma is a specialty pharma company
developing new generation medicinal products through
encapsulation of drugs into red blood cells. It is developing
a pipeline of innovative personalized medicine therapeutics
addressing current specific unmet clinical needs. It creates
high value products, mainly in oncology, hematology and
immunology fields.
Products based on ERYtech Pharma’s technology are safe
and offer innovative therapies for hospital market. Thanks to its
unique technology, ERYtech Pharma is able to load red blood
cells with therapeutic molecules while keeping red blood cells
natural properties. It has a first clinical success with its lead
compound Graspa®, which demonstrated positive results
and excellent safety profile in Phase II trials.
ERYtech Pharma’s business and revenue model is both:
– an integrated business and revenue model for proprietary
product to maximize value creation
– a business development revenue model based on its R&D
platform and partnership.
Other status: Yes (JEI and CIR)
Other contact
First name: Yann
Last name: Godfrin
Position: EVP and CSO
Phone: +33 (0)4 78 74 44 38
Fax: +33 (0)4 78 75 56 29
Business model
Value chain
Activities
Cell therapy, Biomanufacturing, Clinical trials, Preclinical trials,
Drug delivery.
Application fields
Funding
Private funding obtained: June 2006: 12 Millions Euros
Human health, Immunology, Inflammatory diseases,
Autoimmune diseases, Orphan diseases, Genetic / Rare
diseases, Metabolic diseases, Cancer.
Public funding obtained: Since 2008
2008: € 600 248 / subsidy; 2009: € 766 951 / subsidy, € 215 k /
repayable advance; 2010: € 77 505 / subsidy
Activities
June 2010: 5,2 Millions Euros
R&D PROJECTS FUNDED
GR-CAV1: A novel immunotherapy approach for cancer
with Vaccin’ERY System®
POLYBIO: Innovative plastics for a better packaging
of pharmaceutical products
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company activities
ERYtech Pharma has a first clinical success with its lead
product Graspa® (new medicinal product consisting
in L-asparaginase entrapped into human homologous red
blood cells) which was an opportunity to validate its industrial
process.
Three clinical trials are currently ongoing for this product:
– Phase III in relapsed and allergic Acute Lymphoblastic
Leukemia (ALL) patients
– Phase II as first line in patients with ALL aged 55 and older
– Phase I in pancreatic adenocarcinoma.
63
ERYtech Pharma has also several projects in preclinical / proof
of concept status. It is developing its technological platform
with partners or alone by looking for new product candidates to
load into red blood cells.
Thanks to the specific technology developed by ERYtech
Pharma, a powerful platform has been validated:
– to develop new products with long circulating action with no
release of the compounds:
– bio-reaction into the red cells
– oxygen-hemoglobin affinity reduction
– to rapidly target specific cells involved in the
erythrophagocytosis (Kupffer cells, dendritic cells,
macrophages): immune modulation platform:
– immuno-inflammation
– immune tolerance induction
– immuno stimulation
The ambition of the company is to become a world leader in
the pharmaceutical industry using red blood cells.
– Thanks to its unique ant patented technology, ERYtech
Pharma is the only company in the world able to load red blood
cells with therapeutic molecules at industrial scale
– Its first clinical success was an opportunity to validate its
industrial process, its very good reproducibility and the logistic
aspects involved in treating patients
– Its technological platform offers large possibilities to create
new products and strong intellectual property
Recent news
– ERYtech Pharma and Genzyme Corporation sign
collaborative research agreement in rare diseases
– ERYtech Pharma signs an agreement with M. D. Anderson
Cancer Center to develop a companion test for Graspa® in solid
tumors
– FDA grants Orphan Drug Designation to Graspa® for
treatment of Acute Lymphoblastic Leukaemia
Skills and know-how
ERYtech Pharma has built a strong pipeline with very
ambitious programs based on its proprietary technology and
expertise in the physiological properties of erythrocytes. The
ambition of the company is to become a world leader in the
pharmaceutical industry using red blood cells.
Pipeline product 1
Therapeutic area: hemato/oncology
Therapeutic indication: relapsed Acute Lymphoblastic
Leukemia in children and adults
Phase 3: Graspa
Pipeline product 2
Therapeutic area: hemato/oncology
Therapeutic indication: relapsed Acute Lymphoblastic
Leukemia in older
Phase 2: Graspa
Pipeline product 3
Therapeutic area: oncology
Therapeutic indication: pancreatic adenocarcinoma
Phase 1: Graspa
64
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Thanks to its unique ant patented technology, ERYtech Pharma
is the only company in the world able to load red blood cells
with therapeutic molecules at industrial scale.
Main competitive advantages of its process are:
– an industrial process including automated steps
– product manufacturing requires only 2-3 hours
– its reproducibility: the loading of drugs into the red blood
cells is made with constant quality, whatever their initial
characteristics and origin (autologous or homologous)
– its specificity: the product is personalized and it will be
considered as a single batch
– its safety: the therapeutic index of encapsulated drugs is
improved compared to conventional therapies.
Partnership
ERYtech Pharma is opened to discuss partnership
opportunities with pharma/biotech companies dealing with:
– its own proprietary products
– its technological platform.
ERYtech Pharma welcomes partnership discussions on
entrapment of therapeutic molecules to develop new high
value products mainly in these therapeutic areas:
– immune tolerance induction (entrapment of therapeutic
proteins eliciting inhibitors or neutralizing antibodies or
proteins/antigens/peptides eliciting autoimmune diseases)
– active immunotherapy (entrapment of antigens/adjuvants)
– inflammatory diseases, infectious diseases, autoimmune
diseases (entrapment of compounds with anti-inflammatory
properties).
Business model
Value chain
Activities
Biomanufacturing, Drug discovery, Nanotechnology, Drug
delivery, Other.
Application fields
Animal health, Human health, Cancer, Nutrition / Food, Other.
Company name: ESRF
(European Synchrotron Radiation Facility)
Address: 6, rue Jules Horowitz
Zip code: 38043
City: Grenoble
Website: www.esrf.eu
Main activity: The European Synchrotron Radiation Facility
(ESRF) is the world’s most successful third-generation
synchrotron X-ray research centre. Owned and financed
by 18 European countries and Israel, it offers academic
and industrial researchers a world-class array of powerful
X-ray beams to explore the microstructure of matter and
materials, like protein and drug structures at high resolution,
and high speed and throughput. The ESRF facilities and expert
scientists are available for industrial R&D through purchasing
services, contract research and joint research programmes.
Incubator: No
Other status: Yes (CIR)
The key techniques used by pharma and biotech to accelerate
R&D programmes and achieve breakthroughs in innovation
are (a) protein crystallography to speed up lead optimisation,
fragment-based screening and tackle challenging protein
crystallographic projects with structural biology data (b) high
resolution powder diffraction for drug characterisation and
polymorphism studies (c) high resolution (sub-micron) X-ray
tomography with phase contrast for visualising 3D images
of (e.g.) drug delivery systems.
All ESRF clients can count on the full cooperation
of the facility’s 400 expert scientists, engineers and technicians
who, every year, work closely with 4,000 researchers
from all horizons. Its academic and industrial user community
is made up of over 10,000 international scientists working
in both pure and applied research. The ESRF’s collaborative
research culture is an integral part of its service offer, ensuring
that its industrial clients obtain the best results from
the facility.
Company services
Company contact
CEO contact detail
First name: Edward
Last name: Mitchell
Position: Business Development Manager
Phone: +33 (0)4 76 88 26 64
s c i e n c e s
Company activities
Funding
l i f e
Activities
d i r e c t o r y
2 0 1 1
- Structural Biology: Our team of expert scientists with 15 years
experience working with pharma and biotech get the best
out of your samples with the full-service MXpress™, or bring
the power of the synchrotron to the comfort of your lab with
secured remote control from anywhere in the world. We also
offer comprehensive crystallisation-to-structure services
for when you need to fully outsource a project.
- X-ray powder diffraction and 3D tomography: Our 35 other
leading beamlines offer mail-in high-resolution powder
diffraction (formulation and polymorphs) and sub-micron
3D tomography (API distribution) amongst other powerful
techniques.
65
Company name: Estenity
Address: Villa Créatis - 2, rue des Mûriers
Zip code: 69009
City: Lyon
Website: www.estenity-europe.com
Main activity: Estenity is dedicated to the development of
natural high purity excipients for the cosmetic and dermocosmetic industries.
Incubator: Yes (Pepiniere Laennec)
Subsidiary of a group: Yes (Kokyu Alcohol Kogyo Co)
Other status: No
Research.
Activities
Other.
Application fields
Dermocosmetics.
Activities
Company activities
Recent news
Development of new ingredients issued from sugarcane
and new sustainable vegetal sources.
Other contact
First name: Christel
Last name: Lorenzi
Position: R&D laboratory Manager
d i r e c t o r y
Value chain
– a close partnership with our R&D la in Japan
– a huge know-how and a great expertise in the cosmetic field
– natural, vegetal-oriented research.
CEO contact detail
First name: Kiyotaka
Last name: Kawai
Position: CEO
Phone: +33 (0)4 26 23 41 30
s c i e n c e s
Company contacts
l i f e
Business model
Estenity is dedicated to the development of natural high purity
excipients for the cosmetic and dermo-cosmetic industries.
Its application laboratory also develops application formulas
to illustrate our ingredients and prove their effects
in cosmetics.
Funding
66
2 0 1 1
Company name: Ethera
Zip code: 38040
City: Grenoble Cedex 9
Website: www.ethera-labs.com
Main activity: Ethera develops and markets measuring kits
for indoor chemical pollution.
Business model
Laboratory equipment supplier, other.
Value chain
Manufacturing.
Activities
Nanotechnology.
Application fields
Human health.
Other status: Yes
Activities
Ethera develops and markets measuring kits for indoor
chemical pollution.
Funding
R&D PROJECT FUNDED
COVADIS: innovative nanoporous sensors to detect volatile
organic compounds (VOC) for applications responding to two
major needs in human health.
Company contacts
CEO contact detail
First name: Yves
Last name: Bigay
Position: CEO
Phone: +33 (0)6 85 94 92 70
Other contact
First name: Sylvain
Last name: Colomb
Position: Marketing and Business Development
Phone: +33 (0)6 83 29 27 11
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
67
Company name: Eurofins Optimed Lyon
Address: 1, rue des Essarts
Zip code: 38610
City: Gières
Website: www.optimed.fr
Main activity: Eurofins Optimed Lyon is a CRO certified
ISO 9001: 2008, providing its experience and services in clinical
research: from early clinical development (Phase I and IIa)
to Phases IIb to IV clinical trials and surveys.
Incubator: No
Subsidiary of a group: Yes (Eurofins)
Business model
Value chain
Clinical.
Activities
Clinical trials.
Application fields
diseases, Metabolic diseases, CNS related diseases, Cancer,
Activities
Funding
Company activities
Company contacts
CEO contact detail
First name: Yves
Last name: Donazzolo
Position: President
Phone: +33 (0)4 38 37 27 40
Other contact
First name: Marie
Last name: Gilbert-Collet
Position: Customer Relations Manager
Phone: +33 (0)4 38 37 27 46
Fax: +33 (0)4 38 37 27 41
CRO offering a large panel of services for the set-up and
realisation of clinical studies from Phase I to IV and surveys:
– study initiation (methodological advice, study document
writing, management of regulatory submissions, etc.)
– study conduct (recruitment of healthy volunteers or patients,
study conduct in our two Clinical Pharmacology Units
of 100 beds, etc.)
– collaboration with the Lyon Sud Hospital - monitoring - study
data exploitation (data management, statistics, final report
writing, etc.).
– 20 years of experience in clinical research
– stable team of clinical research professionals
– medium-sized company integrated into an international
group (Eurofins)
– access to a network of Experts in various fields.
Recent news
Implementation of the Remote Data Capture (RDC) system,
the online user interface for the ORACLE Clinical database.
Skills and know-how
– Approximately 800 studies conducted (First Into Human,
interactions, QT/QTc, bioequivalences, etc.) in various fields
(CNS, cardiovascular, respiratory, etc.)
– Two Clinical Pharmacology Units comprising 100 beds,
including 32 beds within the Lyon Sud Hospital
– Technical platform and network of Experts.
68
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Service provider - Non Scientific, Product developer - Other
health.
Value chain
Activities
Nanotechnology, Drug delivery, Other.
Application fields
Company name: Eveon
Address: 345, rue Lavoisier
Zip code: 38330
City: Montbonnot Saint-Martin
Website: www.eveon.eu/en/index.html
Main activity: Eveon is a French company created
in December, 2008. Eveon dedicates itself to the design,
development and manufacture of injection medical device,
fully automated and secure, piston-free, perfectly adapted
for subcutaneous, intradermal, intramuscular and intravenous
injections. Eveon provides customized developments
and manufacturing of injection medical devices from the
specifications of our clients, the pharmaceutical and biotech
laboratories. All our solutions are designed from configurable
technological bricks which we can assemble according to
precise criteria, and, in particular viscosity of the solution,
injection time, volume to be injected, temperature, kind of
injection and depth. We propose partnership agreements
which include:
– Elaboration of the specifications
– Development of prototypes and pre-series
– CE mark and FDA approval of the device
– Manufacture from thousands to millions
Other status: Yes
Funding
Company contacts
CEO contact detail
First name: Vincent
Last name: Tempelaere
Position: CEO
Phone: +33 (0)4 76 44 84 17
Other contact
First name: Valérie
Last name: Roux-Jallet
Position: VP Marketing
Phone: +33 (0)4 76 41 43 82
l i f e
s c i e n c e s
d i r e c t o r y
diseases, Autoimmune diseases, Genetic / Rare diseases, CNS
related diseases, Cancer.
Activities
Company activities
Eveon is a French company created in December, 2008. Eveon
dedicates itself to the design, development and manufacture
of injection medical device, fully automated and secure,
piston-free, perfectly adapted for subcutaneous, intradermal,
intramuscular and intravenous injections. Eveon provides
customized developments and manufacturing of injection
medical devices from the specifications of our clients,
the pharmaceutical and biotech laboratories. All our solutions
are designed from configurable technological bricks which we
can assemble according to precise criteria, and, in particular
viscosity of the solution, injection time, volume to be injected,
temperature, kind of injection and depth.
We propose partnership agreements which include:
– Manufacture from thousands to millions.
Eveon is a pioneer in the design of automatic and completely
secure, plunger-free injection medical devices. Eveon owns
a portfolio of 6 international patents to cover all the innovative
aspects of its technology. The injection device is based
on 4 major innovations:
– A microsystem (MEMS) injects precisely volumes ranging
from µl to ml. The calibration of the MEMS insures injection
time adapted to the viscosity of the solutions and avoid
the degradation of sensitive molecules by shearing. Contrary
to the mechanical syringes with plunger, the injection
is silicone-free and rubber-free.
– Integrated sensors detect and analyze human tissues
(thickness, depth, consistency) to differentiate precisely
a muscle from a nerve, a dermis or a vein. For example
these sensors guarantee that an intramuscular injection
is not made in a vein.
– A retractable needle standard or customized penetrates
at the right depth only when the device is in contact with
the skin. After injection, the needle retracts and is
auto-blocked thanks to a double security, mechanical
and electronical.
– A cartridge contains one or several standard vials to adapt
easily and at lower cost to the standard filling lines of our
clients. The cartridge is adapted for mono or multi-doses and
also allows in situ rehydration of lyophilisats.
The originality of the devices developped by Eveon is based on:
– The safety of the injection with a needle inaccessible before,
during and after injection - auto-injection subcutaneous, but
also intradermal, intramuscular and tomorrow intravenous.
2 0 1 1
69
– Programmable and automatic injection thanks to a MEMS
(microsystem, core technology of the device) and integrated
sensors.
– Dead volume reducd to few µl thanks to an innovating design.
– Adaptation to the gold standards of the pharmaceutical
industry, vial, cartridge.
Skills and know-how
Bring a real solution to the needle stick injuries due
to syringes, pens and auto-injectors. Widen the auto-injection
from subcutaneous to intradermal, intramuscular and the
intravenous Propose a piston-free concept to solve the
problems associated to the presence
of silicone in the traditional syringes Integrate tissue sensors
to control the needle and injection site.
Company services
Eveon provides customized developments and manufacturing
of injection medical devices from the specifications of our
clients, the pharmaceutical and biotech laboratories. All our
solutions are designed from configurable technological bricks
which we can assemble according to precise criteria, and, in
particular viscosity of the solution, injection time, volume to be
injected, temperature, kind of injection and depth. We propose
partnership agreements which include:
– Manufacture from thousands to millions
The injection device is based on 4 major innovations:
– A microsystem (MEMS) injects precisely volumes ranging
from µl to ml. The calibration of the MEMS insures injection
time adapted to the viscosity of the solutions and avoid
the degradation of sensitive molecules by shearing. Contrary
to the mechanical syringes with plunger, the injection is
silicone-free and rubber-free.
– Integrated sensors detect and analyze human tissues
(thickness, depth, consistency) to differentiate precisely
a muscle from a nerve, a dermis or a vein. For example these
sensors guarantee that an intramuscular injection is not made
in a vein.
– A retractable needle standard or customized penetrates at
the right depth only when the device is in contact with the skin.
After injection, the needle retracts and is auto-blocked thanks
to a double security, mechanical and electronical.
– A cartridge contains one or several standard vials to adapt
easily and at lower cost to the standard filling lines
of our clients. The cartridge is adapted for mono
or multi-doses and also allows in situ rehydration
of lyophilisats.
70
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Partnership
Eveon proposes partnership agreements for the design,
develop and manufacture of customized injection
medical devices from the specifications of our clients, the
pharmaceutical and biotech laboratories. All our solutions
are designed from configurable technological bricks which we
can assemble according to precise criteria, and, in particular
viscosity of the solution, injection time, volume to be injected,
temperature, kind of injection and depth. We propose modular
solutions from:
– Manufacture from thousands to millions.
Business model
Value chain
Company name: EyeTechCare
Address: 2871, avenue de l’Europe
Zip code: 69140
City: Rillieux la Pape
Website: www.eyetechcare.com
Main activity: EyeTechCare is developing non-invasive
therapeutic medical devices for the ophthalmology market
based on high-intensity focused ultrasound (HIFU). HIFU
technology allows ambulatory and rapid treatment
to be performed, thereby limiting the cost and the risk
for the patient.
EyeOP1, the first device developed by the company, is
for the treatment of glaucoma. EyeOP1 has been undergoing
clinical trials in Lyon since March this year and is due to be
launched onto the market in 2011. The device utilizes the
UC3 (ultrasound circular cyclo-coagulation) procedure, which
makes it possible to reduce intraocular pressure by partially
and accurately destroying the ciliary bodies that produce
aqueous humor.
Other status: Yes
Funding
Research.
Activities
Medical device, Drug delivery, Other.
Application fields
Human health.
Activities
Company activities
– Conception and Development of an innovative medical device
for non invasive glaucoma treatment
– Research and Development for new non-invasive medical
devices for the treatment of ocular pathologies.
– Complementarity and experiences of the founders
of the company in the Medical Devices
– Need and interest opthtalmologistes / patients for a new
treatment for glaucoma
– Glaucoma is a market of $ 7 billion/year of which
approximately $500 million of medical devices (90% of the
overall treatment is represented by glaucoma medical
treatment)
– Very good results on preclinical results. Clinical trials still in
progress
– 5 patents granted in conjunction with the INSERM (French
National Institute of Health and Medical Research-Unit 556
Lyon)
– JEI status, and support of OSEO.
Recent news
Total of funds raised to date: € 8.7 million (USD 10.6M) in
two rounds: € 1.2M in July 2008 and € 7.5M in June 2010)
Public funding obtained: € 500,000 in aid and subsidies from
OSEO (the French national innovation promotion agency) and
€ 250,000 from France’s ministry of research.
Clinical study started in March 2010: Single-center pilot
study aimed to determine the tolerability and efficacy of new
therapeutic method UC3 (CycloCoagulation Circular Ultrasonic)
(Product EYEOP1)
1st prize TMI AGBM in May 2010 2nd fundraising of 7.5 million
in June 2010 Certification of the company ISO 9001
and ISO 13485 in July 2010.
Skills and know-how
Developpement of new therapies for ocular diseases Use
of Ultrasons for therapeutic application.
Company contacts
CEO contact detail
First name: Fabrice
Last name: Romano
Position: CEO
Phone: +33 (0)4 78 88 09 00
Other contact
First name: Aurélie
Last name: Begle
Phone: +33 (0)4 72 01 79 95
Fax: +33 (0)4 78 97 45 11
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Pipeline product 1
Therapeutic area: Medical Device in ophthalmology
Therapeutic indication: glaucoma
Preclinical: completed
EyeOP1, the company’s first device, was developed
for the treatment of glaucoma. EyeOP1 has been in clinical
trials in Lyon since March 2010 and should be on the market
in 2011. The device utilizes the UC3 (ultrasound circular
cyclo-coagulation) procedure, which makes it possible
to reduce intraocular pressure by partially and accurately
destroying the ciliary bodies that produce aqueous humor.
71
EyeOP1 offers numerous advantages compared to other
available therapies. It is a quick procedure that takes less
than a minute. It is less costly than eye drops or surgery,
and is well tolerated. In effect, it causes necrosis of the tissue,
not its destruction. It is a technique that requires no manual
intervention and does not depend on the operator.
Partnership
We develop a new research project to study the impact of
ultrasound on the delivery of active molecules in the eye (Drug
Delivery). We are in the stage
of feasibility study.
We could work with pharmaceutical industry (small and
medium size) to develop and find adequate formulation of
active molecules.
72
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Product developer - Biopharmaceuticals, Service provider Scientific, Product developer - Pharmaceuticals.
Value chain
Activities
Clinical trials, Preclinical trials, Nanotechnology, Other.
Application fields
Company name: Flamel Technologies
Address: Parc Club moulin à Vent, 33, av. du Dr Georges Lévy
Zip code: 69693
City: Vénissieux
Founded in: 1990
Turnover: 30 Millions e (in 2010)
Main activity: FLAMEL Technologies (Nasdaq: FLML) is
a leading drug delivery company. Flamel has developed two
innovative proprietary drug formulation platforms:
– Medusa® for the formulation and the delivery of biologics
(peptides, proteins)
– Micropump® for the formulation and the delivery of small
molecule drugs. Flamel is a partnership-oriented company
and has major collaborations with major pharmaceutical
companies (Merck-Serono, Pfizer/Wyeth, GSK, Baxter…).
Incubator: No
Other status: No
Activities
Company activities
Flamel, in collaboration with major pharmaceutical
and biotech companies, develops better and safer drugs using
its proprietary advanced formulation technology platforms.
– Unique formulation and delivery capabilities
– Breakthrough know-how in the delivery of proteins
and peptides
– Technologies validated by an impressive track-record
of succesful partnerships.
Recent news
Completion of key steps in the Company’s development
program with Merck Serono on an extended release
formulation of Interferon-beta 1-a, which led to EUR 4 million
milestone announcement regarding clinical development.
Signing of two further projects: one for Medusa and the other
for a Micropump formulation.
Skills and know-how
Funding
– Drug delivery
– Drug formulation
– Drug development.
R&D PROJECT FUNDED
ALPHA VAC: New therapeutic approach for the treatment
of hepatitis C virus infection based on the combination of a
therapeutic vaccine and a nanoparticle-based formulation of IFN
Company contacts
CEO contact detail
First name: Stephen
Last name: Willard
Phone: +33 (0)4 72 78 34 34
Other contact
First name: Grégoire
Last name: Franoux
Position: Director Licensing & Business
Development
Phone: +33 (0)4 72 78 34 34
Fax: +33 (0)4 72 78 34 35
l i f e
Immunology, Infectious diseases, Autoimmune diseases,
Metabolic diseases, CNS related diseases, Cancer.
s c i e n c e s
d i r e c t o r y
2 0 1 1
Pipeline product 1
Therapeutic area: Infectious Diseases
Therapeutic indication: Hepatitis C
Preclinical: Completed
Phase 1: Completed
Phase 2: Ongoing
Pipeline product 2
Therapeutic area: Metabolic dieases
Therapeutic indication: Diabetes
Preclinical: Completed
Phase 1: Completed
Company services
Flamel is a world leader in innovative formulation
and delivery technologies for small molecule, peptide
and protein drugs. The company, alone or in partnership with
leading pharmaceutical and biotech companies, is developing
better and safer drugs using its proprietary technology
platforms.
Medusa
Medusa is a nanogel depot for the formulation of any biological
drug (peptide, antibodies, fragments, vaccines, large protein
drugs etc.). Medusa allows the controlled delivery of fully
bioactive drugs. Flamel has Medusa partnerships with 8
of the TOP-25 pharmaceutical companies (Baxter,
Merck-Serono, Pfizer etc.).
73
Micropump
Micropump is a microparticle oral controlled release
technology. Micropump is designed to extend the bioabsorbtion
time of small molecule drugs in the small intestine. It is used
by GSK in its COREG CR (Carvedilol Controlled Release),
marketed in the US since 2007.
Partnership
Flamel is looking for new pharmaceutical & biotech partners
to apply its breakthrough technologies to develop more
efficient and safer drugs.
Flamel is looking for new pharmaceutical & biotech partners
to apply its breakthrough technologies to develop more
efficient and safer drugs.
– Medusa technology platform
– Micropump technology platform
– IFN alpha XL
– FT-105 Basal insulin.
74
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Product developer - Biopharmaceuticals, Product developer Other health, Laboratory equipment supplier.
Value chain
Activities
Diagnostics / Analysis method, Nanotechnology, Medical device.
Application fields
Animal health, Human health, Cancer.
Activities
Company activities
Company name: Fluoptics
Address: BHT - Bât. 52 - 7, parvis Louis Néel - BP 50
Zip code: 38040
Website: www.fluoptics.com
Turnover: 500 k Euros (in 2010)
Main activity: Fluoptics designs, develops and commercializes
an innovative device to assist surgeons in cancerous tumors
resection. This solution consists in “highlighting” tumors cells
to help the surgeon during the operation to locate and remove
them in real time.
This technology combines the use of a fluorescent probe which
specifically targets tumors cells and a near infrared imaging
system. Therefore closely guided to cancerous tissues,
the surgeon can make a complete resection while preserving
healthy tissues as much as possible.
In terms of public health, this technology brings a new hope
of recovery for thousands of patients insofar as the surgery
is still the main line of defense and one of the most efficient
therapy against cancer. Every year, 5 million people suffering
from cancer undergo surgery all over the world.
Prize winner for innovative start-up: Yes (Creation 2008)
Other status: Yes (CIR & JEI)
Funding
Fluoptics developed an innovative device to assist surgeons
in cancerous tumors resection. This solution consists in
“highlighting” tumors cells to help the surgeon during the
operation to visualize it in real time in order to ease the exerese.
Fluoptics expects to be one of the first to launch this technology
and looks to be a European leader in this field.
This technology combines the use of a fluorescent probe which
specifically targets tumors cells and a near infrared imaging
system. The action of the fluorescent probe that concentrates
in the tumor offers to the surgeon an acute intraoperative
screen visualization of the borders of the primary tumor,
the close metastasis including those invisible to the unaided
eye.
This way closely guided to cancerous tissues, the surgeon can
make a complete resection while preserving healthy tissues
as much as possible.
In terms of public health, this technology is the sign of a new
hope of recovery for thousands of patients insofar as the
surgery is still the main line of defense and one of the most
efficient therapy against cancer. Every year, 5 million people
suffering from cancer undergo surgery all over the world.
In France, 250.000 people are concerned that is one person
every 45 seconds.
This innovative solution showed very encouraging preclinical
in vivo results. It is already commercialized on the preclinical
research market under the name Fluobeam® and Angiostamp®.
The first customers are: on one side research labs from
pharmaceutical industry for the development of new drugs
and on the other side surgeons for their clinical research.
Multi skills integration: Physics- Biology-Chemistry
Simultaneous development of both an imaging system
and a fluorescent probe
Scientific excellence of its technological research partners such
as CEA-LETI and Université Joseph Fourier.
The expertise of its partners for proofs of clinical concept
through the collaboration of the main French cancer treatment
and research centers.
Recent news
Differents french newspaper speak about Fluoptics.
Please find it on Fluoptics website www.fluoptics.com.
Company contact
CEO contact detail
First name: Odile
Last name: Allard
Position: CEO
Phone: +33 (0)6 80 00 01 78
Skills and know-how
Development of optical imaging – fluorescent probes.
Pipeline product 1
Preclinical: FLUOBEAM
Pipeline product 2
Preclinical: AngioStamp
Pipeline product 3
Preclinical: SentiDye
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
75
Company name: Fondation Mérieux
Address: 17 rue Bourgelat
Zip code: 69002
City: Lyon
Website: www.fondation-merieux.org
Founded in: 1967
Main activity: Fondation Mérieux is an independent family
foundation, ‘reconnue d’utilité publique’. Its mission is
to strengthen local capacities in developing countries to reduce
the impact of infectious diseases on vulnerable population.
It has four main areas of action: applied research, traning
and sharing of knowledge, strengthening of health
infrastructures and mother and child health. With the support
of Fondation Christophe et Rodolphe Mérieux, it develops
a network of biology laboratories dedicated to research
and training in the field, at the heart of infected areas.
Current field sites are located in Mali, Cambodia, Laos, Haiti,
Madagascar, China, Lebanon and very soon in Tajikistan.
Funding
Company contacts
CEO contact detail
First name: Benoit
Last name: Miribel
Position: Director General
Phone: +33 (0)4 72 40 79 79
Other contact
First name: Amal
Last name: Darghouth
Position: Communication
Email:
[email protected]
Phone: +33 (0)4 50 64 80 80
Fax: +33 (0)5 40 60 07 21
76
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Other.
Value chain
Research, Other.
Activities
Other.
Application fields
Activities
Company activities
Fondation Mérieux is an independent family foundation,
‘reconnue d’utilité publique’. Its mission is to strengthen local
capacities in developing countries to reduce the impact
of infectious diseases on vulnerable population. It has four
main areas of action: applied research, traning and sharing
of knowledge, strengthening of health infrastructures
and mother and child health. With the support of Fondation
Christophe et Rodolphe Mérieux, it develops a network
of biology laboratories dedicated to research and training
in the field, at the heart of infected areas. Current field sites
are located in Mali, Cambodia, Laos, Haiti, Madagascar, China,
Lebanon and very soon in Tajikistan.
Company name: GCS-Etoile
Zip code: 69008
City: Lyon
Website: www.centre-etoile.org
Main activity: The sanitary Cooperation Group Etoile aims
at developing the National Center for Hadrontherapy for the
treatment of radioresistant cancers and for applied research
in hadrontherapy. The Etoile Center will open its doors in
2016 and will treat over 2,000 patients per year and will
host permanent research teams involved in hadrontherapy
particularly in the fields of radiobiology, dosimetry and
instrumentation. Part of the research center will provide
a platform open to international research teams and industry.
It will provide a research room dedicated to research with a
permanent access to the ion beam and scientific and technical
environment for the preparation and support to experimenters.
The main partners of the Etoile Center are University of Lyon,
local authorities, the Ministry of Health, CNRS, IRSN, CNES
the CLARA and Lyonbiopole.
Incubator: No
Other status: Yes
Business model
Other.
Value chain
Other.
Activities
Diagnostics / Analysis method, Instrumentation, Models
(animal - cellular - …), Clinical trials, Preclinical trials, Medical
device, Other.
Application fields
Activities
Company activities
The GCS-Etoile conducts tenders for the construction of the
Center, coordinates the preliminary studies and clinical trials
related to its future activity in hadrontherapy. He is looking for
the necessary funding for the operation. The Etoile Center will
be designed to accommodate research laboratories dedicated
to applied research in hadrontherapy and enhancement
of research in the fields of radiobiology, dosimetry and medical
instrumentation around the patient. The GCS will become
at the signature of the contract, a Public Health Establishment
of national or regional scale.
Funding
Nature of funding searches: During 2011 the GCS-Etoile will
look for bank loan for the financial support of the project.
Company contacts
CEO contact detail
First name: Jacques
Last name: Balosso
Position: Director
Phone: +33 (0)4 72 78 89 20
Other contact
Last name: Wasmer
Position: General officer
Phone: +33 (0)4 72 78 89 25
Fax: +33 (0)4 78 76 06 43
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
77
Business model
Company name: Geneuro
Address: 60, avenue de Rockefeller
Zip code: 69008
City: Lyon
Website: www.geneuro.com
Main activity: Geneuro is a product development company,
developing a pioneering approach for the therapy of diseases
associated with human endogeneous retrovirus expression,
with a primary focus on nervous system diseases. Geneuro
anticipates the first clinical trial of its monoclonal antibody
early 2011 in multiple sclerosis and also carries out extensive
preclinical research in other diseases such as schizophrenia.
Geneuro breakthrough innovation targets the envelope protein
of human endegeneous retrovirus. Its lead product,
a monoclonal antibody, acts upstream of the pro-inflammatory
cascade, thus increasing efficacy and safety over existing drugs
which mainly delay neurological damages and disability caused
by Multiple sclerosis. Geneuro is driven by entrepreneurial
spirit and supported by a well established network
of worldwide leading industrial and academic partners.
Incubator: Yes (Eclosion)
Subsidiary of a group: Yes (Eclosion et Institut Mérieux)
Other status: No
Funding
Public funding obtained: No
Company contacts
CEO contact detail
Last name: Curtin
Position: CEO
Phone: +41 22 794 50 85
Other contact
Last name: Guichard
Phone: +41 22 794 50 85
Fax: +41 22 794 50 86
78
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Value chain
Activities
Models (animal - cellular - …), Clinical trials, Preclinical trials,
Drug discovery.
Application fields
Human health, Inflammatory diseases, Autoimmune diseases,
CNS related diseases.
Activities
Company activities
GeNeuro’s novel approach primarily focuses
on the development of therapeutic monoclonal antibodies,
which will target and neutralize the pathogenic MSRV/HERV-W
proteins and thereby prevent the initiation of the inflammatory
and autoimmune cascades induced by these proteins
in Multiple Sclerosis. A similar approach is applied
for Schizophrenia.
These antibodies have been tested in new experimental
models developed by GeNeuro and have shown effective
inhibitory properties, both in vitro and in vivo with no evidence
of adverse effect in animal models.
Unlike other drugs currently used to treat MS, which are aimed
at slowing down the neurological damage and disability caused
by the disease, GeNeuro’s approach is directed upstream
of the inflammatory demyelinating cascade, at the origin
of brain lesions.
Targeting pathogenic effects of human endogenous
retroviruses.
The sequencing of the human genome revealed that nearly
one-half of the genome is composed of repeated
or retrotransposable elements. Among them, human
endogenous retroviruses (HERVs) represent more than 8%
of the human genome and result from integration
of exogenous retroviruses that have infected the germline
of their host during the primate evolution.
HERVs appear to have a critical significance in physiology
and in diseases, at the crossroads of genetics, virology and
physiopathology.
A human endogenous retrovirus, the MS associated retrovirus
(MSRV), a member of the HERV-W family, had been initially
isolated in cell cultures from patients affected with MS. MSRV
is normally latent in the genome of individuals, but when
activated by certain co-factors, it can be reactivated and
express an envelope protein (HERV-W/ENV). This appears to be
a major triggering and aggravating factor in the development
and progression of MS. Depending on environmental
co-factors, HERV-W MSRV could be involved in both Multiple
Sclerosis and Schizophrenia.
Geneuro is the leading company developing new therapies
targeting Human Endegeneous Retroviruses, focusing
on nervous system diseases.
GeNeuro core technology is protected by a patent portfolio
of more than 20 original patents covering sequences, products
and particular applications for diagnostic and therapeutic
development. The portfolio includes licenses on therapeutic
monoclonal antibodies neutralizing endogenous retroviruses.
Pipeline product 1
Therapeutic area: autoimmune diseases
Therapeutic indication: Multiple sclerosis
Pipeline product 2
Therapeutic area: CNS
Therapeutic indication: Schizophrenia
Partnership
GeNeuro is aiming at excellence, both in internal activities and
in collaboration with our partners. The company has a well
established network of industrial partners, academic alliances,
and is constantly seeking to further develop its collaborative
approach.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
79
Company name: Genostar
Address: 60, rue Lavoisier
Zip code: 38330
City: Montbonnot
Website: www.genostar.com
Main activity: Genostar provides bioinformatics solutions
for microbial research from genome to metabolome.
We offer data analysis and management services as well
as a powerful and user-friendly software and database
platform. Our solutions are well adapted to analysis of high
throughput “NGS” sequence data as well as expression data.
Our solutions enable scientists to characterize their microbial
organisms quickly and efficiently, from sequence assembly
and annotation through enzymatic characterization, metabolic
pathway studies and expression data analysis. We also provide
solutions for metagenomics analyses.
We understand that data compatibility, centralization
and accessibility are important to research organizations:
our platform enables organizations to save, centralize
and manage their results, building on their internal knowledge
base.
Incubator: No
Funding
Company contacts
CEO contact detail
First name: Patrice
Last name: Garnier
Position:CEO
Phone: +33 (0)6 62 28 67 66
Other contact
First name: Adrienne
Last name: Kennard
Position: COO
Phone: +33 (0)6 47 88 23 43
Fax: +33 (0)4 76 97 18 81
80
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Service provider - Scientific, Other.
Value chain
Research.
Activities
Application fields
Animal health, Human health, Infectious diseases, Metabolic
diseases, Nutrition / Food, Dermocosmetics.
Activities
Company activities
Genostar provides complete data analysis services, software
and databases for microbial research. Our solutions enable life
scientists to interpret their sequence and expression data both
easily and visually. We have an experienced, in-house team
of bioinformaticians, bioanalysts, biologists, & software
engineers. This allows us to meet the challenges of new and
evolving needs in bioinformatics data analysis, both in terms
of software and database development and in the wide range
of services that we provide to our customers. The range of our
service offer is quite wide, and includes fast, largely automatic,
annotation as well as comprehensive annotation, enzymatic
characterization and metabolism studies, calculation of core
and pan genomes, virulence studies, and metagenomics
analyses.
Our solutions are currently used in many fields including
vaccine discovery, antibiotics and antivirulence research,
probiotics (nutrition and agro-foods), diagnostics,
biotechnology, green energies and more.
Genostar’s flagship product is the Metabolic Pathway Builder
software and database platform. The platform enables
scientists to perform fast, in-depth functional and comparative
annotation (genomic and proteic), comprehensive metabolic
analyses, and to both save and manage their results.
The platform is very well suited to high throughput, comparative
analyses. The platform also enables metagenomics studies.
The MicroB database is part of the Metabolic Pathway Builder
platform. This database contains a constantly increasing
number of complete reference genomes. For each organism,
MicroB contains the complete genome, proteome and
metabolome. The genomic and proteic annotations are
connected the biochemical and metabolic data. This network
of connections between genomes, proteomes and pathways
enables scientists to quickly discover relationships, reconstruct
metabolic systems and improve understanding of cellular
processes.
MicroB serves as both a reference database for comparative
analysis and as a knowledge base: customers can easily
integrate, manage, explore and visualize their annotated
genomes. Data is easy to access and export as needed.
Genostar creates value by providing scientists with services
and tools to conduct both in-depth annotation and complex
analyses linking genome to metabolome. We place
an extremely high value on customer service, both in software
support and training and in the quality and punctuality
of our services.
Key platform features include streamlined integration of a wide
range of methods and heterogeneous data, a very user-friendly
interface and the facility to rapidly store, manage, export
and share results. In addition to the many pre-programmed
queries, customers also have user-friendly query-building
tools that provide even greater flexibility. The result is powerful
products that are easy for researchers to use.
Genostar’s products are both customizable and extendable.
Customers can integrate new analytical methods, including
proprietary ones written by their scientists into the software,
just as they can integrate their proprietary genomes into their
database.
Recent news
Release of Metabolic Pathway Builder 3.8: This release
contains new methods for both data analysis
and for centralization, management and sharing of results. Please
See www.genostar.com/en/news.html?actu_id_97=31&actu_
page_97=1
Genostar now offers comprehensive bioinformatics solutions for
metagenomics analyses.
Genostar continues development of a bioinformatics suite for
the analysis of viral genomes and proteomes. The objective
of the project is to offer virologists tools specifically designed
to help them better analyze and understand the structure,
function and evolution of viral genomes, in particular for
vaccine discovery and optimization. This project is co-funded by
Oséo and FEDER.
Skills and know-how
Genostar’s core expertise is three-fold: we have significant
experience and expertise in both software and database design
as well as in microbial, and in particular, bacterial, sequence
analysis.
Company services
Genostar provides a full range of services for genome
annotation and reannotation, comparative analysis, expression
data analysis and metagenomics analyses.
- Genome annotation
• Sequence assessment and assembly
• Gene prediction
• Functional characterization of genes/proteins
- Annotations and classification terms
- Proteic domains
• Exploration of regulatory signals and co-regulation.
- Comparative analysis
s c i e n c e s
d i r e c t o r y
• Identification of genes and regions that are specific
to an organism or to a set of organisms
• Comparative metabolic analyses
- Identification of specific and shared metabolic reactions
and pathways
- Identification of specific and shared compounds
• Computation of core- and pan- genomes
- Expression Data Analysis
• Analyze gene expression in terms of genomic localization,
functional annotation and metabolism
• Visualize expression on genomic and metabolic maps
- Metagenomics Analysis
• Sequence assembly
• Identification of genes and organisms in a sample
• Identification of enzymatic activities and the metabolic reactions
and pathways of a metagenome.
Company technologies: Genostar’s software is integrated.
This means that the user can focus on the analysis process
itself, rather than having to deal with the management
of data between the many different methods for analysis,
the visualizers and the data repositories.
The software efficiently and automatically handles data
compliance, conversion and transfer. All the data are explicitly
represented in an object-oriented model. Organisms,
chromosomes, sequences, and sequence features such as
CDS, signals, classification nodes, reactions, pathways, and so
on are represented as objects. These objects are connected by
relationships to form a large data web.
Since the software recognizes methods as objects with typed
input and output arguments, all necessary information is
available for very thorough data checking and conversion.
The software performs these tasks automatically.
The dataweb can be explored and queried. The user can either
follow the links between the objects and thus discover their
relationships, or express a query to retrieve all the objects
that satisfy some constraints; for instance, all the metabolic
reactions that are catalyzed by products of genes that have
been identified to be specific to an organism. The most frequent
queries are built in and can be easily run. The user can easily
construct other queries, from simple to complex, with a
graphical tool. These queries can then be saved for regular use.
Objects and relationships are mapped onto the tables that
make up the structure of MicroB, so that their contents can be
stored and integrated in this relational database, and retrieved
as necessary.
Partnership
Opportunities for partnerships with companies having
complementary technologies.
Licenses for Genostar’s software and databases are available
on an annual and a perpetual basis.
• Sequence comparison
• Computation of SNPs and DIPs
• Multiple sequence alignment
l i f e
- Phylogenetic analysis
2 0 1 1
81
Company name: genOway
City: Lyon
Website: www.genoway.com
Turnover: 8,4 M Euros (in 2009)
Main activity: genOway is dedicated to the development
of tailor-made genetically modified rat and mouse models
of the highest reliability. Based on proprietary technologies
(humanization, RNAi, inducible system) and strategic alliances,
genOway proposes time saving and cost effective strategies
for in vivo target validation and drug development programs.
Moreover, genOway offers ready-to-use transgenic rat
and mouse models as tools to increase the predictability
of in vivo preclinical studies in immunology, neurology,
metabolic disorders and ADMET.
Prize winner for innovative start-up: Yes (1999)
Other status: No
Funding
R&D PROJECTS FUNDED
ACTIVRAT: Real time control of signaling events during the
period of egg activation for the generation of clones by nuclear
transfer in the rat species
HU’S-MAP: Human and species monoclonal antibody
production
Funding: Local authorities (2007)
Business model
Value chain
Activities
Other.
Application fields
Pediatrics, Human health, Immunology, Inflammatory
diseases, Infectious diseases, Allergology, Orphan diseases,
diseases, Cancer, Nutrition / Food.
Activities
Company activities
genOway is fully dedicated to the development of tailor made
transgenic mouse and rat models. genOway has developed
a complete range of innovative technological solutions
to create a new generation of improved models. genOway’s
expertise combines technologies classically used
in transgenesis and several cutting-edge proprietary
technologies aiming at enhancing the efficiency, security
and relevance of the animal model ultimately developed.
Our license policy allows our partners to have a free use
of the model developed. In order to maximize the use of
in vivo models, genOway has developed the concept of “3-in-1”
models, providing time- and cost-saving solutions. Target
validation (Knock-out), in vivo evaluation of compounds
towards the human target (humanized mouse) and compound
specificity studies can all be addressed within a single
animal model. Moreover, genOway develops animal models
as ready-to-use tools aiming at increasing the predictability
of in vivo pre-clinical analysis in many areas as ADME-tox,
Immunology, Neurology, Metabolic disorders. Indeed, the use
of these ready-to-use models enables more relevant analysis
of physiopathological studies compare to human physiology
and increases the relevance of candidate molecules selection.
These rat and mouse lines are available with a total freedom
to operate as research licenses are provided.
Company contacts
CEO contact detail
First name: Alexandre
Last name: Fraichard
Position: CEO
Phone: +33 (0)4 37 65 41 00
82
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
genOway is already involved in large scale projects with
pharmaceutical companies (Pfizer, Bayer Corp, Boehringer
Ingelheim, Eisai), with academic centres (University College,
London; Kings College, London, Max Planck Institute, BIDMCHarvard, University of Pennsylvania…) and networks (German
National Genome Research Network, EUGeneHeart). Our
industrialized production facility guarantees the parallel
development of all projects. A partnership is in place in Europe
and North America with Charles River (MA, USA), the world
leader in animal breeding and related services, to co-promote
our core business. This collaboration provides partners of
each company with the highest quality service. Operating in
22 countries in Europe, North America and Asia, genOway has
developed rat and mouse lines for more than 60 companies
and 200 research institutions.
Recent news
- Nov-Dec 2009: genOway signed four important framework
agreements with prestigious academic research centres
and university in US:
• University of Pennsylvania
• Tufts University
• University of Pittsburg
• BIDMC, Harvard Medical School
- Oct 2009: genOway acquires exclusive license for Flex
technology developed by Professor Pierre Chambon
and Dr. Norbert Ghyselinck at the IGBM.
genOway offers an extensive portfolio of transgenic
technologies including innovative approaches
to secure and speed up the availability of developed animal
model with:
– Consultancy to define the most adapted solution before
project begins
– ES Cell based technology (Knock-out, Knock-in, point
mutation, humanization)
– Ready-to-use genetic tools and ES Cells from various genetic
backgrounds
– In vivo RNAi and inducible systems
genOway proposes also ready-to–use transgenic mouse
and rat models:
– Research models aiming at increasing the predictability
of analysis in ADMET, Immunology, Neurology, Metabolic
disorders.
– Research tools aiming at securing gene overexpression
or knock-out in a time- or tissue-specific manner
(recombinase expressing lines).
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
83
Business model
Company name: Genzyme Polyclonals
Address: 23, bd Chambaud de la Bruyère
Zip code: 69007
City: Lyon
Main activity: Biotechnology.
Subsidiary of a group: Yes (Genzyme)
Other status: No
Funding
Activities
Value chain
Manufacturing.
Activities
Biomanufacturing, Other.
Application fields
Human health, Immunology, Autoimmune diseases.
Company activities
Biotech company.
R&D PROJECT FUNDED
THYMO 2010: From thymoglobulin technical advances
MA: Thymoglobuline
to manufacturing process improvements and new
pharmaceutical applications
Funding: Local authorities
Company contacts
CEO contact detail
First name: Pascal
Last name: Reber
Position: VP - General manager
Phone: +33 (0)4 37 28 16 43
Other contact
First name: Didier
Last name: Santucci
Position: Technical Services director
84
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Pipeline product 1
Pipeline product 2
MA: Celsior
Company name: Laboratoires Gifrer Barbezat
Address: 8/10, rue Paul-Bert
Zip code: 69153
City: Décines Cedex
Website: www.Gifrer.fr
Founded in: 1912
Number of employees: 240.
Turnover: 40 014 M€ (in 2010)
Main activity: Pharmaceutical laboratory. Manufacturing -
Supply/Storage/Logistics - Development - City/Hospital
Marketing - France/Export Main customers: Pharmacies,
Wholesalers/Distributors, Hospitals/Private hospitals,
Pharmaceutical industry. Sectors: France - Overseas
departments - Export.
Subsidiary of a group: Yes (Qualiphar)
Other status: No
Funding
Business model
Value chain
Activities
Other.
Application fields
Pediatrics, Human health, Infectious diseases.
Activities
Company activities
- Manufacturing and subcontracting of three main categories of
products: sterile unit-doses, plant extracts, flammable products.
- Marketing: City: direct selling network in pharmacies - Hospital:
market unit.
- Pharmaceutical field: mainly non-refundable products/OTC.
- Markets: Antisepsis, Dermatology, Ophthalmology, Pediatrics,
Gastroenterology, ENT/Pneumology, Hygiene, Analgesis.
Strong presence in pharmacies:
about 16,000 active accounts out of 22,800 pharmacies
in France and 1,300 hospitals/private hospitals out of 3,200
in France. Fame - Customer service.
Company contacts
CEO contact detail
First name: Karl
Last name: Verlinden
Position: President
Phone: +33 (0)4 72 93 34 34
Recent news
Launch of many products: Megatone Junior, chexable tablets
(multivitamin for kids) - 20 and 30 volumes Hydrogen Peroxide
(dermatology) - Cold Cream (Cérat de Galien) 125 ml and 250 g
(dermatology/pediatrics) - Ostrin, tablets (tonic) - Babyfen
(pediatrics) - Lamiderm 80 ml (dermatology) - Proseptine
(hygiene/dermatology) - Megatone Intellect, tablets (memory) Natural Touch (young nursery).
Other contact
First name: Tom
Last name: Verlinden
Position: Pharmaceutic Manager
Phone: +33 (0)4 72 93 34 34
Fax: +33 (0)4 72 93 34 37
Skills and know-how
- Industrial: sterile unit-doses, plant extracts, flammable line.
- Commercial: market penetration, acknowledgement
and leaderchip in city and hospital pharmacies.
- Logistics: order processing, preparation, delivery.
Pipeline product 3
Therapeutic area: antisepsis
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
85
Value chain
Activities
Biomanufacturing, Biobank, Drug discovery, Other.
Application fields
diseases, Genetic / Rare diseases, Cancer, Other.
Activities
Company activities
Company name: Glycode
Main Address: 6, rue Porte Baffat 19140 Uzerche
Second address: Lyonbiopole Business Center
321, avenue Jean Jaurès 69007 Lyon
Website: www.glycode.fr
Main activity: Design of cost-effective yeast-based innovative
expression systems dedicated to therapeutic glycoproteins.
GlycoEngineering yeast strains to humanize glycosylation
pathway in order to produce glycoproteins with homogeneous
and humanized glycosylation.
Incubator: No
Other status: Yes
Private funding obtained: Seed Financing round (2004)
€ 150 K (Sofimac Partners) Series A, 2009, € 3 M (Sofimac
Partners, Octalfa, SHAM, Limousin Participations)
Company contacts
CEO contact detail
Last name: Javaud
Position: President and Chief Executive
Officer
Phone: +33 (0)5 55 73 77 19
Other contact
First name: Lucie
Last name: Guinoiseau
Position: Management Assistant
Phone: +33 (0)5 55 73 77 19
Fax: +33 (0)5 55 73 48 09
Business model
developer - Pharmaceuticals, Other.
l i f e
s c i e n c e s
IP secured Worldwide freedom
to operate Strong knowledge of glycosylation issues Business
Developement Office based in Lyon Skills in yeast genetic
engineering.
Skills and know-how
Yeast molecular and cellular biology Glycosciences
Development of «BioBetter» molecules Protein production and
purification.
Funding
86
Glycode is a biotechnology company which aims to become
a leader in the field of protein glycosylation. Founded in 2004,
the company has developed a proprietary innovative
and powerful technology, GlycodExpress™, which consists
of a bank of yeast strains genetically optimized
for the production of recombinant therapeutic glycoproteins
(antibodies, EPOs, growth factors…). These strains have been
genetically glycoengineered to synthesize fully humanized
N-glycans. Recently, Glycode has finalized the YACExpress™ technology, a 1-step method to recreate any given
metabolic pathway (Glycosylation or other) by adding a stable
chromosome containing all the required genetical information.
Located in Uzerche (Headquarter) and Lyon (Business
Developement Office), Glycode has 14 employees.
d i r e c t o r y
2 0 1 1
Company services
A new and innovative production platform, matching with
quality and cost issues, will be the answer. In this context, the
goal of Glycode is to provide to its customers a unique and
powerful service in the field of protein glycosylation.
The patented GlycodExpress™ technology relies on a collection
of glycoengineered yeast strains optimized for production
of recombinant proteins, and which glycosylation process has
been genetically humanized. Then it becomes possible
to produce in yeast every kind of glycoproteins, carrying glycan
structures, since basic Man8-9, up to most complex (with
peripheral galactose or sialic acid residues). GlycodExpress™,
a Glycan-on-Demand™ technology, offers to customers the
choice of protein glycosylation, and the opportunity to optimize
native structure, half-life time and therapeutic power. Glycode
expertise can provide to biotech and pharma companies
numerous tailor-made solutions, from gene to purified protein,
or outsourcing (license sales).
– Engineering strains to produce glycoprotein(s) (antibodies, IL,
growth factors, enzymes…),
– Lab scale production and purification,
– Out-licensing proprietary strains.
Partnership
Business Model: Out-licensing in 2 steps:
1- evaluation phase (10-12 months)
2- Granting to customer a non-exclusive license in the case
of a successful evaluation phase.
Glycoengineered Strains
GlycodExpress™ and YAC-Express™ technologies.
Company contacts
CEO contact detail
First name: Jacques-François
Last name: Martin
Position: President
Phone: +33 (0)4 72 40 26 77
Company name: HLA-G Technologies
Address: 41, quai Fulchiron
Zip code: 69005
City: Lyon
Website: www.parteurop.com
Main activity: HLA-G Technologies is developing new
immunomodulatory compounds based on HLA-G molecule
properties in tranplantation, cancer and auto immune diseases.
The company focused the development of their products in
two first indications: the treatment of graft rejection and the
treatment of liquid cancers. The company conducted studies
in 2 different graft animal models (skin graft and heart graft
models), the studies showed that the injection of HLA-G peptides
increase graft survival in these 2 models. The company also
showed the same efficacy of our HLA-G molecule than current
gold standard treatments in transplantation but with less toxicity.
Another in vitro study has been conducted with hematologic
cancer cell lines, the study showed that injection
of a different peptidic form of the HLA-G molecule decrease
tumoral cell lines proliferation. HLA-G Technologies is now
moving toward full preclinical studies in transplantation.
Incubator: No
Subsidiary of a group: Yes (Parteurop Développement)
Other status: No
Funding
Nature of funding searches: HLA-G Technologies is looking
for 3 M euros to finalise the proof of concept studies in
oncology indications and to conduct toxicology, kinetics studies
and also to produce our lead product under GMP conditions
in transplantation.
Private funding obtained: 2.5 M Euros have been raised since
1998
Public funding obtained: ANVAR in 2001, 460 000 euros
in warrants
Stock exchange listing: no
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Other contact
First name: Laurence
Last name: Rulleau
Position: Director
Phone: +33 (0)4 72 40 26 77
Fax: +33 (0)4 78 42 34 24
Business model
Value chain
Activities
Other.
Application fields
Human health, Immunology, Inflammatory diseases,
Autoimmune diseases, Cancer.
Activities
Company activities
HLA-G Technologies is a company involved in research
and development activities in the field of immunotolerance.
The company’s goal is to develop a new treatment
for transplant patients with a better efficacy and moreover less
toxicity as immunosuppressive treatments currently used
in transplantation whose present severe side effects.
The company conducted studies in 2 different graft animal
models (skin graft and heart graft models), the studies showed
that the injection of HLA-G peptides increase graft survival in
these 2 models. The company also showed the same efficacy
of our HLA-G molecule than current gold standard treatments
in transplantation but with less toxicity. In oncology,
the company showed that another form of HLA-G molecule,
with new mechanism of action, should improve the efficacy
of current cancer treatments when administered together
(with less resistance of the patients to these treatments).
In liquid cancers such as Non Hodgkin’s lymphoma (NHL),
Rituxan is considered as the gold standard treatment but
several patients developed resistance to this treatment. There
is a need for a new drug treatment in this indication and other
hematological cancers.
87
HLA-G Technologies has been studying HLA-G molecules
for over a decade and has the best knowledge of their
mechanism of action, structure and expression. The company
has been involved in prospective clinical trials and has been
the first to show that HLA-G expression is correlated
with higher graft survival. The company owns different families
of patents covering the molecule, the gene, the antibodies
and the different indications.
Pipeline product 1
Therapeutic area: Transplantation
Preclinical: research
Pipeline product 2
Therapeutic area: Oncology
Therapeutic indication: Liquid cancers
Preclinical: research
The company developed:
1. Peptidic forms of HLA-G
2. Recombinant proteins and fusion proteins
3. Antibodies
These different products have been tested
and used in different applications.
Partnership
The company is looking
for a collaboration with a laboratory using oncological animal
models. The company is also looking for a collaboration with
a laboratory able to evaluate allogenic responses mainly doing
evaluation of NK , CTL and MLR responses.
HLA-G Technologies will look
for a pharmaceutical partner to out-license its molecule
in transplantation after the first human efficacy clinical trial.
88
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company contacts
CEO contact detail
First name: Hélène
Last name: Rouquette
Position: CEO
Phone: +33 (0)1 45 89 60 00
Company name: iDD biotech
Address: 27, chemin des peupliers
Zip code: 69570
City: Dardilly
Main activity: iDD-Biotech is a leading biopharmaceutical
R&D company operating in the emerging field of monoclonal
antibody therapies for the treatment of cancer, autoimmune
diseases or neurological disorders. With its proprietary
hybridoma library following MAb engineering, iDD biotech
develops the next generation of therapeutic antibodies.
iDD-Biotech has IP on «best in class» compounds which are
in preclinical developments.
Incubator: No
Other status: Yes (JEI CIR)
Other contact
First name: Claudine
Last name: Vermot-Desroches
Position: R&D Manager
Phone: +33 (0)4 72 52 30 88
Fax: +33 (0)4 72 523075
Business model
Funding
Nature of funding searches: We are looking for the first
financial round from Capital development.
Private funding obtained: In progress
Public funding obtained: Financial FUI support: Project
PRAVIC (€ 537 K), Project GLIADYS (€ 1 474 K) CLARA
financial support: Project IPROMAH (€ 250 K)
R&D PROJECTS FUNDED
PRAVIC: Innovative recombinant proteins with immune
modulatory and anti-tumour activities
Funding: FUI (2005)
GLIADYS: Malignant glioma and brain dysorders new targeted
therapies
Value chain
Activities
Biomanufacturing, Drug discovery, Nanotechnology, Other.
Application fields
Allergology, Orphan diseases, CNS related diseases, Cancer.
Activities
Company activities
iDD biotech’s aim is the development of new therapeutic
candidates from its proprietary MAb portfolio with in parallel
the industrial bio production support. In accordance with key
challenges related to science, medical need and business, iDD
biotech leads several R&D projects accredited by Lyonbiopole
or CLARA…
A wide range of murine MAb (1000 hybridoma, 75 specificities).
Three complementary technical platforms (R&D and
Bioprocess development).
A project porfolio (2 preclinal programs and 5 R&D programs).
Three patents.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
89
Recent news
Since September 2009, iDD biotech has been working
on strategies facilitating the industrial development
of its candidate biomedicines. One of the key areas identified
is the need for a cGMP-grade bioproduction unit operating
on a 200-l scale and capable of producing MoAb batches
for Phase I clinical trials by January 2012.
Skills and know-how
Know how in MAb engeeniering: naked chimeric / humanized
MAbs, Antibody drug conjugate Target identification
Establishment of in vitro proof of concept Managment of R&D
collaborative projects.
Pipeline product 1
Therapeutic area: Onco hematology
Therapeutic indication: Autoimmunity
Preclinical: R005
Pipeline product 2
Therapeutic area: Onco hematology
Preclinical: R007
Pipeline product 3
Therapeutic area: Glioma
Preclinical: R&D R008-R011
Therapeutic MAb engeenering Therapeutic MAb expression
Functional MAb characterization.
Partnership
iDD biotech strategic orientation - medical need related and
market driven - prosecutes in three operating segments:
– by developing immunotherapeutic molecules in major
indications and partnering with pharmaceutical companies
for later stage development,
– by independently developing and commercializing
therapeutic MAbs for certain special markets,
– by licensing antibodies to companies for short and medium
term revenues.
90
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: ILL (Institut Laue Langevin)
Address: 6, rue Jules Horowitz
Zip code: 38042
City: Grenoble
Website: www.ill.fr
Main activity: The Institut Laue-Langevin (ILL) is
an international central facility located in Grenoble, France
on a science campus that also contains the European
Synchrotron Radiation Facility (ESRF), the European Molecular
Biology Laboratory (EMBL), the CNRS/CEA Institute
of Structural Biology (IBS) and the Institute of Cellular
and Molecular Virology. Collectively the partners on the site
contribute to the Partnership for Structural Biology (PSB)
which provides a powerful interdisciplinary framework
for the study of biological systems over a wide range of
resolutions and using a wide variety of techniques. ILL facilities
and expert scientists are available for industrial R&D through
purchasing services, contract research and joint research
programmes.
Incubator: No
Other status: No
Funding
Value chain
Research.
Activities
Diagnostics / Analysis method, Instrumentation.
Application fields
Human health, Nutrition / Food, Other.
Activities
Company activities
The Institut Laue-Langevin (ILL) is an international central
facility located in Grenoble, France on a science campus that
also contains the European Synchrotron Radiation Facility
(ESRF), the European Molecular Biology Laboratory (EMBL),
the CNRS/CEA Institute of Structural Biology (IBS) and the
Institute of Cellular and Molecular Virology (UVHCI). Collectively
the partners on the site contribute to the Partnership
for Structural Biology (PSB) which provides a powerful
interdisciplinary framework for the study of biological systems
over a wide range of resolutions and using a wide variety
of techniques. ILL facilities and expert scientists are available
for industrial R&D through purchasing services, contract
research and joint research programmes.
CEO contact detail
First name: Trevor
Last name: Forsyth
Position: Professor of Biophysics
Phone: +33 (0)4 76 20 71 58
d i r e c t o r y
Molecular biology and biophysics X-ray and neutron scattering
studies of biological and soft matter systems.
Company contact
s c i e n c e s
Business model
Skills and know-how
l i f e
2 0 1 1
Company services & technologies
Molecular biology and biophysics X-ray and neutron scattering
studies of biological and soft matter systems.
91
Business model
Product developer - Biopharmaceuticals, Service provider Scientific.
Value chain
Research, Preclinical, Marketing / Distribution.
Activities
Diagnostics / Analysis method, Vaccine, Preclinical trials,
Bioinformatics / Modeling, Other.
Company name: Imaxio
Address: 181, avenue Jean Jaurès
Zip code: 69007
City: Lyon
Website: www.imaxio.com
Main activity: Development and marketing of vaccines: Human
Leptospirosis vaccine marketed in France and development
of new vaccines using a genetic adjuvant IMX313. Development
of genomic diagnostic tests. Genomic services in DNA & CGH
biochips, RT-PCR, highthroughput genotyping and sequencing.
Incubator: Yes (BUSI)
Other status: Yes (CIR accreditation)
Funding
Application fields
diseases, Cancer.
Activities
Company activities
Imaxio markets the only human leptospirosis vaccine available
in Europe and develops new vaccines with both academic
and industrial partners. Imaxio also develops genomic tests,
particularly in partnership with Pierre Fabre Laboratories.
Human leptopirosis vaccine on the market. Proprietary genetic
adjuvant for new recombinant vaccines and state-of-the-art
technology platforms in genomics.
Skills and know-how
Protein engineering Genomic Technologies Pharmaceutical
affairs.
Company services
R&D PROJECT FUNDED
GR-CAV1: A novel immunotherapy approach for cancer with
Vaccin’ERY System®
Imaxio proposes services in genomics:
DNA Biochips & CGH arrays - Agilent Technologies
RT / Q-PCR - Applied Biosystems
Genotyping and High Throughput Sequencing - Illumina.
Imaxio has patented a protein domain IMX313, which improves
the T- and B-cell responses to antigens. This technology
is used in projects with industrial and academic partners
to create new vaccines.
Company contact
CEO contact detail
First name: Fergal
Last name: Hill
Position: Deputy Managing Director
Phone: +33 (0)4 37 65 55 04
Partnership
Genetic adjuvant technology
for new vaccine development available for out-licensing.
Genetic adjuvant technology IMX313.
Niche vaccines, either marketed
or in development.
92
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company contacts
CEO contact detail
First name: Nicolas
Last name: Pasqual
Phone: +33 (0)4 38 78 57 70
Company name: ImmunID Technologies
Address: 17, rue des Martyrs, CEA/IRTSV
Zip code: 38054
City: Grenoble
Website: www.immunid.com
Main activity: ImmunID, offers immunomonitoring solutions
to measure the impact of immunotherapy on the immune
repertoire. ImmunID answers Biotech & Pharma needs
enhancing success rate and decreasing cost of clinical trials.
ImmunTraCkeR and Immun’Ig tests contribute to measure
efficiency and safety of immunomodulators and to select
patients who will benefit from the treatment. In addition, these
tests are biomarkers of early diagnostic of certain pathologies
(ie: leukemia, GvHD…) and of monitoring of efficacy / infectious
risk ratio of a treatment to help clinician to make right decision
for their patients.
ImmunID proposed first the test for detection of Divpenia®
and the clinical score NDL®. This biomarker, currently
in clinical validation, will allow stratification of patients
with infectious or toxicity risk related to pathology
or to immunosuppressive effect of a treatment.
The measure of Divpenia allows monitoring of immune
reconstitution and measure efficiency of immune stimulating
treatment.
(Création 2006 et emmergence 2005)
Funding
Private funding obtained: 2,6 Millions Euros
Public funding obtained: 1,8 Million Euros
R&D PROJECT FUNDED
PLATINE: European immunomonitoring platform
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Other contact
First name: Nadia
Last name: Plantier
Position: Dir External Collaborations
& Business Development
Phone: +33 (0)4 38 78 57 70
Business model
Service provider - CRO, Product developer - Other health.
Value chain
Activities
Application fields
diseases, Cancer, Nutrition / Food.
Activities
Company activities
ImmunID’s business model is dual:
In a context where personalized medicine cannot be ignored
anymore by physicians and patients, and where each treatment
has its companion diagnostic tool to determine its efficacy,
ImmunID, a diagnostic company, develops tests
and biomarkers to measure Immune diversity for medical
and industrial applications.
93
The company sells Immunomonitoring services to
pharmaceutical and Biotech Companies as well as research
labs. These services are possible thanks to sustained R&D
activity in immunogenetic and Bio-information system.
In parallel, the clinical validation of ImmunID’s kits
for diagnostic of Divpenia combined with Constel’ID® software
and NDL® clinical score is currently in progress in order
to validate the medical relevance of this new biomarker.
The company has launched a large program of clinical research on
more than 700 patients in collaboration with
Centre Leon Berard and Hospices Civils de Lyon.
ImmunID Technologies offers innovative immunomonitoring
solutions to measure the impact of immunotherapy
on the immune repertoire (i.e. measurement of treatment
safety and efficacy).
ImmunTraCkeR® and Immun’Ig® are available for research,
preclinical and clinical validation steps.
Applications include:
– Clonal expansion identification and characterization
– Measurement of immunodeficiency infectious risk
– Measurement of combinatorial diversity kinetics
– Cohorte stratification
– Selection of patients to be included in clinical trials
(depending on their immune profile or immune forecast)
– Targeted immunotherapy monitoring
– Identification of responding and non responding patients
– Follow-up of clinical studies
– Vaccine, adjuvants, MAb candidates screening
– Humanized mice: characterization of immune response
and immunoreconstitution
– Databanking and datamining
In addition, ImmunID Technologies solutions contribute to
the identification of appropriate biomarkers that could give
information about early disease detection, progression and
response to treatment.
More importantly, ImmunID Technologies solutions can:
– Lower drug development costs and increase success rate
– Accelerate time to market
– Increase drug safety.
Recent news
ImmunID published first the divpenia definition
on www.divpenia.com
Ripal clinical trial (128 patients) in collaboration with HCL.
Susa clinical trial (n=100) sponsored by ImmunID
Roche Diagnostics France and ImmunID signed a technical
collaboration
Charles River and ImmunID have associated their expertise in
co-marketing agreement.
l i f e
s c i e n c e s
d i r e c t o r y
The technical development of Divpenie detection is based
on competences in Immunology, Cellular Biology, Molecular
Biology (qPCR), software and secure web solutions
development, and relies on clinical validation of diagnostic
Biomarker and CE mark regulation.
ImmunID technologies is certified ISO 9001-2008
and ISO 13485-2004 and complies with GLP procedures.
Pipeline product 1
94
Skills and know-how
2 0 1 1
Phase 1: ImmunTraCkeR Diagnostic Biomarker CE Marked
Phase 2: ImmunTraCkeR Diagnostic Biomarker CE Marked
Pipeline product 2
Phase 1: Immun’Ig Diagnostic Biomarker
Phase 2: Immun’Ig Diagnostic Biomarker
Company services
“Because we believe in personalized medicine we dedicate
our solutions and know-how to human health”
Founded to address pharmaceutical, diagnostic and
theranostic needs, ImmunID is a leader in Immune Diversity
analysis. Based on its original concept of immune forecast,
ImmunID contributes to the future of healthcare and ultimately
to a personalized medicine.
Based on patented biomolecular and bioinformatic methods,
ImmunID toolbox allows exhaustive and integrated view
of the whole T and B cell repertoires by screening gene
rearrangements.
This approach contributes to stratify patients with infectious
and early death risks following a pathology or a treatment.
This biomarker helps to select and better characterize patients
to be included in a clinical trial and contribute to enhance
success rate of clinical trials of immuno modulator treatments.
Partnership
Validation of biomarker
of Divpenia® and NDL® score on large cohorts (300 patients)
in following domains: anti-infective treatments; immune
stimulating treatments; anti-cancer treatments, pathologies:
HIV, HCV, Breast cancers and metastatic cancers, leukemia
and lymphoma.
Immunomonitoring Technologies: Cellular, Molecular Biology,
Sequencing.
Company contacts
CEO contact detail
Last name: Legastelois
Phone: +33 (0)4 72 39 14 92
Company name: Indicia Biotechnology
Address: 33, avenue de la Californie
Zip code: 69600
City: Oullins
Website: www.indicia.fr
Main activity: Indicia Biotechnology is a global provider
of outsourced development and bioanalytical services
to the pharmaceutical, biotechnology and medical device
industries.
As an immunotechnology specialist, Indicia Biotechnology
supports bio-industries in their R&D projects, and provides
services relating to immunoassays.
The company is currently focusing its strategy on protein
biomarkers of clinical interest and their applications for in-vitro
diagnostic.
By combining three competencies into a single offer:
– sample bio-analysis,
– assay development and
– in vitro diagnostic test production
Indicia Biotechnology is intended on contributing to the boost
in clinical programmes and in providing new theranostic
solutions. In the same time, Indicia Biotechnology intends
to develop proprietary products and analyses thanks to
collaborative and internal research projects..
Incubator: No
Other status: No
Funding
Nature of funding searches: In process.
R&D PROJECTS FUNDED
tomanufacturingprocessimprovementsandnewpharmaceutical
applications
GLIADYS: Malignant glioma and brain dysorders new targeted
therapies
of Crohn disease relapses and for therapeutic monitoring.
Clinical validation.
s c i e n c e s
d i r e c t o r y
Business model
developer - Biopharmaceuticals, Service provider - Scientific,
Value chain
Activities
Clinical trials, Preclinical trials, Drug discovery, Medical device,
Other.
Application fields
Autoimmune diseases, Allergology, Orphan diseases, Genetic /
Rare diseases, Metabolic diseases, CNS related diseases,
Cancer, Nutrition / Food, Dermocosmetics, Other.
Activities
Company activities
Indicia Biotechnology is positioning as a specialist
in immunotechnology and biochemistry. We offer R&D
and bioanalysis services to biopharmaceutical, CRO &
diagnostic companies. We support research and development
of bioanalytical methods.
FEMTOKINE: High sensitive immunoassays for the prediction
l i f e
Other contact
First name: Elodie
Last name: Panier
Position: General manager
Phone: +33 (0)4 72 39 14 92
Fax: +33 (0)4 72 39 16 01
2 0 1 1
Indicia Biotechnology is an ISO 9001/ISO 13485 certified
company, meet GMP guidelines and is duly approved within
the framework of the French Research Tax Credit.
95
Recent news
– June 2011: co-exposition with LyonBiopole at the BIO event
in Washington
– September 2010: Femtokine FUI project (Crohn’s disease)
– May 2010: collaboration with Singulex (USA) to provide
ultrasensitive and early biomarker detection through Erenna®
Immunoassay System
– September 2009: Gliadys project (based on therapeutic
antibodies against different glioma forms)
– June 2009: Septick shock project (development of an assay
to adjust treatments for people with septic shock).
Skills and know-how
Our expertise allows us to offer tailor-made solutions
to measure biological targets (companion diag tests, methods
to evaluate immunogenicity, assays for biomarkers, QC
methods…).
Company services
Custom immunoassay based on conventional and emergent
technologies: Erenna Singulex, ELISA, Luminex, Lateral flow…
– Custom monoclonal and polyclonal antibodies and associated
services
– Custom coated microparticles and separation methods...
– OEM Sterile liquid reagents: chemical and biological API,
solvents and preservative solutions for injectable forms,
chromatographic media for protein purification…
– OEM media for cell culture, microbiology, in process control Different packaging: tubes, bottles,bags.
Indicia Biotechnology’s offer includes bioanalysis and
developpment on the following technological plateforms:
– Immunoassays: Luminex®, Erenna® Singulex, ELISA, EIA,
– Rapid tests: lateral flow tests, slide agglutination tests,
– Raw material: polyclonal and monoclonal antibodies, coated
microparticles.
96
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Activities
Company activities
Company name: InfYnity Biomarkers
Address: 40, avenue Guy de Collongue
Zip code: 69130
City: Ecully
Website: www.infynity-biomarkers.com
Main activity: Identification and validation of biomarkers
of clinical interest in infectious and inflammatory diseases.
Identification of biomarkers of clinical interest, biological
validation
Identification and optimization of antigenic structures (epitopes)
on protein; design of antigenic and immunogenic peptides
Development of immunoassays for the determination
of biomarkers
Design and production of the peptide, recombinant proteins
and monoclonal antibodies for use in diagnostic
and therapeutic products
Design and validation of immunoassays for monitoring clinical
trials of therapeutic molecules (companion diagnostics).
Strong experience in the identification of epitopes on proteins
of human pathogens.
Design of protein antigens for the development
of immunodiagnostic tests
Design and Optimization of immunoassay methods on different
platforms (solid-phase, beads, membrane, etc.).
Recent news
Funding
Developing a test for detecting antibodies associated
with inflammatory processes leading to heart disease
(cardiomyopathy).
Skills and know-how
Company contacts
CEO contact detail
First name: Maan
Last name: Zrein
Position: President & CSO
Phone: +33 (0)6 30 56 57 34
Expertise in the development of multiparameter testing,
immunoassay methods, design of peptides with antigenic
or immunogenic properties.
Expertise in regulatory processes concerning biosimilars
including monoclonal antibodies.
Pipeline product 1
Therapeutic area: Cardiovascular
Business model
Service provider - CRO, Product developer Biopharmaceuticals, Service provider - Scientific, Product
Value chain
Partnership
Partnership covering the biopharmaceutical company with
HIKMA (www.hikma.com).
Partnership for the adaptation of a novel biomarker
in an automated immunoassay.
Activities
Diagnostics / Analysis method, Biomanufacturing, Clinical
trials, Biobank, Preclinical trials, Bioinformatics / Modeling.
Application fields
Human health, Inflammatory diseases, Infectious diseases,
Autoimmune diseases.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Automation of immunoassays.
Patent for an inflammatory biomarker involved in cardiac
complications.
Interest for in-licensing of any new biomarker infection and
monitored clinical trials.
97
Company contacts
CEO contact detail
First name: Hervé
Last name: Brailly
Position: Director
Phone: +33 (0)4 30 30 30 30
Company name: Innate Pharma
Main address: 117, avenue de Luminy
Zip code: 13009
City: Marseille
Second address: Bâtiment Domylion - 321 avenue JeanJaurès
Zip code: 69007
City: Lyon
Website: www.innate-pharma.com
Main activity: Innate Pharma SA is a biopharmarceutical
company developing first in class immunotherapy durgs for
cancer and inflammatory diseases. The company specializes in
development of new monoclonal antibodies targeting receptors
and pathways controlling the activation of innate immunity
cells.
Incubator: Yes
Other status: Yes
Stock exchange listing: Euronext 2006 ISIN
Code FR 0010331421 Ticket code IPH
R&D PROJECTS FUNDED
GR-CAV1: A novel immunotherapy approach for cancer
with Vaccin’ERY System®
l i f e
s c i e n c e s
Business model
Value chain
Activities
Models (animal - cellular - …), Clinical trials, Preclinical trials,
Drug discovery.
Application fields
Human health, Immunology, Inflammatory diseases, Cancer.
Activities
Funding
98
Other contact
First name: Yannis
Last name: Morel
Phone: +33 (0)4 30 30 30 30
d i r e c t o r y
2 0 1 1
Company activities
Innate Pharma SA is a biopharmarceutical company developing
first in class immunotherapy durgs for cancer
and inflammatory diseases. The company specializes
in development of new monoclonal antibodies targeting
receptors and pathways controlling the activation of innate
immunity cells.It has 2 priorietary clinical stage drug
candidates: IPH 1101, a small molecule agonist of gamma
delta T cells, has achieved proof of concept in 2 phases IIA
trials in type C viral hepatitis and follicular lymphoma. IPH
2101, an anti-KIR monoclonal antibody potentiating NK cells
activation, is currently in Phase II clinical trials in hematologic
cancers. Innate Pharma is also developing a preclinical
portfolio of immunomodulatory or cytotoxic monoclonal
antibodies. Two of its preclinical programs in chronic
inflammation have been out-licensed to Novo Nordisk A/S.
Innate Pharma ’s key expertise is in immunopharmacology
and antibody technology. The Company has implemented
in-house a large panel of molecular and cellular assays and
in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate
Pharma has access to a very large set of unique research
tools in cellular immunology through its worldwide network of
scientific collaborations.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in
2006, Innate Pharma is based in Marseilles, France, and had 85
employees as at December 31, 2010. Learn more about Innate
Pharma at www.innate-pharma.com
Company name: Institut Mérieux
Address: 17, rue Bourgelat
Zip code: 69002
City: Lyon
Website: www.institut-merieux.com
Number of employees: 1 000
Turnover: 1 400 000 000 Euros (en 2010)
Main activity: Holding with major stakes in the bioindustrial
companies bioMérieux (diagnostics), Transgene
(immunotherapy) and Mérieux NuriSciences (food safety
and quality controls, nutrition) and also in the R&D company
ABL, in the invesment company Mérieux Développement
and in IMAccess, a not for profit company dedicated
to diagnostics in developing countries.
Incubator: No
CEO contact detail
First name: Michel
Last name: Baguenault de Puchesse
Position: Chief operating officer
Email:
[email protected]
Phone: +33 (0)4 78 87 70 70
Other contact
First name: Dominique
Last name: Takizawa
Position: Chief financial officer
Email:
[email protected]
Phone: +33 (0)4 78 87 70 70
s c i e n c e s
d i r e c t o r y
Business model
Service provider - CRO, Product developer Biopharmaceuticals, Service provider - Scientific, Laboratory
equipment supplier.
Value chain
Research, Manufacturing / Production, Preclinical, Marketing /
Distribution, Clinical.
Activities
Clinical trials, Preclinical trials, Drug discovery, Other.
Application fields
Human health, Immunology, Infectious diseases, Cancer,
Nutrition / Food.
Activities
Company activities
In vitro diagnostics with bioMérieux and IMAccess
Company contacts
l i f e
2 0 1 1
Immunotherapy with Transgene Food safety and quality
controls, R&D in the field of nutrition with Mérieux
NutriSciences R&D in virology with ABL.
Expertise in infectious diseases and cancers Bioindustrial
capacities International network R&D capacities.
Recent news
Structuring of a nutrition and health division : Mérieux
NutriSciences creation of IMAccess dedicated to diagnostics
in developing countries.
Skills and know-how
Diagnostics and immunotherapy of Infectious diseases
and cancers Biomanufacturing clinical surveys microbiological
and chemical analysis in agrifood industry.
99
Business model
Company name: IntuiSKin
Address: Parc Activillage des Fontaines ZI Bernin
Zip code: 38926
City: Crolles
Website: www.intuiskin.com
Turnover: 2 M Euro (in 2009)
Main activity: Research, Development and Commercialization
Product developer - Other health, Laboratory equipment
supplier.
Subsidiary of a group: Yes (MEMSCAP)
Other status: No
Application fields
Funding
Company activities
of innovative skindiagnostic and skin care solutions.
R&D PROJECT FUNDED
MELASCAN: Innovative solution for screening and monitoring
in vivo of skin cancer, standardized for general practitioners
and specialists
Funding: ANR (2010 Tecsan)
Company contact
CEO contact detail
First name: Pascal
Last name: Ränsch
Phone: +33 (0)4 76 92 85 15
100
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Value chain
Research, Manufacturing, Clinical.
Activities
Diagnostics / Analysis method, Instrumentation, Medical
device, Other.
Human health, Cancer, Dermocosmetics.
Activities
Development of micro and macroscopic imaging devices /
physico-chemical MEMS based measurements.
Development of dermocosmetic and cosmetic products.
Brands: IOMA Esthetics, IOMA Derm, IOMA Beuty Proline
Innovative skin care solutions.
Company contact
CEO contact detail
First name: Jung
Last name: Jean François
Position: Director
Phone: +33 (0)6 87 27 37 02
Company name: jlm lab
Address: 18, rue du Bourgamon
Zip code: 38400
City: Saint Martin d’Hères
Main activity: JLM Lab designs and makes level 2
and 3 biosafe laboratories, innovative in many aspects.
These products are offered ready to use and turn-key.
Their reliability,mobility (every transport mode is possible:
maritime, road and air transports) and standalone (water,
electricity, and special fluids) qualities authorize their fast
setting up and implementation in any area of the world.These
modular laboratories provide as well, by their design (clean
rooms expertise, high technology materials…) outstanding
security and containment guaranties, and respect the
standards and legislation (ISO 16 644-4 and ISO 14 644-1,
legislation concerning the biological risks prevention
and the containment use of GMO).This offer, which is today
a quasi unique concept in the market, comes from
a constructive approach trough 5 innovation strong guiding
axis :
– Search of an optimal hygene by using welded partition walls
with half-round fillet (no silicone).
– Search of a maximum security with an engineering
concerned by containment, ergony and flood management.
– Provide a true energetic autonomy, based on technologies
allowing a prompt mobility, an easy transport and reduced
costs.
– Supply products designed with high technology materials,
guarantying outstanding containment and no porosity qualities
(synthesized resin(3)).
– Design to allow an easy maintenance.
Other status: Yes
Business model
Laboratory equipment supplier.
Value chain
Activities
Other.
Application fields
Immunology, Infectious diseases.
Activities
Company activities
JLM Lab offers standalone and mobile level 2 & 3 biosafe
laboratories, wich could be uded in particular by civilian,
military and NGO health services, for missions such
asepidemiologic watch, pandemic risks, and sanitary
emergencies.Furthermore, these modular laboratories can
also be an extremely pertinent answer (reduced costs, setting
up responsiveness) for the provision of directly operational
premises, for pharmaceutical and biotechnologies sectors,
within the framework of R&D missions with definite duration.
Funding
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
101
Company name: Kendle
Address: Espace Brotteaux - 13, place Jules Ferry
Zip code: 69006
City: Lyon
Website: www.kendle.com
Main activity: Kendle is a leading global clinical research
organization providing the full range of early - to late - stage
clinical development services. We focus on innovative solutions
that reduce cycle times for our customers and accelerate
delivery of life-enhancing drugs to market for patients
worldwide. The Lyon Office opened in 2005. (Kendle was
founded in 1981 in Cincinnati, USA and the French affiliate
was created in France in Issy-Les-Moulineaux in 1999).
Winner of Aderly Award 2008 – Best Company progress
over 3 Years 3 352 employees Worldwide and 100 in France.
Incubator: No
Subsidiary of a group: Yes (Kendle International)
Other status: No
Funding
Company contacts
CEO contact detail
First name: Eric
Last name: Leray
Position: General Manager Kendle France
Phone: +33 (0)1 70 36 78 86
Other contact
First name: Fabien
Last name: Berthomeau
Position: Associate Director Clinical Operations,
Lyon Office Head
Phone: +33 (0)4 78 65 15 21
Fax: +33 (0)4 78 65 09 44
102
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Research, Clinical.
Activities
Vaccine, Clinical trials, Drug discovery, Medical device.
Application fields
Activities
Company activities
As one of the world’s largest global providers of Phase
I-IV services, we offer experience spanning more than
100 countries, along with industry-leading patient access
and retention capabilities and broad therapeutic expertise,
to meet our customers’ clinical development challenges.
Focused on five regions, North America, Europe, Asia/Pacific,
Latin America and Africa, we ensure on-the-ground presence
wherever you need it. We are one of the few CROs positioned
to deliver in the next generation of strategic partnerships.
We’re committed to success in every partnership, large
or small, and are focused on delivering consistent quality
and value for every one of our customers. We believe that
strategic partnerships are the business model of the future,
where earlier and fuller collaboration will provide
the foundation for innovation and accelerated productivity.
Our vision «To be the best-in-class provider of clinical
development services to the biopharmaceutical industry
through broad therapeutic and geographic expertise».
– Top-tier CRO uniquely positioned to deliver Phase I-IV clinical
trials
– Services provided in more than 100 countries
– Customers include 44 of the world’s top
50 biopharmaceutical companies
– 51 clinical development locations in 31 countries spanning six
continents Experience across all major therapeutic areas.
We contribute to the development, approval and life cycle
management of innovative therapies for a broad range
of medical conditions. Our global and local therapeutic
expertise includes oncology, central nervous system,
cardiovascular, inflammatory and respiratory diseases,
endocrinology, analgesia, women’s health, vaccines
and dermatology. We focus our therapeutic offerings
on market needs and already are aligned with the top areas
expected to represent more than 70 percent of worldwide drug
sales through 2014: cancer/oncology/hematology, antibiotics/
antivirals, cardiology, arthritis/rheumatology/inflammation,
respiratory and diabetes.1 Independent research shows Kendle
is your ideal partner At Kendle, our strong site relationships
and ability to deliver consistent quality services make us
an excellent partner for biopharmaceutical companies.
In fact, independent quantitative research has demonstrated
our ability to maintain excellent site relationships and deliver
consistent quality services.
Recent news
– Kendle is the only CRO to have been ranked consistently
among the top two providers in the 2009, 2008 and 2007
CenterWatch Surveys of U.S. and European Investigative Sites 2
– In a March 2009 survey conducted by Industry Standard
Research, Kendle was: The top-rated CRO for “Efficient Site
Start-up”: Found to deliver «the most consistent quality services»
out of all CROs. One of only two CROs to be rated as exceeding
expectation for project manager quality/experience.
Kendle was named Winner “Best Technological Development
in Clinical Trials
– Software Solution” at the GCPj Clinical Research Excellence
Awards.
Skills and know-how
Committed project teams: We provide highly experienced
Project Leaders and multi-functional study teams who will
work with you proactively and creatively to accelerate the
clinical development process. Project Leaders are given clear
authority and accountability for study performance and are
involved in projects from the onset. Because they have primary
responsibility for customer relationships and repeat business,
they carefully plan study strategy, drive the development
of project-specific operating procedures and control team
assignments and activities.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company services
Preview Kendle’s capabilities:
– Early Stage – Phase I - Innovative solutions based on
ground-breaking science to accelerate your product’s clinical
development
– Late Stage – Phase II - IV Expert help for large, complex
global studies or smaller, regional trials
– Clinical Trial Elements: Critical key services to ensure your
project’s success:
– Getting started – Robust and proactive strategies to
accelerate study start-up and lay the foundation for trial
success
– The right advice – Invaluable regulatory expertise and advice
to help you navigate through the regulatory landscape
– Tech tools – Ground-breaking technologies for efficient
communication and high-quality clinical trial data
– Managing sites – Strong site relationships integrated
with innovative data technologies
– Medical know-how – Experience in every major therapeutic
area, along with many niche diseases
– Protecting patients – Accurate adverse event reporting
and risk assessment document preparation
– Medical writing – Expertise ranging from protocols
to regulatory submissions and study reports
– Delivering data – Expertise in Electronic Data Capture
and Biostatistical analysis, along with submitting ISS/ISEsupported NDAs and SDTM- and ADaM-formatted documents.
Unique study and data management tools Kendle’s proprietary
suite of software products, TrialWare®, allows our customers
to conduct their clinical trials faster, with greater accuracy and
efficiency. The TrialWare® family of technology includes everything
from TrialWatch®, our global clinical trial management system to
TrialEAS™, our award-winning, Web-based solution that expedites
the review of documents, scans and other medical materials
by independent adjudicators. In addition, we are at the forefront
of Electronic Data Capture. Our statisticians are highly trained
and knowledgeable in this field, with strong international
expertise. Kendle has experience utilizing the leading EDC
software packages, a dedicated EDC Support Center
and the expertise gained through the successful completion
of hundreds of EDC trials.
Partnership
We’re experts in managing successful partnerships – it’s
what we do best With Kendle, each partnership is different.
Whether you need a long-term strategic partner or you’re
simply looking for a partner to help you with a single project,
we have unique capabilities and the flexibility to act quickly and
efficiently. Kendle is specifically organized to realize operational
efficiencies, so we can streamline activities, accelerate
productivity and reduce your costs, while still maintaining the
highest quality standards. The Kendle difference Kendle is the
first of a new generation of CROs. We are committed to success
in every partnership. Whether it’s a large-scale strategic
collaboration or a functional service provider relationship,
making it happen is where we truly excel.
103
Company name: Khorionyx
Address: 1, rue des Greffières
Zip code: 69890
City: La Tour de Salvagny - France
Website: www.khorionyx.com
Main activity: Development of the medical applications
of human globin. Autologous implant as a dermal filler
for injection in skin folds and wrinkles. Other formulations
for bone augmentation and wound healing.
Other status: No
Funding
Nature of funding searches: Need to raise 3 millions euros
in June 2011 in order to perform the pivotal clinical trial in USA
necessary to get the BLA (Biologics License Application)
for producing and distributing the autologous globin dermal
filler in USA. This capital raise is conditioned by the results
of the ongoing pilot clinical trial in USA.
Private funding obtained: Feb 27, 2009: first raise
of 250.000 euros including the participation of Groupe Saint
Olive in Lyon Nov 15, 2010: Second raise of 250.000 euros
including the participation of Groupe Saint Olive in Lyon
Public funding obtained: Sep 12, 2006: loan granted by Oséo
of 100.000 euros
Business model
Product developer - Biopharmaceuticals,
Value chain
Activities
Biomanufacturing, Clinical trials, Other.
Application fields
Human health, Dermocosmetics, Other.
Activities
Company activities
Development of the medical applications of human globin,
the colourless insoluble protein derived from hemoglobin.
Autologous paste for injection and filling of dermal folds
and wrinkles. Other formulations or associations for bone
augmentation and wound healing.
Products, technology and applications protected by 5 recent
and complementary international patent families
(2003 to 2010). Product prepared in 1 hour: 8 syringes
of 1ml from a 10 ml blood sample of the patient (autologous
globin) or about 500 syringes from an outdated individual red cell
pouch (homologous globin). Competitive approach
for different existing applications of animal collagens.
Biological component to create new composite active
biomaterials.
Recent news
Company contacts
CEO contact detail
First name: Jean-Louis
Last name: Tayot
Position: Manager
Phone: +33 (0)6 73 89 53 00
August 24, 2010: I.N.D. (Investigational New Drug) granted by FDA,
to start the first pilot clinical trial of the autologous globin implant
for correction of nasolabial folds in 15 subjects. Human globin is
considered as a biologically active product by FDA. November 15,
2010: Capital raise of 250.000 euros including the participation of
Groupe Saint Olive in Lyon December 3, 2010: starting the pilot
clinical study
of the autologous globin as dermal filler.
Skills and know-how
Other contact
First name: Jean
Last name: Bernasconi
Position: Property Industrial Direction
Phone: +33 (0)6 71 17 92 83
104
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
20 years experience of biological research and industry
in Pasteur Mérieux, now Sanofi Pasteur. 20 years experience
of the manufacturing and medical applications of collagens
and biomaterials since 1987, shown by the top management
of Imedex and the creation or active contribution to the
development of three biotech companies in Lyon area (Episkin,
Symatese, Imedex Biomateriaux) and a Florida based start up
(Albiorex).
Pipeline product 1
Therapeutic area: dermal implant
Therapeutic indication: skin folds filling
Preclinical: done
Phase 1: ongoing
Phase 2: ongoing
Phase 3: 2012
MA: 2013-2014
Partnership
3 millions euros for the next capital raise.
Financial or corporate company
to become a shareholder and/or partner of Khorionyx.
Pipeline product 2
Therapeutic area: wound healing
Therapeutic indication: chronic wounds
Preclinical: in progress
Dermo-cosmetology, wound healing, bone augmentation,
biological complement to existing devices or composite
biomaterials: chemical adhesives, biological glue, mineral
fillers, meshes.
Pipeline product 3
Therapeutic area: dental implant
Therapeutic indication: bone augmentation
Preclinical: in progress
Company services
No employee. Collaboration with Albiorex and other
subcontracting companies in USA (manufacturing, CRO).
Human globin is the most abundant protein component
in the blood: 140mg/ml. It is easily and largely available
from any patient. Its colourless and insoluble character
at physiological pH enables to use it in the formulation
of new biomaterials. Globin may be prepared from autologous
blood or from fully controlled red cells in sterile conditions.
Also the resistance of globin to denaturation allows its
sterilization if necessary. The process and its control guarantee
the absence of any eventual virus or transmissible agent.
The human origin of globin explains a better biocompatibility
compared to animal collagens, in particular for repeating
injections in the skin.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
105
Company name: K-PLAN
Address: 11, avenue Albert Einstein
Zip code: 69100
City: Villeurbanne
Website: www.k-plan.fr
Turnover: 150Ke (in 2009)
Main activity: Engineering in research and development
of bio-medical applications. Study, development and marketing
of its own range of on-site devices, development
of new technologies in the field of biology and diagnosis.
Incubator: No
Other status: Yes
Funding
R&D PROJECT FUNDED
KALLISTE: Functional and robust equipment for the evauation
of pathogen agents chemosensitivity
Company contacts
CEO contact detail
First name: Dominique
Last name: Parzy
Position: Manager
Phone: +33 (0)6 71 23 84 07
106
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Activities
Instrumentation, Medical device, Other.
Application fields
Animal health, Human health, Infectious diseases, Other.
Activities
Company activities
Engineering company located in the science and technology
center Einstein in Villeurbanne-Lyon, and adhere to the world
competitive cluster Lyonbiopole. Investing since its creation
in research and development of bio-medical applications,
the team developed in parallel to his activity of expertise,
its own range of on-site-devices. Innovation: microbiological
laboratory «all in one», system patented, all equiped
(sampling, preparation, analysis, microbiological incubation),
deployable on all fronts by 2 people, air transportable
by standard commercial flight, integrated into 4 flight cases
in carbon fiber. Use: Increase the capacity of biological
response teams on site (epidemic, war, natural disaster…),
Military teams, NGO, Humanitarian Foundations. Development
Collaborative (French and Foreign laboratories) since 2007,
patent, trading since June 2009.
Young team consistued of engineers with complementary skills
(electronics, computer, optics and mechanics).
– Responsiveness
– Patents
– Research laboratories working in collaboration with K-Plan
– Expanding Market of the biological and medical mobile
laboratory on site.
Business model
Product developer - Other health, Other.
Company name: La cosmétique alpine avancée
Address: 12, quai du commerce
Zip code: 69009
City: Lyon
Main activity: Research, development and commercialisation
of high performance dermo-cosmetic solutions. The company
is currently cooperating with one of Lyon’s most famous
university laboratories in order to develop an innovative
biochemical process aiming to improve the efficiency of active
principles (mostly derived from natural ingredients from
the Alps) and to better control their activity on and inside
the human skin. The targeted sector of the company’s R&D
programme is dermo-cosmetics but the innovative process
could be potentially used in other sectors (ex. healthcare, food).
Incubator: No
Other status: Yes
Funding
Nature of funding searches: The company was founded with
the support of a small group of investors. We are now seeking
institutional investors. The plan is to raise between 100K
and 200K Euros in 2011 and then another similar sized round
in 2012.
Public funding obtained: The company recently applied
for Oseo’s “Innovation Support Funding Programme”.
Value chain
Research, Marketing / Distribution.
Activities
Other.
Application fields
Dermocosmetics.
Activities
Company activities
The company has two interdependent areas of activity.
The first one, which has just started, is “R&D” (i.e. development
of exclusive biochemical technologies in partnership
with prestigious research organisations). The second one,
which is planned to start at the end of 2012, is the “marketing
and distribution” of high performing dermo-cosmetic products
exclusively through an international selection of luxury points
of sale (i.e. luxury Spas, high end Perfumery and department
stores).
- Developing proprietary technologies in the dermo-cosmetics
sector
- Marketing and distribution of cosmetic products
on an international basis
- Outsourcing any non-core capabilities.
Recent news
Beginning of the research and development programme.
Its completion date is planned for the 2nd quarter of 2012.
Skills and know-how
R&D, Marketing and distribution
on a global scale.
Company contact
CEO contact detail
First name: Florent
Last name: Gerphagnon
Position: CEO & Founder
Phone: +33 (0)6 73 79 39 51
Partnership
Possibilities of cooperation in the areas of research and
development, marketing and distribution of the company’s dermocosmetic products.
Licensing opportunity of the company’s (future) patented
technology in non-core areas.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
107
Company name: Latoxan S.A.S.
Address: 20, rue Léon Blum
Zip code: F-26000
City: Valence
Turnover: 1.6 M Euros (in 2010)
Main activity: Production and sales of natural bioactive
ingredients for Drug Discovery, Life Sciences Research,
cosmetics and antivenom serae production. We supply:
Venoms and Libraries of venom fractions and of animal
toxins Plant extracts and purified plant molecules.
Incubator: No
Other status: No
Business model
Other.
Value chain
Activities
Application fields
diseases, Orphan diseases, CNS related diseases, Cancer,
Activities
Company activities
Nature of funding searches: We are willing to invest
Farming venomous species in facilities duly certified
and controled by authorities and audited by several
international pharmaceutical companies. Production
of venoms, venom fractions and animal toxins. We sell
the world most comprehensive catalogue of venoms
and venom toxins. Purification of venom fractions and toxins
Supply of plant extracts and plant purified molecules through
an exclusive partnership with an asian organism duly certified
by local environment authorities for the controlled harvest
of plants.
Company contacts
CEO contact detail
First name: Harold
Last name: de Pomyers
Position: President
Phone: +33 (0)4 75 41 91 91
Recent news
Funding
in additional capacity for purification and synthesis
of peptides from our unique venom catalogue.
The world widest venom and toxin catalogue Capcity to fetch
venomous specimens from the wild Adaptability and swiftness.
Marketing of Kitoxan a Library of venom fractions
from 60 diffrent venomous species.
Skills and know-how
Other contact
First name: Bénédicte
Last name: Bourgeaud
Position: Assistant
Phone: +33 (0)4 75 41 91 91
Fax: +33 (0)4 75 41 91 99
108
l i f e
s c i e n c e s
d i r e c t o r y
Venomous animals fetching and farming Venom production
Venom peptides purification Peptide hits deconvolution
and synthesis.
2 0 1 1
Business model
Service provider - CRO, Service provider - Non Scientific,
Service provider - CMO, Service provider - Scientific.
Value chain
Activities
Clinical trials, Other.
Application fields
Animal health, Human health, Nutrition / Food,
Dermocosmetics.
Activities
Company activities
Company name: LC2
Address: ZA de Charpenay - 10, rue de l’aqueduc
Zip code: 69210
City: Lentilly
Website: www.lc2.com
Turnover: 2800 k Euros (in 2010)
Main activity: Packaging, logistics and quality control
for the healthcare industries. As a high-quality pharmaceutical
establishment and service provider, since 1995 LC2 has used
its unique expertide for the packaging and logistics of clinical
trials and pilot batches.
– Import/QP Release
– Primary and secondary packaging
– Storage and «forward & reverse» logistics
– Destruction
– Quality control and stability studies
– Batch certification.
Other status: No
Funding
CEO contact detail
First name: Arnaud
Last name: Grivel
Position: Qualified Person - CEO
Phone: +33 (0)4 74 72 17 77
Other contact
First name: Christiane
Last name: Dally
Position: Business Development Marketing Manager
Phone: +33 (0)6 07 65 54 99
Fax: +33 (0)4 74 72 17 60
d i r e c t o r y
Adaptability-reactivity-reliability-quality.
Skills and know-how
– To perform all operations, from receipt of the protocol
to project closure.
– To check all steps in processes and guarantee product
storage under controlled and secure conditions.
– To certify a high degree of quality based on an exhaustive set
of pharmaceutical regulation-compliant procedures.
– To place data management at the heart of our activity,
guaranteeing optimum clarity and confidentiality concerning
the detail of operations performed.
Company services
Company contacts
s c i e n c e s
l i f e
– Project design, advice
– Import
– Purchase of comparators
– Batch file
– Development of placebo units
– Encapsulation
– Primary packaging: blisters, bottles, vials, sachets
– Secondary packaging: boxes, blisters-card, wallet, foam
– Randomization
– Label design and multilingual printing
– Printing code break envelopes/lists
– Analytical method transfer and validation
– Analytical control
– Stability and comparative dissolution studies
– Secured storage, controlled conditions: -25°C to -15°C/+2°C
to +8°C/+15°C to +25°C
– Shipments: France, Europe, International
– Pick up on investigation site
– Inventory of returns, destruction
– Batch certification/QP Release.
2 0 1 1
– Project design, advice
– Import
– Purchase of comparators
– Batch file
– Development of placebo units
– Encapsulation
– Primary packaging: blisters, bottles, vials, sachets
– Secondary packaging: boxes, blisters-card, wallet, foam
– Randomization
– Label design and multilingual printing
– Printing code break envelopes/lists
– Analytical method transfer and validation
– Analytical control
– Stability and comparative dissolution studies
– Secured storage, controlled conditions: -25°C to -15°C/+2°C
to +8°C/+15°C to +25°C
– Shipments: France, Europe, International
– Pick up on investigation site
– Inventory of returns, destruction
– Batch certification/QP Release.
109
Business model
Value chain
Research, Manufacturing, Marketing / Distribution, Other.
Activities
Diagnostics / Analysis method, Medical device, Other.
Application fields
Animal health, Human health, Nutrition / Food.
Company name: Magnisense
Address: 27, chemin des Peupliers - BP 62
Zip code: 69572
City: Dardilly
Website: www.magnisense.com
Main activity: Magnisense is a diagnostics company
that develops and markets magnetic bioassays,
under its own brand or in collaboration with the diagnostics
industry.
Incubator: No
Other status: No
Funding
Company contacts
CEO contact detail
First name: Luc
Last name: Lenglet
Position: President
Phone: +33 (0)4 72 17 50 62
Other contact
First name: Hayat
Last name: El Yousfi
Position: Marketing Manager
110
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Activities
Company activities
Magnisense is a diagnostics company that develops
and markets magnetic bioassays, under its own brand
or in collaboration with the diagnostics industry.
These next-generation bioassays improve rapid diagnostic
performance for human and animal diagnostics, food safety
and environmental protection testing. They are based
on magnetic bead markers, which can be used to achieve
the accuracy of laboratory testing with the ease of use of rapid
test methods Exploiting a unique feature of magnetic bead
markers, Magnisense’s MIAtek®: technology provides true
quantification of a large volume sample. The magnetic signal
is free of interference from environmental factors, permitting
a more sensitive and reproducible detection than possible
with other surface-restricted approaches common in lateral
flow rapid testing. Magnisense is developing two test formats
for different application areas:
– MIAstrip®: Point of care testing with a single dose, producing
objective, quantifiable and traceable results via a portable
reader. MIAstrip enables the identification of a target via
detection of known markers for a number of diseases including
avian flu, cardiac disease, tetanus, and bacterial, viral, parasitic
or mycotic infections.
– MIAflo®: Disposable cartridges for detection of targets,
such as bacterial contamination in food products, e.g. Listeria
and Salmonella, or in water, e.g. Legionella, with a sensitivity
that brings a significant reduction in testing time.
Recent news
– July 10, 2010: Magnisense, a developer of next generation
bioassays for human and animal diagnostics, food safety and
environmental protection, today announced that the US Patent
and Trademark Office has issued the company’s founding
patent entitled Method for Analyzing a Mixture of Biological
and/or Chemical Components using Magnetic Particles and
Device for the Implementation of said Method - a patent which
had already been granted in Europe in 2009.
– March 18, 2009: Magnisense, a developer of next generation
bioassays for human and animal diagnostics, food safety and
environmental protection, announced the launch of a new
discovery platform for the construction and characterization
of next generation nanomagnetic materials. This work, in
collaboration with the Paris 13 University and the Claude
Bernard Lyon 1 University, is funded by a 920,000 EUR grant
from l’Agence Nationale de la Recherche (ANR). It also benefits
the subsidies of the French agency for innovation, OSEO.
– March 5, 2009: Wave 80 Biosciences and Magnisense
announced the establishment of a new strategic partnership
to explore synergies between the companies’ industry-leading
technology platforms, MIAtek® magnetic detection technology
and SCATM assay cartridge technology.
Pipeline product 1
Preclinical: MIAtek®
Pipeline product 2
Preclinical: MIAstrip®
Pipeline product 3
Preclinical: MIAflo®
Magnisense has developed MIAtek®, a novel diagnostic
technology which promises to revolutionize diagnostic assays.
Magnisense uniqueness relies on the assessment of the
magnetic signature of magnetic beads as labels to permit
sensitive detection and precise quantification of a biological
target. Not only a « signal » our readers are looking after, but
a full « signature ». Subsequent robustness (no moving parts)
and versatility (various geometries) allow a wider range of
applications:
– Single tests: from strip tests (MIAstrip®) to flow-through
assays (MIAflo®),
– Multiparametric assays: from chip assays (MIAchip®) to
multi-bead multiparametric assays (MIAplex®),
– Magnetic immunoassays or molecular biology.
We believe it will finally allow tapping into the full potential of
magnetic detection for life sciences:
– Point of care testing: e.g., cardiac markers demanding both
high senstivity and wide dynamic range,
– Faster and quantified bacteria detection in, e.g., agro-food
products, water.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
111
Business model
Value chain
Activities
Clinical trials, Preclinical trials, Drug discovery.
Application fields
Human health, Autoimmune diseases, Metabolic diseases,
Nutrition / Food.
Activities
Company name: Mellitech SAS
Address: CEA Grenoble INAC/SCIB Bat C5
Zip code: 38054
City: Grenoble
Website: www.mellitech.com
Main activity: Mellitech SAS, a biopharmaceutical and drug
discovery company, engages in the discovery and development
of therapies and companion diagnostics for diabetes care.
Other status: Yes
Funding
Company activities
Mellitech SAS, a biopharmaceutical and drug discovery
company, engages in the discovery and development
of anti-diabetics, diagnostic methods, and a functional imaging
technology for the pancreas. The company’s 3 lead projects
are:
– The development of a 1st-in-class ZnT8 agonist for type
2 diabetes through to phase I/IIa, at which point it will be
licensed out.
– The development of a functioning beta cell imaging
technology based on Mellitech’s IP protected anti-body;
– The development of ZnT8 peptides to treat type I diabetes.
ZnT8 is a major new T2D target (Science, Nature, Nature
Genetics, Diabetes, Diabetologia, Diabetes Care,
PNAS 2007-2010) that is expected to revolutionize diabetes
treatment and follow-up. Mellitech is the most advanced
company in the development in ZnT8-derived applications
in diabetes therapy, diagnostics and imaging.
Recent news
Mellitech and their academic partners within CEA, INSERM
and UJF have been selected by the National Research Agency
(ANR) through the call BiotecS 2010 for their 3-year R&D
project «Preclinical development of molecular imaging
antibodies targeting the ZnT8 protein for the diagnosis and
follow-up of diabetes.
Company contacts
CEO contact detail
First name: Richard
Last name: Platford
Position: CEO
Phone: +33 (0)4 38 78 43 54
Skills and know-how
Other contact
First name: Yann
Last name: De Boysson
Position: Head of Business Development
Phone: +33 (0)4 38 78 43 54
Fax: +33 (0)4 38 78 50 90
– ZnT8 biology
– HTS screening for compounds with potential ZnT8 agonist
activity;
– Zinc and insulin testing in-vitro and ex-vivo (animal
and human islets).
Pipeline product 1
Therapeutic area: Type II diabetes
Therapeutic indication: oral treatment
Pipeline product 2
Therapeutic area: Diabetes
Therapeutic indication: in vivo imaging
Pipeline product 3
Therapeutic area: Type I diabetes
Therapeutic indication: Prevention therapy
112
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company contacts
CEO contact detail
Last name: Crosia
Position: Chairman Merial SAS
Phone: +33 (0)4 72 72 30 00
Company name: Merial
Address: 29, avenue Tony Garnier
Zip code: 69007
City: Lyon
Website: www.merial.com
Turnover: 2,6 Mds dollars (in 2009)
Main activity: Merial is a world-leading, innovation-driven
animal health company, providing a comprehensive range
of products to enhance the health, well-being and performance
of a wide range of animals. Merial employs approximately
5,700 people and operates in more than 150 countries
worldwide. Its 2009 sales were over $2.6 billion.
Merial is the Animal Health subsidiary of sanofi-aventis.
Subsidiary of a group: Yes (sanofi-aventis)
Other contact
First name: Corinne
Last name: Demée
Position: Merial SAS Communication Director
Business model
Product developer - Biopharmaceuticals, Product developer Pharmaceuticals, Product developer - Other health.
Other status: No
Value chain
Funding
Activities
Vaccine, Other.
Application fields
R&D PROJECTS FUNDED
GAP: Healthcare shield solutions against avian flu
and flu pandemics
Funding: FUI (2005)
HYPERBAR: Bringing into the vaccine production industry
an alternative to chemicals for bacteria and viruses inactivation
by high pressure treatment
FIV-VAX: Development of a vaccine against feline
immunodeficiency virus (FIV)
PATVAX: Process Analytical Technology for Vaccines
NOVADUCK: Novel avian influenza diva recombinant vaccines
for duck
Funding: Europe (FP6)
l i f e
s c i e n c e s
d i r e c t o r y
Animal health, Immunology, Infectious diseases.
Activities
Company activities
Merial is a world-leading, innovation-driven animal health
company, providing a comprehensive range of products
to enhance the health, well-being and performance of a wide
range of animals. Merial employs approximately 5,700 people
and operates in more than 150 countries worldwide. Its 2009
sales were over $2.6 billion. Merial is the Animal Health
subsidiary of sanofi-aventis.
MERIAL is the only worldwide player exclusively dedicated
to the animal health sector.
N° 1 in the Companion Animal sector
N° 1 in Foot and Mouth Disease (FMD) and Bluetongue (BTV)
vaccines
N° 1 in Rabies vaccines
N° 2 in the Avian market.
Recent news
100% sanofi-aventis from september, 2009.
Skills and know-how
– Vaccines
– Pets infectious diseases
– Developing diseases.
2 0 1 1
113
Company name: Metabolys
Address: Faculté de Médecine Laennec
Zip code: 69372
City: Lyon Cedex 08
Website: www.metabolys.com
Turnover: 35 k€ (in 2009)
Main activity: Metabolys acts as a CRO to predict early during
the preclinical development the safety and efficacy of drug
candidates/chemicals/biologics using cellular metabolomics,
an innovative approach. Cellular metabolomics provides
a panoramic view not only of the metabolic pathways in any
human or animal cell type in vitro but also of the beneficial
and adverse effects of milligram amounts of test compounds
with these metabolic pathways. Metabolys has also a drug
discovery line in the diabetes field.
Incubator: Yes (CREALYS et EML)
(emergence (2007); creation/development (2009))
Other status: Yes
Activities
Company activities
Metabolys acts as a CRO to predict early during the preclinical
development the safety and efficacy of drug candidates/
chemicals/biologics using cellular metabolomics, an innovative
approach. Cellular metabolomics provides a panoramic view
not only of the metabolic pathways in any human or animal
cell type in vitro but also of the beneficial and adverse effects
of milligram amounts of test compounds with these metabolic
pathways. Metabolys has also a drug discovery line in the
diabetes field.
– Prediction of the safety and efficacy of test compounds
early during their discovery/preclinical development - use of
metabolically differentiated cells in vitro
– Use of an innovative approach that accelerates and reduces
the cost of drug development
– Drug discovery (antidiabetic candidates).
Recent news
The activity of Metabolys started on the 1st October 2009.
Metabolys has recently discovered a series of antidiabetic
candidates and would like to develop one of them up
to Phase IIa.
Skills and know-how
Funding
Nature of funding searches: Metabolys would like to raise
funds for the establishment of the preclinical and clinical
proofs of concept (up to Phase IIa) for an antidiabetic candidate.
Private funding obtained: equity: € 170.5 K
Public funding obtained: Ministry of Universities and
Research/OSEO laureate: 2007 (€ 39 K) and 2009 (€ 395 K)
OSEO in July 2010: € 150 K
Cellular metabolomics combines the use of any human
or animal cell type in vitro with (i) the measurement
of substrate utilization and product formation by both
enzymatic and carbon 13 NMR techniques and (ii)
mathematical modelling of cellular metabolic pathways
in the absence and the presence of small amounts of test
compounds.
Pipeline product 1
Company contact
CEO contact detail
First name: Gabriel
Last name: Baverel
Position: CEO
Phone: +33 (0)6 84 85 57 75
Preclinical: cellular metabolomic
Phase 1: metabolomic
Company services
see above.
see above.
Partnership
Business model
Service provider - CRO, Product developer - Pharmaceuticals.
Value chain: Research, Preclinical, Clinical.
Activities
– Study of the safety of drug candidates from any therapeutic
class
– Study of the efficacy of drug candidates aimed at treating
metabolic diseases (diabetes), cancer and neurodegenerative
diseases
– Provision of primary cancer cells.
Models (animal - cellular - …), Preclinical trials,
Application fields
Human health, Infectious diseases, Metabolic diseases, CNS
related diseases, Cancer, Nutrition / Food.
114
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Co-development of an antidiabetic candidate.
One antidiabetic candidate.
Business model
Product developer - Other health, Other.
Value chain
Manufacturing.
Activities
Application fields
Human health, Geriatrics, Genetic / Rare diseases, Other.
Activities
Company activities
Design and sales of tools for joint assessment
for rehabilitations purposes Design of Daily physical activity
monitoring tools.
Unique expertise in human motion features development IP:
250 patents/65 patent families.
Recent news
Company name: Movea
Address: 4, avenue Doyen Louis Weil
Zip code: 38000
City: Grenoble
Website: www.movea.com
Turnover: 12 M dollars (in 2010)
Main activity: Design of intertial measurment units
for consumer electronics and particularly for sports, fitness,
entertainment and wellness applications .
Incubator: Yes (GRAIN)
Prize winner for innovative start-up: Yes (Creadev 2007)
Funding
Nature of funding searches: Enhance our existing tools for
joint assessment for rehabilitations purposes develop Daily
physical activity monitoring tools for massive adoption.
Private funding obtained: € 7.3M in December 2007
and € 4M in September 2010
Public funding obtained: € 1.5M per year from CIR and
funded projects
Developed and manufactured our second generation intertial
measurment units development for rehabilitation purposes
Daily physical activity monitoring demonstrator.
Skills and know-how
Extensive know-how for developping human motion sensing
based on low cost MEMS sensors.
Pipeline product 1
Therapeutic area: Physical rehabilitation
Therapeutic indication: joint assessment and biofeedback
exercises
Pipeline product 2
Therapeutic area: Daily physical activity monitoring
Therapeutic indication: physical activity assessment for aging
population management
Company services
From requirements/specification, Movea can design specific
motion features for specific applications.
Chip/chipset and software solutions for:
– measuring human motion
– classifing human motion.
Partnership
Company contact
Movea is looking for partners who wish to integrate motion
technology and build their own product and take it to market.
CEO contact detail
First name: Sam
Last name: Guilaumé
Position: CEO
Phone: +33 (0)4 38 21 19 21
Looking for system integrators that have access to a end
user market and wish to integrate movea’s motion sensing
technology.
Yes this is part of Movea’s business model, toprovide licenses
to system integrators and solution providers.
Yes, other Motion sensing technology companies that can add
value to Movea existing IP portfolio.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
115
Company contacts
Company name: Nano-H SAS
Address: 2, place de l’Europe - Bât. A - Parc d’activite GVIO
Zip code: 38070
City: Saint Quentin Fallavier
Website: www.nano-h.com
Turnover: 0,5 M Euros (in 2009)
Main activity: Nano-H develops and uses innovative
technology for manufacturing new materials, nanoparticle
hybrids. Innovative company, it offers service and material
for high technology industries and research laboratories:
phosphors, counterfeiting, plotter, medical imaging
and bio-sensors, biological detection and in-vivo or in vitro.
Products are high quality by their size and their chemical
and physical adaptability. The materials are defined by specific
nanoparticle hybrids with size and surface adaptable to graft
hybrid molecules: organic (fluorpohores) or biological.
The many additional properties of these nano-hybrid: optical,
magnetic, radio-active, ensure a real multifunctional tool.
They are also new contrast agents (medical imaging),
therapeutic agents (oncology) and tracers in the fields
of cell labeling and tracking and anti-counterfeit marking mass
or unit.
(Creaction & Development, 2004)
Other status: Yes
Funding
R&D PROJECTS FUNDED
Other contact
First name: Laurence
Last name: Marmuse
Position: R&D Engineer
Phone: +33 (0)4 74 94 53 46
Fax: +33 (0)4 74 94 53 46
Business model
Value chain
Activities
Cell therapy, Preclinical trials, Nanotechnology, Other.
Application fields
Animal health, Human health, Orphan diseases, Cancer.
Activities
Company activities
Nano-H is an innovative company aimed at high technology
industries and research laboratories, users of nanoparticles:
phosphors, counterfeiting, plotter, medical imaging
and bio-sensors, biological detection and in-vivo or in vitro.
It offers its services to manufacturing and marketing
of its products based on nanoparticles. They meet the needs
of high quality by their size and their chemical and physical
adaptability.
THERANEAN: Therapy through Neutron-Activated Nanopar-
Nano-H develops specific materials for its partners based on
functional nano-objects best suited to their specific applications.
The specific products that Nano-H offers are defined by hybrid
nanoparticles: size and surface functionality with adaptable
by grafting hybrid molecules: organic (fluorpohores) or biological.
The many additional properties of these nano-hybrid: optical,
magnetic, radio-active, make a real multifunctional tool available,
with significantly improved performance in many sectors of
industry and nanotechnology.
ticles )
NANOGADO: Rare earth oxyde nanoparticles: new agents
for diagnostic and combined therapy
Funding: ANR (2005 NANO)
CAPTCODE: Labelless diagnostic lab on chip, use of hybrid
luminescent nanoparticles
Funding: ANR (2005 NANO)
APTAPROBE: Nanohybrids grafted with aptamer targeting
tumoral tissue for multimodal detection and therapy
116
First name: Cedric
Last name: Louis
Position: President
Phone: +33 (0)4 74 94 53 46
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
These nano-hybrids can offer and market analysis of biological
probes of high sensitivity capable of lowering the threshold
of current detection. They are also new contrast agents
for the imaging industry medical potential of therapeutic
agents capable of penetrating the market for treatment
of cancer, probes for labeling and for cell therapy, and tracers
for in vivo consider targeting and active treatment for localized
tumors. Several products are currently under preclinical
evaluation. Finally we propose a new generation of tracers
in the field of anti-counterfeit marking mass or unit.
Company name: NatX-ray
Address: Zone Minatec BHT Bat , 7, parvis Louis Neel BP 50
Zip code: 38040
Website: www.natx-ray.com
Turnover: 353000 Euros (in 2010)
Main activity: development, manufacturing and sale
of robotized systems for crystallography resale
of consumable products for crystallography.
Other status: Yes
Funding
Business model
Value chain
Activities
Instrumentation.
Application fields
Activities
Company activities
Development, manufacturing and sale of automated systems
for data collection in crystallography (G-Rob systems)
Resale of consumable products for crystallography labs
(crystallography plates, phasing kits…).
Company contacts
CEO contact detail
Last name: Larive
Position: President
Phone: (0)01 858 775 0207
Other contact
First name: Jean-Luc
Last name: Ferrer
Phone: +33 (0)6 89 45 13 57
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
117
Business model
Value chain
Activities
Company name: NETRIS Pharma
Address: Centre Léon Bérard - 28, rue Laennec
Zip code: 69008
City: Lyon
Website: www.netrispharma.com
Main activity: NETRIS Pharma is a R&D company developping
therapeutic molecules for targeted therapy of cancer, based on
the innovative concept of dependence receptors.
(Category Emergence in 2006 - Category Creation
and Development in 2008)
Other status: No
R&D PROJECT FUNDED
NETRIS: A new targeted anti-tumoral therapy based
on the concept of dependence receptors
Company contacts
CEO contact detail
First name: Agnès
Last name: Bernet
Position: CEO
Phone: +33 (0)4 78 78 59 71
Other contact
First name: Pascale
Last name: Nony
Position: COO
Phone: +33 (0)6 42 32 74 17
Fax: +33 (0)4 78 78 28 87
l i f e
s c i e n c e s
d i r e c t o r y
Activities
Company activities
NETRIS Pharma develops innovative medicine based
on the concept of dependence receptors. The concept has been
described by Patrick Mehlen, leader of the “Apoptose, Cancer
and Development” laboratory (Centre Léon Bérard)
and co-founder of NETRIS Pharma.
In the respect of ethical rules and within a legal framework,
NETRIS Pharma evaluates and optimizes, in both in vitro
and in vivo models, the pharmacological profile of the drug
candidates the company is developing. Pharmacokinetic
and toxicological aspects are integrated from the beginning.
This means that NETRIS Pharma is able to propose, under
the best conditions, licensing and collaborative agreements
to the pharmaceutical industry. In the future, NETRIS Pharma
will be involved in co-development strategies.
Funding
118
Application fields
2 0 1 1
NETRIS Pharma has one drug candidate in preclinical
for which the anti tumoral activity has been validated in lung
cancer animal models. Drug candidates targeting other
dependence receptors are under development.
Company key features:
– Innovative drug candidates for cancer therapy: NETRIS
Pharma is the leader on the market
– The potentiality of the market (Breast cancer, lung cancer
etc.)
– Expertise and know how of the collaborators.
Recent news
Prix Universal Biotech in 2009.
Skills and know-how
R&D Pre-clinical studies Quality procedures Strategic
Development.
Partnership
NETRIS Pharma has an out-licencing strategy for the innovative
drug candidates the company develops. The company is therefore
looking for pharmaceutical industries with interest in NETRIS’
projects for the targeted therapy of cancer.
Company name: Nocosium
Address: 15, rue Jules Romains
Zip code: 69120
City: Vaulx-en-Velin
Website: www.nocosium.com
Turnover: in creation (in 2009)
Main activity: Nocosium is a firm acting principally in
health domains like hospital, transfusion, pharmaceutical,
bioengineering, researches, industrial activities, based
on the mastering of environment and biocontamination. In
its field of activities, Nocosium developed the concept of an
Integrated Operating Theater (“Plateau Technique Hospitalier
Intégré” PTHI in French), which is proposed turnkey. This
approach is innovative
(copyright n°QF-2008-168016938407257-001 2008-05-30)
because of its prophylactic concept.
Subsidiary of a group: Yes
Funding
Nature of funding searches: 3 principal steps are planned:
– Prototype realization end commercialization
– Industrialization plan
– Funding of innovations.
Company contacts
CEO contact detail
First name: Gérard
Last name: Santailler
Position: President
Phone: +33 (0)6 85 55 59 93
Other contact
First name: Amalric
Last name: Montalibet
Position: Scientific Director
Phone: +33 (0)6 67 93 05 41
Fax: +33 (0)4 78 32 87 53
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Other.
Value chain
Other.
Activities
Other.
Application fields
Food, Dermocosmetics, Other.
Activities
Company activities
Nocosium is a firm acting principally in health domains
like hospital, transfusion, pharmaceutical, bioengineering,
researches, industrial activities, based on the mastering
of environment and biocontamination. In its field of activities,
Nocosium developed the concept of an Integrated Operating
Theater (“Plateau Technique Hospitalier Intégré” PTHI in
french), which is proposed turnkey. Prevalence inquiries show
that 6 to 10% of patients situated in an hospital a specified day
have got a nosocomial infection. The most concerned medical
services are by decreased order: intensive care
(30% prevalence) and surgery (7 to 9% prevalence).
For example in surgery services, 3% of operations are
submitted to surgical site infection complications. (origin:
ministère de la santé et des sports, 4 mars 2009). In 2007,
the French National Institute of Sanitary Watching (INVS)
counted 4188 (probably 9000) deceases entirely linked
to a nosocomial infection. On the same period of time,
car accidents made 4274 deceases. (origin: INVS, 12 janvier
2007, Ministère de la sécurité routière) Nosocomial infections
are a major societal health problematic, generating
an estimated over cost of 2,6 to 6 Billion Euros per year.
The approach of construction of PTHI is innovative (copyrighted)
because of its prophylactic concept.
119
Company name: Noraker
Address: 13, avenue Albert Einstein
Zip code: 69100
City: Villeurbanne
Website: www.noraker.com
Other status: Yes
Company contacts
CEO contact detail
First name: Rachid
Last name: Zenati
Phone: +33 (0)4 78 93 30 92
Other contact
First name: Michel
Last name: Domenget
120
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Research.
Activities
Medical device.
Application fields
Human health.
Company name: Novadiscovery
Address: Bioparc Laënnec - 60, avenue Rockefeller
Zip code: 69008
City: Lyon
Website: www.novadiscovery.fr
Main activity: Novadiscovery is a life sciences company
specialised in translational research. We have developed
a proprietary toolbox to ensure the optimal transfer
of knowledge from bench to clinic geared towards applications
in public health and personalised medicine. Member
of the Lyonbiopole centre of excellence, the company has
developed a unique expertise in numerical modelling in biology
(biomathematics, computing and data management) applied
to drug and biomarker R&D programs. Novadiscovery is
the only platform globally to offer partners and clients an
integrated environment to predict the individual and population-level impact in terms of efficacy of all results
produced throughout their research. We are focused
on bringing to our partners and clients best-in-class innovation
capabilities to improve R&D economics through increased
success rates, the ability to de-risk critical decision points
and accelerate proof of concept.
Company contacts
CEO contact detail
First name: François-Henri
Last name: Boissel
Position: CEO
Phone: +33 (0)4 63 60 05 06
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Research, Other.
Activities
Application fields
Activities
Company activities
Our translational research platform brings high value-creating
services to our partners and clients:
– Structured knowledge – a dynamic environment to organise
and manage scientific knowledge, experimental and clinical
data in connection with a given therapeutic area;
– In silico screening of potential drug targets and identification
of biomarker systems – from the very first stages of research,
our technology enables the selection of targets and biomarkers
on the basis of their systemic and populational effects.
The reference criteria is the optimal populational benefit as
measured in terms of the number of averted events or survival;
– Predicting efficacy at the population level – a public health
impact prediction technology over a population of interest
to combine populational benefit and pharmaco-economic
criteria at each decision-point of their R&D programs;
– Personalising treatments – identifying and validating
prognostic biomarkers of a clinical event and efficacy
biomarkers for a treatment or drug candidate;
– In silico experimentation – a versatile approach, comparatively
faster and cheaper than existing alternatives,
to explore and generate new hypotheses ahead of in vitro
and in vivo experiments.
121
Business model
Value chain
Company name: NovoCIB
Zip code: 69003
City: Lyon
Website: www.novocib.com
Turnover: 60 ke (in 2010)
Main activity: Nucleotides are universal metabolites
Diagnostics / Analysis method, Drug discovery.
Application fields
Infectious diseases, Genetic / Rare diseases, Cancer, Other.
Activities
Company activities
Funding
Based on its expertise of the metabolism of nucleotides
and its know-how in enzymology and molecular biology,
NovoCIB has built a portfolio of enzymes and assays
which are marketed since 2008.
This range has already shown numerous opportunities
for answering the needs expressed by the health industry
and the agrifood market. NovoCIB valorizes its enzyme
portfolio by marketing easy-to-use enzymatic kits which
can be used on the field with portable luminometers, already
on the marketed for several years. These apparatus
are currently used for hygiene microbiological control.
They use the ATP-dependent luciferase from firefly. This
bioluminescence (ATP-metry) has already attracted a large
number of industrials (Promega, Berthold, Kikkoman, Hygiena,
Charm…).
Another luciferase exists. It is bacterial, NAD(P)H-dependent,
and its potential of applications is comparable to ATP-metry,
but for other uses. However, the industrial production
of the enzyme has always come up against technical problems
regarding yield and stabilization of the heterodimeric enzyme.
After 2 years of research, NovoCIB has broken down these
technological barriers and is about to provide the market
with a purified highly active bacterial luciferase and to develop
a range of innovative bioluminescence kits for Research,
Diagnosis, Food and environmental markets.
Private funding obtained: 2009: € 270 K from Business
of all earth-living organisms. Buiding blocks of DNA, RNA,
they are also substrates of numerous enzymes involved
in cell metabolism processes.
NovoCIB has developed:
– a range of unique recombinant enzymes of nucleotide
metabolism
– a bacterial luciferase (NAD(P)H-dependent) for the
ultrasensitive detection of metabolites by bioluminescence
This portfolio is the technological basis from which NovoCIB
develop and market new enzymatic assays and kits to answer
the needs of:
– pharmaceutical market, by providing enzymatic assays for
the ultrasensitive detection of the metabolites produced by
therapeutic target enzymes
– diagnosis in metabolic disorder
– food industry, through the development of a portable system
for freshness analysis of perishable foodstuffs.
2003 (Emergence), 2005 (Creation & Development)
Other status: Yes (JEI, Certified )
Angels (Savoie Angels & its Investments Funds)
Public funding obtained: € 450 K (2005)
Company contacts
CEO contact detail
First name: Larissa
Last name: Balakierva
Position: President, CSO
Phone: +33 (0)4 78 53 63 95
l i f e
s c i e n c e s
d i r e c t o r y
A well-defined positioning centered on the study of a precise
metabolism (nucleotide). NovoCIB’s expertise in this field is
now recognized by its partners and customers.
A unique range of enzymes and kits.
A global vision of the application range that NovoCIB’s R&D
results and enzyme technology can offer to other unsatisfied
markets.
Recent news
Partnership with ChemRAR (Moscow, Russia) for the research
and Development of new drugs against Hepatitis C Virus.
Skills and know-how
Other contact
First name: Nicolas
Last name: Godard
Position: Partner, Development Manager
Phone: +33 (0)4 78 53 63 95
Fax: +33 (0)4 78 53 63 95
122
Activities
2 0 1 1
Besides its enzyme portfolio, NovoCIB offers in vitro assays and
whole-cell assays for a fast evaluation of the pharmacological
potential of new nucleoside analogs (pro-drugs) whose efficacy
depends upon:
– their activation by nucleoside kinases
– their resistance to cellular hydrolases (phosphohydrolases,
pyrophosphohydrolases, deaminases)
– the intracellular concentration of the natural competing
nucleotide.
Business model
Value chain
Activities
Biomanufacturing, Models (animal - cellular - …), Preclinical
trials.
Application fields
Animal health, Human health, Immunology, Cancer.
Activities
Company name: Novotec
Address: 13-15, rue J. Monod
Zip code: 69007
City: Lyon
Website: www.novotec-labs.com
Turnover: 0.4 M Euros (in 2010)
Main activity: Development, production and distribution
of a large line of polyclonal and monoclonal antibodies
directed against macromolecules of the ExtraCellular Matrix:
collagens, elastin, fibronectin and laminin, purified from
human and various animal species. Special expertises on the
immunohistochemistry of ECM components and the tissular
and serological evaluation of ECM remodeling, in particular
during organ fibrosis. Global array of services related
to the tissular evaluation (histology, immunohistochemistry,
image analysis, in situ hybridization ..) and to cell cultures
(cytocompatibility, viability, RNA and protein expression…).
Incubator: No
Company activities
Development, production and distribution of a large line
of polyclonal and monoclonal antibodies directed against
macromolecules of the ExtraCellular Matrix: collagens,
elastin, fibronectin and laminin, purified from human
and various animal species. Special expertises on the
immunohistochemistry of ECM components and the tissular
and serological evaluation of ECM remodeling, in particular
during organ fibrosis. Global array of services related to
the tissular evaluation (histology, immunohistochemistry,
image analysis, in situ hybridization…) and to cell cultures
(cytocompatibility, viability, RNA and protein expression…).
ECM, fibrosis evaluation, extra- and intracellular expertise
(kidney, liver, lung, skin) animal models.
Recent news
The scientific background of Novotec is linked to the Claude
Bernard University of Lyon, in the tissular evaluation
of a few pathological diseases.
Skills and know-how
20 years experience and know-how of its senior scientific
staff in these fields. Whatever the experiment, histological
and immunohistochemical analysis can be carry out to study
different Moreover, Novotec has the advantage to propose
experimental models to test the effect of different molecules
or specific treatments .
R&D PROJECT FUNDED
Company services
to manufacturing process improvements and new
pharmaceutical
Novotec has developed several investigation methods
at the tissular level: histological and immunohistochemical
techniques In vitro cell proliferation assay Detection
of gelatin in process food (food industry, interspecies gelatine
contamination).
Company contacts
CEO contact detail
First name: Daniel
Last name: Hartmann
Position: Manager
Phone: +33 (0)4 78 61 46 31
Other contact
First name: Martine
Last name: Melin
Position: Scientist
Phone: +33 (0)4 78 61 46 31
Fax: +33 (0)4 78 61 46 32
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
At tissular level:macroscopic, histological and
immunohistochemistry observations; semi-quantitative
or quantitative evaluation using histological scores, image
analysis, colorimetric dosage. In biological fluids:RIA, ELISA
tests.
Partnership
Biomnis Laboratory(Lyon), IBCP (Biochemical and chemical
Proteins Intitute, Lyon), INSA (National Applied Sciences
Institute, Lyon), Biomaterials laboratory (UCBL-1, Lyon), ENVL
(National VeterinarySchool, Lyon).
Organogenesis Inc Genzyme Polyclonals Rousselot.
123
Company name: Orega Biotech
Address: Espace Européen, 15, chemin du Saquin
Zip code: 69130
City: Ecully
Website: www.orega-biotech.com
Main activity: Orega-Biotech is a biotech company committed
to the development of innovative immunotherapeutics
(monoclonal antibodies) for cancer. Backed by INSERMTransfert and Octalfa, Orega-Biotech was set up in March
2010. Gilles Alberici (PharmD, PhD), with more than 20-year
experience in the pharmaceutical industry and biotech
start-ups, is the President. Orega-Biotech is based
on the research conducted by the other founders, Nathalie
Bonnefoy-Berard (PhD) and Armand Bensussan (PhD),
Research Directors at INSERM, and Jean-François Eliaou
(MD, PhD), Professor of Medicine and Head of the Department
of Immunology at the University Hospital of Montpellier.
Initially, the company has developed antibodies for modulating
regulatory T cells activity in cancer. In 2009, two new projects
at different R&D stages were included in the pipeline.
The business strategy is to bring several R&D programs
into early clinical stages, and then to license them out
to larger pharmaceutical companies. .
Other status: Yes
Funding
Public funding obtained: Region Rhone Alpes (€ 45 k),
OSEO emergence (€ 40 K), OSEO creation (€ 350 K),
OSEO help to transfert (€ 270 K), ANR (€ 300 K)
Company contacts
CEO contact detail
First name: Gilles
Last name: Alberici
Position: President
Phone: +33 (0)4 37 49 87 70
Other contact
First name: Jeremy
Last name: Bastid
Position: Program Director
Phone: +33 (0)4 37 49 87 72
124
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Activities
Drug discovery.
Application fields
Human health, Immunology, Cancer.
Activities
Company activities
Orega-Biotech is a biotech company committed
to the development of innovative immunotherapeutics
(monoclonal antibodies) for cancer.
Business model
Value chain
Activities
Diagnostics / Analysis method, Vaccine, Models (animal cellular - …), Preclinical trials, Drug delivery.
Application fields
Company name: Phatophy
Address: 17, rue Thimonnier
Zip code: 69160
City: Tassin la Demi Lune
Website: www.phatophy.com
Main activity: Phatophy is a CRO providing 4 kinds of services:
– in-vivo studies on animals to test veterinary medicinal
products (with Marketing Authorization or not) and other
products as shampoo, pets food, but also health products
for Humans…
– development and validation of analytical methods
for the determination of molecules in biological matrices
for application in pharmacokinetic, efficacy and residue
studies,
– quality controls for products (medicinal or other),
with development and validation of analytical methods
and stability studies,
– expert valuation and writing of regulatory dossiers
Incubator: No
Other status: No
Funding
Animal health, Human health, Cancer, Nutrition / Food,
Dermocosmetics.
Activities
Company activities
In-life phases: pre-clinical studies on animals
(pharmacokinetic, pharmacodynamy, tolerance, residues…)
or for preliminary steps. Development of animal models
(veterinary or human medicine) ether for various studies
(cancer, infection, inflammation…) or for comprehension
of pathology itself.
Bioanalysis: analysis (by HPLC or LC-MS/MS methods)
of molecules in biological specimens (blood, plasma, urine,
faeces, tissues, milk, eggs…) supplied by our customer
or issued from experimental studies, according to validated
methods, developed by Phatophy or not.
Pharmaceutical analysis (Quality of product): analysis
and physico-chemical tests to characterize active substances,
degradation products, preservatives or other substance
in every kind of product (veterinary or human products,
cosmetics, pet food, feed additives…) under every forms
(powder, tablet, solution…). Storage and stability studies
(long-term, accelerated, in-use, stability to light…). Validation
of manufacturing process. Possible development of analytical
method.
Regulatoryaffairs:expertise(dataanalysis)andwritingofregulatory
reports (variations, marketing authorization, MRLs…).
Company contacts
CEO contact detail
First name: Jacques
Last name: Goutalier
Position: manager
Phone: +33 (0)4 78 87 17 37
Other contact
First name: Sandrine
Last name: Combeau
Phone: +33 (0)4 78 87 17 37
Fax: +33 (0)4 78 44 21 95
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Thanks to its various activities, Phatophy can propose global
services to answer to customer projects.
- Established within the Veterinary School of Lyon (VetAgro Sup
Lyon),Phatophyhasaccesstovariousandcomplementaryservices:
surgery, medical imaging, conventional animal housing…
- Full compliance with Good Laboratory Practices.
- High capacities of animal housing, thanks to various partnerships
- Respect of animals included in tests by protocol submission
to an independant ethic committee.
Recent news
- May 2010: new GLP inspection, concluding to our full compliance
with GLP requirements (level A) for the major part of our activities.
- July 2010: association with an experimental test site
for the increase of our capacities, in the housing of large
animals.
- Participation to a MATWIN project on a new formulation
of anticancer drugs.
125
Skills and know-how
Studies on every animal species, through every routes
of administration and with every kinds of sampling.
30 years of experience allow the mastery of a large number of
analytical methods in every kind of biological or pharmaceutical
matrices, with a high level in sample preparation.
Our competence extend from health products (veterinary
or human) to every form of finished products like cosmetics,
biomaterials, products dedicated to hygiene…
Company services
Five study directors agreed for experimental studies in a very
large panel of animal species and on various test sites with a
real ability in the different methods of treatment and sampling
(including non-usual routes, such as ocular, intranasal, intraauricular…).
Five study directors for analytical phases, with good knowledge
in analytical chemistry and preparation methods to apply to
biological samples or to pharmaceutical preparations, working
with qualified equipments.
HPLC equipment with validated acquisition software, qualified
according to Good Laboratory Practices, with UV (diode array
detector), refractometry and fluorimetry detections.
Six climatic cabinets for stability studies (including
photostability), under alarm 24h/24.
Dissolution equipment, disaggregation equipment for tablet
forms, titrators (including Karl Fisher), densimeter, UV-Vis
spetrophotomer, and various other laboratory materials…
Data analysis and pharmacokinetic modeling thanks to
Kinetica software.
126
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
health, Laboratory equipment supplier.
Value chain
Manufacturing.
Activities
Other.
Application fields
Company name: Powder Systems Limited
Address: 5, rue de Brest
Zip code: 69002
City: Lyon
Website: www.powdersystems.com
Main activity: PSL is an international manufacturer
of filtration, drying and high containment solutions. We have
been supporting the pharmaceutical, biopharmaceutical,
sterile, chemical and laboratory industries for 22 years.
Our solutions enable clients to bring new generation drugs
into the market place faster, using the latest technology
in containment and production equipment.
PSL is an original pioneer of containment and has significant
experience designing and engineering advanced containment
processes for highly potent and valuable products, from small
scale production to full process systems.
Incubator: No
Other status: No
Funding
Company activities
PSL is an international manufacturer of filtration, drying
and high containment solutions. We have been supporting
the pharmaceutical, biopharmaceutical, sterile, chemical
and laboratory industries for 22 years. Our solutions enable
clients to bring new generation drugs into the market place
faster, using the latest technology in containment
and production equipment.
PSL is an original pioneer of containment and has significant
experience designing and engineering advanced containment
processes for highly potent and valuable products, from small
scale production to full process systems.
Core Products
Filter Dryers, from lab scale bench top units, pilot plant
through to full production scale units.
Tray Dryers, Innovative tray dryer designs engineered
with ergonomics, efficiency and safety in minds.
Containment systems, for operations such as charging,
dispensing, sampling, milling and processing potent powders.
GFD, Glass Lab Filter Dryer, small scale filter dryer, scale up
is simplified.
Simplefilter, versatile & cost effective filtration solution.
Total process solutions: from front end design studies, through
to equipment assembly, testing, installation and commission,
all the way to preventative maintenance and after sales service.
Company contacts
CEO contact detail
First name: Rémy
Last name: Wattiaux
Position: Office & Sales Manager
Phone: +33 (0)9 53 40 44 48
Other contact
First name: Hayat
Last name: Meguellati
Position: European Sales Executive
Phone: +33 (0)9 53 40 44 48
s c i e n c e s
Activities
New Products
l i f e
d i r e c t o r y
2 0 1 1
22 years of experience providing main blue-chip companies
worldwide. Global presence with Sales offices and Factory in
Liverpool, UK. Sales offices in Lyon, France and USA. Logistic
and Supply Chain office in Czech Republic. Business Partner
in Japan, and future Sales and Engineering Offices in India.
Global Clientele: Bio / Pharmaceutical companies, including
all of the Top 10 pharmaceutical organizations such as GSK,
AstraZeneca, Pfizer, Merck, BMS, Lilly, Roche, Sanofi Aventis,
etc.
Recent news
To celebrate 22 years of providing innovative pharmaceutical
processes and containment solutions to blue chip companies
across the world, PSL launch the GFD into the laboratory
market. Based on the concepts of the larger PSL Filter Dryers,
the laboratory scale Glass Filter Dryers (GFDs) are a real
development… that you can see!
Powder Systems Ltd will be exhibiting at the next Interphex NewYork show, booth 1827 on March 29th 31st, 2011
127
Skills and know-how
Our experienced engineering teams work closely with our
skilled chemists to accelerate process development and create
the most suitable and ergonomic solutions. PSL’s established
supply chain management ensures all components, sourced
from across the globe, are of the highest quality and value. This
enables market savings to be passed directly onto
our customers.
Company services
Engineering Services: From front end design studies, through
to equipment assembly, testing, installation and commission,
all the way to preventative maintenance and after sales service.
PSL Serve team ensures that equipement remains in peak
condition with the supply of quality approved spare parts,
meeting industry regulations. PSL can provide a full Operator
Exposure Level (OEL) certification program. Process systems
can be tested and validated to achieve guaranteed containment
to nanograms level. Finally, our service engineers maintain,
validate or if needed upgrade equipment, making sure that
each piece of installed system meets industry regulations
and that people, products and business are protected.
PSL is a centre of excellence in the design and manufacture
of Filter Dryers. With a range of sizes and specifications
to meet all requirements, from chemical development
to bulk production, PSL Filter Dryers provide the total reliability
needed in the pharmaceutical industry. PSL offers a complete
product range suitable for API and high potency oncology
production with a complete heal recovery solution at 1ppm
cleaning.
PSL has the process expertise to provide a complete solution
for production ofyour HAPI with containment protection dow
to nanograms level. PSL offer containment solution for all your
chemical and formulation processes: Dispensing, sampling,
vessel charging, tray drying, filtration, milling, micronizing and
sieving. Mulitple process steps can be integrated within
a single isolator.
PSL quality is assured by embracing the principles
and requirements of both PAT and GAMP.
128
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company contacts
CEO contact detail
First name: Thomas
Last name: Kuhn
Position: CEO
Phone: +33 (0)4 37 37 20 10
Other contact
First name: Pascale
Last name: Malgouyres
Position: Business Development Director
Email:
[email protected]
Phone: +33 (0)4 37 37 20 10
Fax: +33 (0)4 37 70 88 15
Business model
Product developer - Pharmaceuticals
Company name: Poxel
Address: 200, avenue Jean Jaurès
Zip code: 69007
City: Lyon
Website: www.poxel.com
Main activity: Poxel is a biopharmaceutical company
developing innovative first-in-class drugs with a primary focus
on Type 2 diabetes. The company develops drug candidates to
clinical proof of concept before partnering with pharmaceutical
companies. Poxel operates independently as a lean
organization with strong in-house drug development expertise.
Incubator: Yes (EM Lyon)
Funding
Nature of funding searches: Poxel seeks for non diluting
financing.
Private funding obtained: July 2010: €16M from Edmond de
Rothschild Investment Partners, CDC Entreprises, and Credit
Agricole Private Equity.
Public funding obtained: Sept. 2009: €215,000 euros as a
grant from FEDER and €250,000 as a grant from the Greater
Lyon for the collaborative NATHEB project.
R&D PROJECT FUNDED
chronic hepatitis B
Value chain
Research, Preclinical, Marketing / Distribution, Clinical
Activities
Clinical trials, Preclinical trials, Drug discovery, Other
Application fields
Human health, Metabolic diseases
Activities
Company activities
Poxel is a biopharmaceutical company developing innovative
first-in-class drugs with a primary focus on Type 2 diabetes.
The company develops drug candidates to clinical proof
of concept before partnering with pharmaceutical companies.
Poxel operates independently as a lean organization with strong
in-house drug development expertise. Its pipeline consists
in innovative projects with new mechanisms of action, with
an activity on glucose metabolism, other cardiovascular risk
factors and with an improved safety profile compared
to currently available therapies.
Imeglimin, 1st-in-class oral antidiabetic agent, having already
achieved its clinical proof of concept. Excellent benefit/risk
ratio. 5 other innovative programs in early stage development.
Strong IP position. Seasoned team of executives coming from
the Pharma Industry. Network of international key opinion
leaders, experts and suppliers.
Pipeline product 1
Therapeutic area: Metabolism
Therapeutic indication: Type 2 diabetes
Phase 1: Imeglimin
Phase 2: Imeglimin
Partnership
Poxel will look at any partnership opportunity, depending on the
program concerned.
Poxel will look at any opportunity, depending on the program
concerned.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
129
Business model
Product developer - Biopharmaceuticals, Product developer Other health.
Value chain
Research, Clinical.
Activities
Medical device.
Application fields
Company name: Prediction BioSciences SAS
Address: 60, avenue Rockfeller
Zip code: 69008
City: Lyon
Website: www.predict.net
Main activity: Our company mainly focuses its R&D activities
on molecular markers to develop biomarker-based diagnostic
to predict more accurately risk of specific disease recurrence
or treatment with indications in stroke and oncology.
We use a cross-disciplinary approach between medical biology
and advanced informatics to accurately classify individual
patients into risk of recurrence categories. The tests
under development will lead to more personalized medicine
and provide patients with early, accurate, and individualized
prognostic information to guide their treatment choices.
The company has a currently marketed test for prediction
of chemotherapy benefit in breast cancer on the market
in the U.S., with EU introduction planned for 2012.
Incubator: No
Other status: No
Company contacts
CEO contact detail
First name: Cornelius
Last name: Diamond
Position: CEO
Phone: +33 (0)6 43 52 10 24
Activities
Company activities
Some of the prognosis and diagnosis we are developing are
presented below:
(I) InsightDXTM Breast Cancer profile. We have develop
a marker-based test using a nonlinear algorithm that combines
protein with standard clinicopathologic features to predict more
accurately risk of metastases in hormone receptor-positive
breast cancer patients. This test establishes risk scores
and risk categories obtained by incorporating immunoscores
for 9 molecular markers (eight of them collected by IHC
and one detected by FISH) plus three clinicopathologic factors
into a non-linear algorithm developed by our company.
It accurately estimates distant recurrence and disease-related
death and outperforms current clinical guidelines (such
as NPI, Adj!Online, 2007 St Gallen) providing valuable guidance
in adjuvant treatment choices, such as cytotoxic chemotherapy.
This test has been introduced on US market in 2009 and EU
introduction is scheduled at the end 2011.
(II) Gene RxTM Colorectal Cancer progression. Current
clinical guidelines recommend cytotoxic chemotherapy
for approximately 95% of stage II colorectal cancer patients,
even though less than 5% of them would likely derive any direct
benefit. Cytotoxic chemotherapy can lead to serious adverse
events, as well as both short-term and long-term quality of life
issues. We have conducted a study designed to produce a model
to predict outcome in chemotherapy-treated colorectal cancer
patients. Using the same methodology as for InsightDXTM Breast
Cancer profile, we already have identified five protein markers
with accurate prediction value to discriminate “good” and “bad”
prognosis colorectal cancer. This profile is still under evaluation
and validation.
(III) RapidResponseTM c-Fn Diagnosis. Currently, there is no
way to predict the evolution of ischemic stroke
to hemorrhage following thrombolytic therapy. A bloodbased marker has been shown to be predictive of severe
hemorrhagic transformation (HT) in thrombolytic-treated
ischemic stroke patients. However, all proteomic quantification
measurements in prior studies were done with enzyme-linked
immunoabsorbant assays (ELISA), which is a slow
analytical method. To bring a biomarker-based diagnostic
for an emergency setting (POC test), it is necessary to develop
a faster test to determine biomarker levels for patients being
considered for thrombolytic treatment. This rapid test is
currently under development by Prediction Biosciences.
The end result of this R&D program is to product a diagnostic
which will predict patients likely to have a severe hemorrhage
if given a thrombolytic and prevent severe and often deadly side
effect occuring in 6%-11% of patients treated with tPa.
Other contact
First name: Caroline
Last name: Bourgin-Hierle
Position: Research manager
Phone: +33 (0)6 16 50 75 52
Fax: +33 (0)4 26 78 08 38
(iv) Others biomarker-based diagnostic are currently under
development (training and validation phases in retrospective
studies) with indications in neurovascular disease and oncology.
130
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Pipeline product 1
Therapeutic area: oncologie
Therapeutic indication: breast cancer
MA: 2011/2012
Pipeline product 2
Therapeutic area: oncologie
Therapeutic indication: Colorectal cancer
Pipeline product 3
Therapeutic area: cardiovascular
Therapeutic indication: ischemic stroke
Preclinical: 2011
Biomarkers-based prognosis and diagnostic to be used
as medical device in stoke (RapidResponseTM c-Fn Test)
and oncology (GeneRxTM Breast Cancer Profile)
Pipeline
GeneRxTM Colorectal Cancer Profile; GeneRxTM
Lithium/Bipolar Test; GeneRxTM for Hypertension Treatment.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
131
Business model
Value chain
Company name: Presbeasy
Address: 24, rue Jean Baldassini
Zip code: 69007
City: Lyon
Main activity: The target of Presbeasy is the development
of diffractive multifocal intracorneal lenses for the chirurgical
correction of presbyopia, by a unique combination of optical
conception and materials and processes. Diffractive lenses are
known to have a better efficiency compared to refractive lenses
which are too sensitive to the environment. The reversibility
of the technique will remove a psychological barrier
for the patient, as opposed to laser techniques which are not
reversible. The intracorneal surgery is not invasive for the eye,
which garantees innocuity, as opposed to endocular surgery
(like cataract surgery).
Funding
Nature of funding searches: The financing needs must
support the operations till the validation of the technology
following clinical trials, i.e. 2 to 3 years.
Activities
Other.
Application fields
Human health.
Activities
Company activities
The Presbeasy lens is a multifocal diffractive intracorneal lens,
which combines the efficiency of the multifocal diffractiion
which is necessary for the correction of presbyopia,
to the innocuity of the corneal surgery and its full reversibility.
This innovative solution brings a good response to the growing
population of people suffering from presbyopia and who do not
want to wear spectacles when they reach 40.
The project has been initiated by an ophtalmologist
practising surgery, who knows the need of such solution
for the correction of presbyopia in his daily practise.
This guarantees the value of the approach. He has protected
the key concepts. The technology will allow a combined
correction with other visual defects (myopia, hypermetropy,
astigmatism). The project is supported by a complementary
team : a specialist of ophtalmic surgery and a manager
familiar with industrialisation of innovative products.
Recent news
Company contacts
CEO contact detail
First name: Gilbert
Last name: Cohen
Position: President
Phone: +33 (0)6 17 45 28 99
Other contact
First name: Jean-Christophe
Last name: Robert
Position: CEO
Phone: +33 (0)6 15 65 23 15
The basic features have been validated, the first samples
of the product are now being produced, in order to have final
confirmation of the proof of concept. A first business study
has helped to position the future company. Another study
in partnership with the Wesford Business School (Grenoble)
will be based on interviews of specialists in the field, in order
to havecnfirmation of the value proposition by key decision
makers.
Skills and know-how
The project has made significant progress through a triple
partnership: -on materials design and optimization
with the LCPP chemistry lab CNRS/CPE -on the optimisation
of optical properties with the Currien lab in Saint-Etienne on biocompatibility constraints with the biomaterials research
lab CNRS/Lyon I University The first samples of the lens are
produced with a leader in moulding of optical components.
Partnership
We are looking for financial partners, first round will target
€ 1.5 to 2.5 M.
132
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Activities
Application fields
Company name: Promise Advanced Proteomics
Address: 7, parvis Louis Néel, BP50, Minatec BHT/52B
Zip code: 38040
City: Grenoble
Website: www.promise-proteomics.com
Main activity: Promise Advanced Proteomics is a subsidiary of
PX’Therapeutics group which holds an exclusive license
of a patented technology called PSAQ (Protein standard
for Absolute Quantification). This technology allows
the absolute quantification of proteins in complex biological
samples using mass spectrometry. Quantification results
obtained using this technology are more accurate, sensitive
and specific than the ones obtained using classical
immunologic approaches or other MS-based techniques.
Therefore, PSAQ technology is the brand new method
for the quantification of proteins such as biomarkers
or therapeutic proteins.
Incubator: No
Subsidiary of a group: Yes (PX’Therapeutics)
Other status: Yes
R&D PROJECT FUNDED
OPTIMABS: Optimization of monoclonal antibodies drugability
by emergent analytical and structural methods: from lead
to clinical candidate.
Activities
Company activities
Promise Advanced Proteomics’ technology can be of interest for:
– diagnostic companies, as PSAQ technology permits
the quantification of several biomarkers in one single analysis,
with very high levels of sensitivity and specificity (pg/mL of
serum scale). PSAQ technology is compatible with
any biological matrices (serum, urine, plasma…),
– biopharmaceutical or biotechnology companies,
for the quantification of their protein candidate during
pharmacokinetics or bioavailability studies for example,
– any other applications for which there is a need for very
accurate or sensitive results which are not possible with
classical immunological techniques: doping control or food
quality control for example. Promise Advanced Proteomics
proposes to its clients the production of protein standards
and/or the development of the MS-based assay and the transfer
of the method to the client or to a third party (CRO).
Promise Advanced Proteomics holds an exclusive license
of PSAQ technology and has acquired a great expertise
in the development of labeled protein standards, thanks also
to its mother company PX’Therapeutics. Promise’s team has
a very good understanding of mass spectrometry techniques
and is able to propose clever strategies to address the accurate
quantification of proteins in complex matrices.
Recent news
Promise Advanced Proteomics is involved in a granted project
(FUI) certified by Lyon BioPole and lead by the CIPF (Centre
d’Immunologie Pierre fabre), called OPTIMABS.
This collaborative project aims at improving the development
of therapeutic monoclonal antibodies.
Skills and know-how
Company contacts
CEO contact detail
First name: Nicolas
Last name: Mouz
Position: President
Phone: +33 (0)4 38 02 36 50
Other contact
First name: Claire
Last name: Untereiner
Position: Director, Business Development
Phone: +33 (0)4 38 02 36 50
Fax: +33 (0)4 76 96 10 38
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
- Mass spectrometry
- Biological sample preparation (enrichment, depletion…)
- Development of stable isotope-labeled full-length protein
standards.
Company services
Production of PSAQ (Protein Standard for Absolute
Quantification) Development of MS-based method.
PSAQ: Protein Standard for Absolute Quantification, based
on the development of protein standard and using mass
spectrometry.
133
SASTIM: Sorting of Antigen Specific T cells for Immunotherapy
of Melanoma
Company name: PX’Therapeutics
Address: 7, parvis Louis Néel BP50 , Minatec BHT/52B
Zip code: 38040
City: Grenoble
Website: www.px-therapeutics.com
Main activity: PX’Therapeutics provides integrated
HU’S-MAP: Human and species monoclonal antibody
production
Company contacts
CEO contact detail
First name: Tristan
Last name: Rousselle
Position: CEO
Phone: +33 (0)4 38 02 36 50
biotherapeutics and recombinant vaccines development
and manufacturing services. Organized around 4 integrated
platforms (recombinant protein R&D, monoclonal
antibody development, cGMP manufacturing, analytics),
PX’Therapeutics offers custom programs which may include
depending on clients specifications, murine antibody
generation, humanization strategies, protein engineering,
process development and/or small scale cGMP manufacturing
services. In 2010 a new subsidiary named Promise Advanced
Proteomics was created to offer mass spec based absolute
quantification of proteins.
(Tremplin Fondation Aventis)
Other status: Yes
Funding
Other contact
First name: Claire
Last name: Untereiner
Position: DIrector, Business Development
Email:
[email protected]
Phone: +33 (0)4 38 02 36 50
Business model
Service provider - CRO, Service provider - CMO.
R&D PROJECTS FUNDED
PRAVIC: Innovative recombinant proteins with immune
modulatory and anti-tumour activities
Funding: FUI (2005)
Activities
FIV-VAX: Development of a vaccine against feline
immunodeficiency virus (FIV)
Application fields
TBDERMATEST: Development of a novel skin test using
the HBHA antigen for the diagnosis of latent M. tuberculosis
infection
ASPAREC: Development of a new RECombinant
L-ASPAraginase with long acting properties
TTMCMV: Development of GMP compliant MHC/tetramers and
cell sorting procedures for adoptive immunotherapy against
CMV infections
134
Value chain
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Other.
Animal health, Pediatrics, Human health, Immunology,
Activities
Company activities
1/DevelopmentandProductionofRecombinantProteins(research
grade)
- Gene synthesis and molecular biology (including mutagenesis) Protein engineering
- Optimization of the protein sequence in order to solve specific
solubility or refolding issues for instance
- Definition of relevant combinations of vectors, signal peptides,
strains/hostcellstoachieveimprovedexpressionorsecretionyield
- Production protocol transfer from the client and protein batch
production
- Development and optimization of expression and purification
protocols
- Development of refolding protocols for insoluble proteins
- Cell culture in transient conditions
- Development of stable cell lines
- Development of fermentation process (batch, fed-batch) and
scale up of purification scheme in view of large scale industrial or
GMP manufacturing
- Production of protein batches (from mg to gram scale, research
to crystallography grade)
- Quality controls
Expression Systems
– bacterial (E. coli). Specific know-how for insoluble protein.
– yeast (S. cerevisiae, Pichia pastoris)
– baculovirus / insect cells
– mammalian cell lines (CHO, HEK, COS, etc.)
2/ Development and Production of Monoclonal Antibodies
We differentiate from other service companies by our vocation
to propose:
– original and relevant approaches to address antibody
development related issues such as immunization of animals
with difficult-to-express antigens or generation of antibodies
directed against rare and weakly antigenic epitopes
– strategies for the development humanized antibodies based
on a « fee for service » model. Those strategies are essentially
based on know-how and not on proprietary technologies
in order to lower the level of intellectual property associated
to the product and increase its value for the client.
A. Development of Murine Monoclonal Antibodies
- Mice immunization protocols adapted to the material available from DNA if the protein material is not accessible
- from peptide and protein
- from transfected cells
- Substractive immunization strategy for the development of
antibodies directed against rare or weakly antigenic epitopes
- Fusion with myeloma cells, generation and screening of
hybridomas
- Development of screening methods: Western-Blot, ELISA,
Immunofluoresence, FACS
- Cloning and characterization of producing hydridomas
- Production and purification of antibody batch (optional)
- Other services upon request
Our Added Value
Our specific organization and the mix of R&D and
manufacturing competences of our team ensure added value to
customers. Our strengths rely on:
– a strong scientific expertise associated to the regulatory
understanding of biotherapeutic products development
– the capability to accompany our clients from early stage
research and engineering up to clinical batches manufacturing
– the optimization of timelines for the development
of therapeutic candidates due to the synergy between
the research and cGMP manufacturing platforms.
Recent news
Opening of a new cGMP biomanufacturing facility dedicated
to mammalian cells in Q3 2010.
PSAQ (through PX’Therapeutics subsidiary Promise
Advanced Proteomics) PSAQ (Protein Standard for Absolute
Quantification) is a patented technology for absolute
quantification of proteins in biological samples. The technology
is based on the development of protein standard which are
full-length stable isotope labelled protein and mass
spectrometry analysis. It allows unequalled results in terms
of specificity, sensitiviy, accuracy and precision of the protein
dosage.
B. Development of Humanized Antibodies Molecular
engineering strategy: RT-PCR cloning of variable part
of the antibody, gene optimization and sub-cloning into
expression vectors adapted to the production in CHO cell
lines, chimerization of constant human Ig parts, humanization
based upon structural biology data in order to prevent
immunogenicity.
3/ Bioproduction
- Cell banking (Master Cell Bank / Working Cell Bank)
- Development and validation of analytical methods
- Scale up of production process
- Preclinical & Clinical batch manufacturing (Phase I/II, niche
market) and batch release
- Fill & Finish (through qualified partners) - Regulatory support all
along the project.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
135
Company name: RCTs
Address: 38, rue du Plat
Zip code: 69002
City: Lyon
Turnover: 2,9 Me (in 2009)
Main activity: Clinical trials, pharmacoepidemiologic studies.
Other status: No
Funding
Business model
Value chain
Clinical.
Activities
Application fields
Pediatrics, Human health, Geriatrics, Immunology, Infectious
diseases, Autoimmune diseases, Allergology, Orphan diseases,
diseases, Cancer, Nutrition / Food, Dermocosmetics.
Activities
Company activities
See our website www.rcts.fr.
Company contacts
CEO contact detail
First name: Yves
Last name: Alamercery
Position: CEO
Phone: +33 (0)4 37 45 17 48
136
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: ReproXX SAS
Address: 80, rue de la Garenne
Zip code: 69005
City: Lyon
Website: www.reproxx.com
Main activity: Based on research from INSERM - (French
research Institute for Human Health), Reproxx’s mission is
to develop and market tools to facilitate the management
of reproduction in animals. Reproxx, is preparing the launch
of its product in the first half of 2011, this product will be
the first rapid test for early pregnancy diagnosis in the cow.
This innovative tool will allow an unprecedented optimization
of the management in bovine reproduction.
(tremplin entreprises 2010)
Other status: Yes (JEI et CIR)
Business mode
Value chain
Activities
Diagnostics / Analysis method, Biomanufacturing, Other.
Application fields
Animal health, Human health, Nutrition / Food, Other.
Activities
Company activities
Reproxx, is preparing the launch of its product in the first
half of 2011, this product will be the first rapid test for early
pregnancy diagnosis in the cow. This innovative tool will allow
an unprecedented optimization of the management in bovine
reproduction.
A team of experienced researchers and veterinarians has
worked many years to develop the first rapid test diagnostic
of pregnancy in the cow. The unique combination of expertise
in immunology, and specialists in the rapid testing turns
Reproxx in one of the most advanced company in this field.
Company contacts
Recent news
Funding
CEO contact detail
First name: Pascal
Last name: Vallejo
Position: CEO
Phone: +33 (0)06 28 04 48 72
Reproxx is now labelised by NOVACITE The Lyon Chamber
of Commerce innovation incubator.
Other contact
First name: Jean-Christophe
Last name: Vullierme
Phone: +33 (0)6 07 80 71 69
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
137
Company name: Roche Diagnostics
Address: 2, avenue du vercors
Zip code: 38240
City: Meylan
Website: www.rochediagnostics.fr
Turnover: 342 000 000e (in 2009)
Main activity: Diagnostic in vitro (marketing sales, training,
services and logistic for analytical systems for labs) Diabete
(blood glucose mnitoring and pump therapy).
Subsidiary of a group: Yes (ROCHE)
Other status: No
CEO contact detail
First name: Bertrand
Last name: Le bert
Phone: +33 (0)4 76 76 30 02
Other contact
First name: Frank
Last name: Leenhardt
Position: Business development manager
Phone: +33 (0)4 76 76 46 85
Fax: +33 (0)4 76 76 46 11
s c i e n c e s
d i r e c t o r y
health, Laboratory equipment supplier.
Value chain
Activities
Diagnostics / Analysis method, Instrumentation, Other.
Application fields
diseases, Metabolic diseases, CNS related diseases, Cancer.
Activities
and logistic for analytical systems for labs) Diabete
(blood glucose mnitoring and pump therapy).
Company contacts
l i f e
Business model
Company activities
Diagnostic in vitro (marketing, sales, training, services
Funding
138
2 0 1 1
Company contacts
CEO contact detail
First name: Eric
Last name: Meunier
Position: Sanofi Pasteur France General
Manager
Phone: +33 (0)4 37 37 01 00
Other contact
First name: Marie-José
Last name: Quentin-Millet
Position: Product Conception & Development
Vice-President
Phone: +33 (0)4 37 37 01 00
Company name: Sanofi Pasteur
Address: 2, avenue Pont Pasteur
Zip code: 69007
City: Lyon
Website: www.sanofipasteur.com
Turnover: 3 483 M e (in 2009)
Main activity: Sanofi Pasteur, the vaccines division
of sanofi-aventis Group, is the largest company in the world
entirely dedicated to human vaccines. Our vision is a world
in which no one suffers or dies from a vaccine-preventable
disease. Our mission is to protect and improve human health
worldwide by providing superior, innovative vaccines
for the prevention and treatment of disease, playing an active
role in the immunization community.
Incubator: No
Subsidiary of a group: Yes (Sanofi-Aventis)
Value chain
Clinical, Other.
Activities
Vaccine, Other.
Application fields
Human health.
Company activities
R&D PROJECTS FUNDED
GAP: Healthcare shield solutions against avian flu and flu
pandemics
Funding: FUI (2005)
MICROVAX: Skin immunology and vaccination
EXPANDID: Extending the scope of application of intradermal
vaccination
PATVAX: Process analytical technology for vaccines
EMER-FAB: Establishment and regulatory validation
of a model to develop and produce passive immunotherapy
solutions against the hemontagic fevers
s c i e n c e s
Business model
Activities
Funding
l i f e
d i r e c t o r y
2 0 1 1
Sanofi Pasteur is the vaccines division of sanofi-aventis Group,
a leading global pharmaceutical company that discovers,
develops and distributes therapeutic solutions to improve
the lives of everyone. Sanofi Pasteur is the largest company
entirely dedicated to vaccines. The company distributes more
than 1.6 billion doses of vaccine per year, making it possible
to immunize more than 500 million people across the globe.
A world leader in the vaccine industry, sanofi pasteur offers
the broadest range of vaccines, protecting against 20 infectious
diseases.
Sanofi Pasteur: a global company
• Headquarters: Lyon, France
• Revenue: 3,483 million euros in 2009, a 19.2% increase from
2008 (on a comparable basis)
• Market share: approximately a quarter of the world’s vaccine
market
• R&D and industrial sites worldwide:
– 11 production and/or R&D sites located in Marcy l’Etoile and
Val de Reuil, France; in Swiftwater (Pennsylvania), Cambridge
and Canton (Massachusetts), and Rockville (Maryland), USA;
in Toronto, Canada; in Pilar, Argentina; in Shenzhen, China;
in Hyderabad, India and in Chachoengsao, Thailand.
– 3 new facilities under construction in Ocoyoacac, Mexico ;
Neuville, France ; and Shenzhen, China.
Our Assets:
• The broadest vaccine portfolio in the industry
• A global presence
• A leadership position in influenza, pediatrics, meningitis and
boosters
139
• R&D: more than €1 million invested per day and a promising
pipeline with 18 vaccines in development
• Significant on-going investments to expand production
capacity
• At the forefront of the immunization community (Who,
UNICEF, PAHO, CDC, GAVI Alliance, AAP, etc.)
Recent news
• Final stage of clinical development for sanofi pasteur’s
dengue vaccine, the world’s most clinically advanced dengue
vaccine candidate - Nov 2010
• Acquisition of Vaxdesign, a U.S. biotechnology company Sept 2010
• Partnership with Vivalis for the discovery of human
monoclonal antibodies against infectious diseases - June 2010
• Partnership with Kalobios on novel biologic for the prevention
and treatment of pseudomonas aeruginosa infections - Jan
2010.
Skills and know-how
• More than a century of innovation since the foundation
of the Institut Mérieux in Lyon in 1897
• Promising research pipe-line including:
-New vaccines against endemic diseases (dengue,
hospital-acquired infections, etc.)
-Next-generation vaccines
-New combination vaccines
• A strong commitment to R&D partnerships with major
universities,researchinstitutes,governmentbodies,biotechnology
companies and contract research organizations
Partnership
When partnering with Sanofi Pasteur, you will interact with a
multidisciplinary team that has years of experience in working to
ensure that partnerships are executed successfully and nurtured
for the mutual benefit of all parties. This approach utilizes the
value-addedsanofipasteuralliancemanagementcapability,which
focuses on the relationship by facilitating open communication,
trust, understanding, and clear expectations across the project
lifecycle. Combined with the technical competencies of the
alliance,thisbalanceprovidesawell-roundedenvironmentforyour
technology to flourish.
SanofiPasteurisinterestedinpotentialpartneringopportunitiesin
the field of active and passive human immunization, including:
• New antigens, vaccines, and supporting technologies,
such as:
– Antigen discovery and characterization for infectious
diseases
– Carrier proteins and protein-polysaccharide conjugation
methods or alternative technologies
– Monoclonal antibodies for infectious diseases
• Agents to enhance vaccine immune responses such
as adjuvants and immunomodulators
• New routes of vaccine administration and vaccine delivery
systems
• Tools for improving vaccine research, development and
production
In the field of immunology, microbiology, vaccine.
140
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: Shimadzu France
Address: Bureau de Lyon - 213, rue de Gerland - Bât.F1
Zip code: 69007
City: Lyon
Website: www.shimadzu.fr
Turnover: 13 M e (in 2009)
Main activity: Shimadzu is a world-leading developer
Business model
Service provider - Scientific, Laboratory equipment supplier.
Value chain
Activities
Diagnostics / Analysis method, Instrumentation, Drug
discovery, Nanotechnology.
and manufacturer in innovative products for laboratories
in industry, science and governmental institutions since
1875.The main activity of Shimadzu consists of analytical
instrumentation, biotechnologies and medical technology.
Shimadzu is a world wide company with R&D and production
centers located in japan, USA, Europe, China and Australia.
Listed on the Tokyo Stock Exchange, Shimadzu is strong of
10,000 employes. The french Headquarter is based near Paris.
Shimadzu France has also an agency in Lyon which is the first
regional office of the group. Its goal is to be within close reach
of our customers, offering demonstrative room and customer
training.
Subsidiary of a group: Yes (Shimadzu Corporation)
Other status: No
Application fields
Funding
Shimadzu has a broad bandwidth of solutions for physicschemistry analysis.
A long history since 1875.
Success is based on R&D and instrumental development which
lead M. Tanaka to be awarded with Nobel Prize in Chemistry
in 2002 (SHIMADZU Japan).
Company contacts
d i r e c t o r y
Company activities
Shimadzu offers a broad bandwidth of product for analytical
instrumentation. Our product lines include analytical systems
for chromatography (HPLC, LCMS, GC, GCMS), spectroscopy
(UV/VIS, FTIR, AAS) and environmental analysis (TOC) but also
Universal Testing machines, hardness testers, particule size
analyzers.
SHIMADZU is one of the world’s leading manufacturers
of advanced imaging systems and equipment for use in medical
diagnosis and treatment based on X-Rays technology.
New World fastest Tandem Quadrupole LC/MS/MS System
Nexera: Next Era of U-HPLC
Industrial partnership with Biomerieux for bacteria
identification based on MALDI technology system.
Skills and know-how
SHIMADZU: the analytical instrumental solution combined
with expertise close to customer.
Other contact
First name: Eric
Last name: Sauvage
Phone: +33 (0)4 72 24 63 82
s c i e n c e s
Activities
Recent news
CEO contact detail
First name: Ronan
Last name: Penlae
Position: Marketing manager
Phone: +33 (0)1 60 95 10 10
l i f e
Animal health, Human health, Nutrition / Food.
2 0 1 1
141
Company name: Singulex R&D Europe
Address: 321, avenue Jean Jaurés, Immeuble Domilyon
Zip code: 69007
City: Lyon
Website: www.Singulex.com
Main activity: Singulex is a biotechnology company
that develops and markets a digital technology Erenna®
of direct molecular detection and assay kits and reagents.
We also offer services of custom test development
and samples analysis.
Incubator: No
Other status: No
Funding
R&D PROJECT FUNDED
FEMTOKINE: Ultrasensitive immunoassay for the prediction
of relapse of Crohn’s disease and monitor treatment. Clinical
validation.
Company contacts
CEO contact detail
First name: Eric
Last name: Cevoz-Goyat
Position: General Manager, European Lifesciences Operations
Phone: + 33 (0)4 72 70 25 78
Other contact
Last name: Rousselot
Position: Research Project Manager; European Application
& Technical Services
Phone: +33 (0)6 68 65 02 22
Fax: + 33 (0)4 72 70 25 78
142
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Value chain
Other.
Activities
Application fields
Autoimmune diseases, Cancer.
Activities
Company activities
Singulex develops and markets digital technology of direct
molecular detection. It also develops biomarkers diagnostic
systems to detect and quantify protein markers in normal
subjects and patients. It allows researchers and clinicians
to understand and manage certain diseases. Singulex offers
various services for the development of immunoassays,
custom assays and access to commercial assay kits, samples
analysis service in a GLP laboratory, technical support
for assays and the technology.
Singulex Europe is developing collaborations with academic
institutions, LyonBiopole and pharmaceutiques partners.
Singulex Europe develops new R & D projects and researchs
and appropriate funding.
Singulex also provided sales and technical services
to customers.
Company name: smartINST
Address: 46, allée d’Italie
Zip code: 69009
City: Lyon
Website: www.smartinst.fr
Other status: Yes
Business model
Service provider - CMO, Service provider - Scientific, Laboratory
equipment supplier.
Value chain
Manufacturing.
Activities
Instrumentation.
Application fields
Other.
R&D PROJECT FUNDED
PATVAX: Process Analytical Technology for Vaccines
Company contacts
CEO contact detail
Last name: Graffin
Phone: +33 (0)4 72 72 89 00
Other contact
First name: Yoann
Last name: Gasteuil
Phone: +33 (0)6 64 19 06 03
Fax: +33 (0)4 72 72 88 81
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
143
Business model
Company name: Sofradim Production
Address: 116, avenue du Formans
Zip code: 01600
City: Trevoux
Main activity: Manufacture of implantable surgical devices
Incubator: No
Subsidiary of a group: Yes (Covidien (USA))
Other status: No
Funding
Company activities
Value chain
Activities
Other.
Application fields
Human health.
Activities
Medical devices manufacturer.
Soft tissue repair.
R&D PROJECT FUNDED
TREBARO: Conception of a bioresorbable, anti-infectious
and MRI visible mesh for soft tissue reinforcement in surgical
treatment of genital prolapsus
Funding: ANR (2008 Tecsan)
Company contacts
CEO contact detail
First name: Thierry
Last name: Darnis
Position: Plant Manager
Phone: +33 (0)4 74 08 92 47
Other contact
First name: Olivier
Last name: Lefranc
Position: R&D Scientist
Phone: +33 (0)4 74 08 79 05
Fax: +33 (0)4 74 08 92 30
144
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: Spygen
Address: Savoie Technolac, 12, allée du Lac de Garde
Zip code: 73370
City: Le Bourget du Lac
Website: www.spygen.fr
Main activity: Spygen has developed an DNA-based innovative
approach for studying biological diversity (animal, plant
and microorganism species) in the environment (water, soil)
or in complex substrates (food products, cosmetics, feces,
etc.). This method can also be used to identify species from
biological samples (fragments of plants, of skin, etc.).
Incubator: Yes (GRAIN)
Other status: No
Funding
CEO contact detail
First name: Tony
Last name: Dejean
Position: Chairman
Phone: +33 (0)4 79 26 15 83
s c i e n c e s
d i r e c t o r y
Business model
Value chain
Other.
Activities
Other.
Application fields
Other.
Activities
Company activities
1. Ecological analysis
The method developed by Spygen enables the detection
of aquatic and semi-aquatic species from a simple water
sample by analyzing the DNA released by organisms into
the environment (environmental DNA - eDNA). This technique
has no impact on the ecosystem and offers unequalled
performance. It is particularly suited to the monitoring of rare
and/or discreet species.
2. Authenticity & traceability checks
With the methods developed by Spygen it is possible
to determine the composition of a processed product (animal,
plant and micro-organism species) by analyzing the fragments
of DNA present in the sample. This innovative method can also
be used on biological samples (fragments of plants, of skin,
etc.) to check the authenticity of a species.
Company contacts
l i f e
3. Diet analysis
The method developed by Spygen is based on the analysis
of feces or stomach contents. It uses the fragments of DNA
present in a sample to identify the plant and/or animal species
ingested.
2 0 1 1
145
Company name: Stragen Services SAS
Address: 1, rue des Quatre Chapeaux
Zip code: 69002
City: Lyon
Website: www.stragen-services.com
Main activity: Service provider for pharmacovigilance and
clinical development strategy. Scope of expertise: Innovative
medicines including orphan drugs, generic products, medical
devices.
Incubator: No
Subsidiary of a group: Yes (Stragen)
Other status: Yes
Business model
Value chain
Research, Marketing / Distribution, Clinical.
Activities
Application fields
Nutrition / Food, Dermocosmetics, Other.
Activities
Funding
Company activities
Pharmacovigilance or tailored solutions for companies
that prefer to work in-house.
Stragen Services assists pharmaceutical & biotech companies
in the design and implementation of innovative Clinical
Development strategies in order to bring products
to registration in the most efficient and cost-effective manner.
Company contacts
CEO contact detail
First name: Annie-Claude
Last name: Benichou
Phone: +33 (0)4 78 42 95 26
Stragen Services helps pharmaceutical & biotech companies
to understand and interpret regulatory requirements and
guidelines and to manage clinical programs, from phase I
to phase IV.
– Solutions and Services designed around Customer Needs
and key business Requirements
– 24/7 Medical Monitoring services
– Regulation-driven experienced team of physicians,
pharmacists and scientists, specialized in bridging clinical
concepts, passionate about medical affairs and familiar
with the challenges that pharmaceutical companies are facing
– Stragen Services is a customer-minded partner.
– Top Quality Services: precision & clarity, aiming at effective
solutions/recommendations.
146
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: SynapCell
Address: Pépinière Biopolis - 5, avenue du Grand Sablon
Zip code: 38700
City: La Tronche
Website: www.synapcell.com
Turnover: 0,19 K e (in 2009)
Main activity: SynapCell is an innovative contract research
company providing pre-clinical services based on functional
activity of neuronal networks in models mimicking human CNS
pathologies.
Prize winner for innovative start-up: Yes (Creation
Development - National contest for innovative companies)
Other status: Yes
Funding
Business model
Value chain
Preclinical.
Activities
Models (animal - cellular - …), Preclinical trials, Other.
Application fields
Human health, CNS related diseases.
Activities
Company activities
SynapCell is an innovative contract research company providing
pre-clinical services based on functional activity of neuronal
networks in models mimicking human CNS pathologies.
SynapCell evaluates potential therapeutic and/or side effects
of drug candidates on translational murine models of epilepsy
(GAERS and MTLE mouse).
Skills and know-how
• Study of neuronal networks with electrophysiology:
– in vivo (deep and cortical EEG on vigil animal)
– in vitro (multi-electrode array with acute and organotypic
slices)
• Stereotaxic surgery (mouse and rat)
• Organotypic culture
of slices (hippocampus), allowing chronic studies (up to one month)
• Behavioural analysis.
Company contacts
R&D PROJECT FUNDED
RHENEPI: Platform of neuronal modeling to discover and
validate pharmacological treatments against epilepsy disease.
Company services
CEO contact detail
First name: Corinne
Last name: Roucard
Position: CEO - president
Phone: +33 (0)4 76 63 75 90
We assess the anti-epileptic, anti-epileptogenic
and pro-epileptic effects of drug candidates with rodent models
of absence (GAERS) or temporal lobe epilepsy (MTLE Mouse).
We define activity profile of drug candidates on neuronal
network contained in brain slices by the use of Multi-Electrode
Array.
Electrophysiology with Electroencephalogram (EEG)
and Multi-Electrode Array (MEA).
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
147
Business model
Service provider - CRO, Product developer Biopharmaceuticals.
Company name: Synthelis
Address: 5, avenue du Grand Sablon
Zip code: 38700
City: La Tronche
Website: www.synthelis.com
Turnover: 160 000 e (in 2009)
Main activity:
– custom membrane protein production
– vectorization of membrane protein for therapeutic or vaccine
development.
Other status: Yes
Funding
Nature of funding searches:
Business Angels, ISF Funds, Holding, Seed capital, Venture
capital, Capital développement, others.
Public funding obtained: Oseo: €170 000 in 2010
Company contacts
CEO contact detail
First name: Bruno
Last name: Tillier
Position: CEO
Phone: +33 (0)6 11 19 21 47
Value chain
Activities
Biomanufacturing, Drug delivery.
Application fields
diseases, Autoimmune diseases, Orphan diseases, CNS
related diseases, Cancer, Dermocosmetics.
Activities
Company activities
Synthelis specializes in the production of customized
membrane proteins.
With our new optimised membrane protein expression system,
we can provide:
– Active proteoliposomes containing one or several different
membrane proteins which preserve protein functionnally
– Customised soluble membrane proteins
– process dedicated to membrane protein production
with functionality and structure preserved
– broad range of applications with the technology
– business model based on service and bioproduct
development
– patent application in national and regional phases
– dedicated know-how.
Skills and know-how
– membrane protein production and characterization.
Pipeline product 1
Therapeutic area: Oncolgy
Therapeutic indication: glioblastoma
Preclinical: x
Pipeline product 2
Therapeutic area: Infectious diseases
Therapeutic indication: vaccine
Preclinical: x
Company services
Custom membrane protein production membrane protein
characterization.
Proprietary cell-free system membrane protein vectorization
for therapeutic or vaccine application.
148
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Company name: Top Industrie
Address: 80, rue Marinoni
Zip code: F77013
City: Vaux le Penil Cedex France
Website: www.top-industrie.com
Turnover: 5.5 M e (in 2011)
Main activity: High Pressure Cells, High Pressure Autoclaves,
very high Pressure «Pascalisation», Chemical Autoclaves,
Pressure test benches.
Incubator: No
Other status: No
Business model
Value chain
Manufacturing.
Activities
Vaccine, Biomanufacturing.
Application fields
Activities
Company activities
Funding
High Pressure Cells, High Pressure Autoclaves, very high
Pressure «Pascalisation», Chemical Autoclaves, Pressure test
benches.
Reactivity, large experience in High Pressure.
Skills and know-how
R&D PROJECT FUNDED
Know how in high Pressure engineering and high Temperature.
HYPERBAR: Bringing into the vaccine production industry
an alternative to chemicals for bacteria and viruses inactivation
by high pressure treatment
Company contacts
CEO contact detail
First name: Gildas
Last name: Merian
Position: President
Phone: +33 (0)1 64 10 45 50
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
149
Company name: Transgene SA
Address: Boulevard Gonthier d’Andernach, Parc d’Innovation
Zip code: 67405
City: Illkirch-Graffenstaden
Website: www.transgene.fr
Turnover: 10 M E (in 2009)
Main activity: Transgene is a biopharmaceutical company
that discovers and develops immunotherapy products
for the treatment of cancers and chronic infectious diseases.
Its expertise covers all product development stages, including
researach, manufacturing of clinical batches and conducting
clinical trials. Five products are currently under clinical
development, four in phase II and one in phase I. Transgene
has signed business agreements with Roche (2007), Novartis
(2010) and Jennerex (2010) Transgene is a partner in a major,
externally funded, research project (ADNA program) that aims
to achieve individualized medicine for cancers, infectious
diseases and genetic diseases. The program focuses
on the identification and development of biological markers,
and its findings are making a substantial contribution to the
future development of its products. Transgene is committed
to scientific excellence and medical innovation, with the
company’s top level scientists focusing on applying their
research findings to developing new therapies in order to treat
unmet medical needs. A strong pre-clinical pipeline bears
witness to this commitment. For over 25 years Transgene has
built on its recognized scientific expertise. Today, it is a major
player in the field of immunotherapy.
Incubator: No
Subsidiary of a group: Yes (Institut Mérieux)
Other status: No
Funding
Nature of funding searches: Transgene is searching
for partners to co-finance/co-develop its pre clinical
and clinical product development pipeline.
Stock exchange listing: NYSE Euronext Paris- Eurolist
(compartment B) Listed 26 March 1998 Nouveau Marchée
and Nasdaq (de-listed Nasdaq 2005)
150
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
R&D PROJECTS FUNDED
BIOTHERAPIC: Therapeutic solutions against hepatitis C virus
Funding: FUI (2005)
ALPHA VAC: New therapeutic approach for the treatment
of hepatitis C virus infection based on the combination of a
therapeutic vaccine and a nanoparticle-based formulation of
IFN Funding: FUI (AAP3 2007)
chronic hepatitis B
ADNA: Advanced diagnostics for new therapeutic approaches
Funding: OSEO (ISI)
Company contacts
CEO contact detail
Last name: Archinard
Position: Chairman & CEO
Phone: + 33 (0)3 88 27 91 22
Other contact
Last name: Boissel
Position: Executive Vice President & CFO
Phone: +33 (0)3 88 27 81 21
Pipeline product 1
Business model
Value chain
Clinical.
Activities
Vaccine, Biomanufacturing, Models (animal - cellular - …),
Clinical trials, Preclinical trials, Other.
Application fields
Human health, Immunology, Infectious diseases, Cancer.
Activities
Company activities
Transgene’s know-how is based on gene transfer technology
that works from inside the patient’s immune system to treat
major unmet medical needs in cancer and infectious diseases.
Since 1992, the company has specialised in developing gene
transfer therapy with the aim of helping patients fight life
threatening diseases through restoring the immune’s system
capacity to eliminate abnormal or infected cells.
Transgene’s R&D teams are currently conducting
investigational programs on innovative immunotherapy
strategies to offer new solutions to treat cancers and infectious
diseases. The company has a three pillars strategy based on
its historic MVA platform, oncolytic viruses and monoclonal
antibodies. To support this research, Transgene is pursuing
a large biomarker R&D program (prognostic and predictive
biomarkers) intended to increase the efficacy of its products.
Recent news
- October 18, 2010 - Third Quarter 2010 Financial Report
- September 29, 2010 - Transgene Signs an Agreement with
Venatana Medical Systems Inc.
- September 8, 2010 - Jennerex and Transgene enter into an
ExclusivePartnershipfortheDevelopmentandCommercialization
of JX-594
-September1,2010-TransgeneReceivesPositiveScientificAdvice
from the EMA for the Phase IIb/III trial of TG4010.
Skills and know-how
At the heart of Transgene’s expertise is the capacity to develop
safe, reliable and modular gene transfer methods and we
currently use three types of vectors: Modified Vaccinia Ankara
(MVA), vaccinia virus and adenovirus. The effectiveness of a
vector is determined by its ability
to carry the desired gene, to transfer sufficient quantities
into the correct target cells, and to allow either the gene to be
expressed, and thus produce the target protein over a sufficient
long period to ensure the effectiveness of the treatment,
or to induce a broad immune response.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Therapeutic area: Cancer
Therapeutic indication: Non Small Cell Lung Cancer (NSCLC)
Phase 2: TG4010 (MVA-Muc1-IL) Phase IIb/III - indication
NSCLC start mid 2011
Pipeline product 2
Therapeutic area: Infectious Diseases
Therapeutic indication: Precancerous cervical lesions caused by
the HPV virus
Phase 2: TG4001/R3484; indication precancerous lesions
of the cervix (HPV16) Phase IIb interim data end 2011
Pipeline product 3
Therapeutic area: Cancer
Therapeutic indication: Hepatocarcinoma & other solid tumors
Phase 2: JX-594/Oncolytic- Phase IIb (HCC) + Phase Ib (CRC)
start mid-2011
Partnership
Collaborative innovation - whether through collaborative
programs or corporate partnerships - is
a key business driver at Transgene and our capacity to generate
a number of important agreements in this domain testifies
to the solidity of our scientific expertise and business model.
We have a strong track record of fruitful collaboration with
pharmaceutical companies, and other third party organizations,
for the research and development of novel product candidates
in the area of oncology and infectious diseases.
Our principal strategy is to seek out co-development
partnership opportunities for advanced clinical product
candidates that aim to treat large unmet medical needs, and
which require the support of major pharmaceutical partners for
phase III trials and beyond.
The strategic agreement with Novartis is an example
of this strategy applied to one of our lead product candidates
TG4010.
Based on our strategy and business needs, Transgene
can make its technologies and products available to the
industry under research or commercial licenses, or through
collaboration agreements. Transgene is seeking, more and
more, out-licensing opportunities structured around codevelopment partnerships so as to fully maximise the value of
its product pipeline.
Transgene is particularly interested in technologies and product
candidates for immunotherapy applications.
These include:
– Poxvirus related technologies (manufacturing process
enhancement, novel formulation, etc.)
– Novel active immunotherapy products
– Novel tumor associated antigens
– Clinically tested adjuvants (to viral vectors and proteins)
– Novel targets in infectious diseases (small molecules)
– Therapeutic monoclonal antibodies
– Oncolytics viruses.
151
Business model
Value chain
Activities
Vaccine, Models (animal - cellular - …), Preclinical trials.
Application fields
Immunology, Infectious diseases, Cancer.
Company name: Vaxeal
City: Lyon
Website: www.vaxeal-group.com
Main activity: Vaxeal and its strategic partner, the CEA (FR),
are strongly focused on developing new long synthetic peptide
(LSP)-based therapeutic vaccines with tremendous medical
need, for the treatment of cancer and infectious diseases.
In the field of oncology, Long Synthetic Peptides (LSP)
containing T cell epitopes of Survivin and Midkine, proteins
over-expressed in large number of carcinomas and
melanomas - but not in normal cells - and associated
with a poor prognosis, have been identified. These targets,
in monotherapy or in combination, represent highly promising
candidates for the treatment of several cancers.
In the field of infectious diseases, we developed 2 novel
therapeutic vaccines against HCV genotype 1a (main
sub-genotype in USA), and Plasmodium falciparum (Malaria).
This Malaria vaccine will be partnered with the UNIL.
Moreover, the company is also acquiring a novel generation
of adjuvants capable of inducing strong and sustainable
systemic and mucosal responses. .
Incubator: No
Subsidiary of a group: Yes (Vaxeal Holding SA)
Other status: No
Funding
Nature of funding searches: Vaxeal is actually preparing
a seed round table of 2 million euros. The seed will allow us
to complete the pre-clinical trials on our 2 first therapeutic
vaccines: Surivvin and hepatits C genotype 1 (CMC packages,
IND).
CEO contact detail
First name: Ahmed
Last name: Bouzidi
Position: CEO
Phone: + (0)41 79 917 1434
Other contact
First name: Bernard
Last name: Maillère
Position: CSO
Phone: +33 (0)1 69 08 94 47
l i f e
s c i e n c e s
d i r e c t o r y
Company activities
Vaxeal and its partners, the CEA, INSERM, and the University
of Lausanne, have developed several technology platforms
in order to develop their vaccine candidates. These platforms
allow us to identify new targets, the peptide synthesis,
the formulation, as well as pre-clinical and clinical validations
of our therapeutic vaccines
Cellular evaluation of immunogenicity
These assays allow us to investigate the capacity of peptides
or proteins to prime CD4+ and CD8+ T cells harvested from
a panel of naïve donors representative of the HLA class II
diversity in human.
This assay allows:
– To evaluate the intensity of the T cell response raised against
tested peptides or proteins in each donor;
– To evaluate the frequency of responders of the tested peptides
or proteins (immunoprevalence);
– To rank tested peptides or proteins based on their
immunogenicity;
– To identify CD4+ and CD8+ T cell stimulating peptides with
a wide frequency of responders;
– To evaluate cross reactivity of natural variants;
– To evaluate the lytic ability of peptide specific T cells:
Fully automated peptide binding assays specific for HLA class II
molecules
Due to the polymorphism of HLA class II molecules,
immunogenic peptides vary from one individual to another.
These binding assays allow:
– To evaluate the binding affinity of each peptide for HLA class
II molecules;
– To identify peptides with a broad specificity for HLA class II
molecules;
– To evaluate the influence of natural sequence variations
on the binding properties;
– To optimize the sequence for the binding to HLA class II
molecules.
Synthesis of Long Synthetic Peptide (LSP)-Based
Therapeutic Vaccines
Company contacts
152
Activities
2 0 1 1
Our peptide based strategy employs cocktails of Multi-epitopic
Long Synthetic Peptides (average of 25 amino acids) that can be
modified with a lipid tail.
The laboratory has developed appropriate synthesis strategy:
– To synthesize long fragments of various size;
– To ligate chemo-selectively a lipid tail to obtain lipopeptides.
Adjuvant Platform (AFP)
The proprietary FAP has been developed in partnership
with the University of Cambridge (UK). The FAP is based
on Proteoliposome (PL).
AFPL1 and AFCo1 induce in mice and human a Th1 immune
response. They are capable of inducing IFN-α responses, and
chemokine secretions, like MIP-1α and MIP-1α, but no IgE, nor
IL4/IL5 responses. AFPL1 and AFCo1 work in neonatal mice
and prime for memory immune response. AFPL1 has already
been injected in humans.
Pre-clinical Platform (INSERM)
This platform has standardized various assays to monitor
immune response in both systemic and mucosal sites in mice.
– Techniques developed include: Tetramer, Elispot, luminex,
CFSE labelled cells, cytotoxicity assay).
– In addition, various animal models are available:
– HLA class I and II transgenic mice
– Spontaneous tumor models associated cancers.
– Human cell lines derived from various human cancers to be
grafted in immunodeficient mice.
Immunomonitoring platform
This platform is labelled by Canceropole d’Ile de France.
This platform is dedicated to the detection and characterization
of T cell response after vaccine and immunotherapy protocols.
This platform has standardized methods (Elispot, Tetramers,
Intracellular cytokine detection by cytometry…) to detect T
cells and has participated to quality control and standardization
programs.
Vaxeal’s key feature is first the know-how of its team.
Our cumulated experience exceeds 140 years in the fields
of vaccine research, immune-therapy, peptide synthesis,
company management, as well as regulatory and medical
affairs.
The IP position is also an asset. Vaxeal has already signed
an exclusive license agreement with the CEA protecting
its products, and is finalizing an agreement regarding
the adjuvants.
Recent news
Vaxeal is actually incorporating its operational affiliate in Lyon.
Lately, Vaxeal signed an exclusive license agreement with the
CEA, protecting key products of the company. The company has
also been awarded with a MIT special prize, and was finalist
of the Intel/Berkeley entrepreneurship challenge. Vaxeal will
also be soon member of Europabio.
Skills and know-how
Vaxeal was incorporated with one of the best team in the
field of immune-therapy in oncology and infectious diseases.
The know-how of the team covers identification of vaccinal
epitopes, adjuvant setting, synthesis of long fragments,
development of relevant animal and in vitro models, as well as
clinical investigation according to the regulatory requirements.
Pipeline product 1
Therapeutic area: Survivin
Therapeutic indication: Urologic cancers
Preclinical: Yes
Pipeline product 2
Therapeutic area: Midkine
Therapeutic indication: NSCLC, colorectal cancer
Preclinical: Yes
– Cellular evaluation of immunogenicity
Investigation of the capacity of peptides or proteins to prime
CD4+ and CD8+ T cells harvested from a panel of naïve donors
representative of the HLA class II diversity in human.
– Fully automated peptide binding assays specific for HLA
class II molecules
A bank of HLA class II molecules has been constituted (most
preponderant HLA class II molecules).
– Synthesis of Long Synthetic Peptide (LSP)
Our peptide based strategy employs cocktails of Multi-epitopic
Long Synthetic Peptides that can be modified with a lipid tail.
– Adjuvant Platform
AFPL1 and AFCo1 adjuvants induce in mice and human a Th1
immune response.
– Pre-clinical Platform
This platform has standardized various assays to monitor
immune response in both systemic and mucosal sites in mice.
– Immunomonitoring platform
This platform is dedicated to the detection and characterization
of T cell response after vaccine and immunotherapy protocols.
Partnership
Vaxeal has defined a strategic partnership with the CEA. The
company has also established ties with other leading European
institutes: INSERM, and University of Lausanne.
Vaxeal is very open to co-development. The company is seeking
academic partnerships in order to consolidate its intellectual
propertyanditsoperationalcapability(diagnosis,clinicalresearch).
The company is also seeking industrial partnerships (CROs,
manufacturing, end users)..
The business model of Vaxeal is to perform the proof of concept
of its products prior to out-license them to the pharmaceutical
industry.
We intend to out-license, after the phase IIa clinical trials,
to our industrial partners, immune-therapy products
that they can integrate into their end user products.
Our partners will be carefully selected for their ability to
continue the development of our immune-therapy products,
sales and marketing capability to maximize the commercial
potential of our products. Nevertheless, the company will
remain open to co-develop a product at an earlier stage
of development if the pharma can bring a clear leverage effect.
Vaxeal is open to any invention allowing the company to
consolidate its IP assets (novel epitopes, delivery systems…).
Pipeline product 3
Therapeutic area: Hepatitis C
Therapeutic indication: Hepatitis C genotype 1
Preclinical: Yes
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
153
Company name: Visoon
Zip code: 69008
City: Lyon
Website: www.visoon.com
Main activity: Visoon is dedicated to developing computerized
decision support systems based on automated image analysis
in Life Sciences. Visoon software programs are intended for
everyone needing to make decisions using images from living
organs, tissues or cells. Visoon has been conducting a clinical
evaluation of its automated analysis system of pigmented skin
lesions.
Incubator: Yes (CREALYS, Novacite)
(Creation/development 2005)
Funding
Nature of funding searches: Visoon is looking for fundings
in order to industrialize and commercialize its Automated
Analysis System of dermoscopic images for melanoma
detection.
Business model
Value chain
Activities
Medical device, Other.
Application fields
Activities
Company activities
Visoon is a French High Tech company dedicated to developing
computerized decision support systems based on automated
image analysis in Life Sciences. Visoon offers innovative
solutions which rely on classification and search of images only
using image content. Visoon software programs are intended
for everyone needing to make decisions using images from
living organs, tissues or cells (medical research laboratories,
pharmaceutical and biotech companies, physicians…). So,
Visoon software programs allow image analysis automation,
and then make safe and speed-up decision taking.
Three examples of applications are listed below:
– Automated Classification of chromosomes
– Automated screening of TMA (Tissue array) slides in Research
Life Sciences Laboratories
– Automated classification of leukocytes.
Skills and know-how
Company contacts
CEO contact detail
First name: André
Last name: Fond
Position: CEO
Phone: +33 (0)6 61 34 86 08
154
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Visoon engineers are specialized in developing systems
and software for Life Sciences image acquisition, processing
and management along with computerized decision support
systems. VISOON offers innovative solutions which rely on
classification and search of images only using image content.
Company name: Vivalis
Address: 41, quai Fulchiron
Zip code: 69005
City: Lyon
Website: www.vivalis.com
Turnover: 4.8 M E (in 2010)
Main activity: Vivalis is a biopharmaceutical company that
provides innovative solutions for the manufacture of vaccines
and proteins and develops new therapeutic molecules..
Incubator: No
Subsidiary of a group: Yes (Grimaud)
Other status: No
Funding
Activities
Company activities
Vivalis has developed an embryonnic avian cell lines dedicated
to the pharmaceutical industry for the manufacture of vaccines
and proteins. Vivalis also generates therapeutic fully human
monoclonal antibodies for the treatment of inflammatory,
auto-immune and infectious diseases. Finally, Vivalis identifies
and develops small molecules against viral targets.
Vivalis is a world leader in ES cells.
Vivalis uses one of the last reamining technology for
the discovery of fully human therapeutic monoclonal
antibodies not owned by a Big Pharma.
Recent news
In June 2010, Vivalis signed with Sanofi Pasteur a commercial
license and collaboration agreement for the discovery
and development of fully human monoclonal antibodies against
several infectious targets.
Skills and know-how
Strong industrial and scientific experience in ES cells,
immunology and B lymphocyte biology.
Company contacts
CEO contact detail
Last name: Guillot-Chêne
Position: Head of Lyon site
Phone: +33 (0)4 72 40 27 31
Other contact
First name: Nicola
Last name: Beltraminelli
Position: Laboratory manager
Phone: +33 (0)4 78 74 80 03
Business model
Value chain
Company technologies:
- EB66® Technology
Based on the properties of duck embryonic stem cells, Vivalis
has developed the EB66® cell line which overcomes the
limitations associated with egg - based vaccine s and allow the
production of monoclonal antibodies (ADCC enhanced).
- Humalex® Platform
Based on an optimized EBV technology, the Humalex platform
allows the isolation of human monoclonal antibodies
of interest produced by immortalized Human B-lymphocytes
harvested from individuals previously exposed to a targeted
pathology. The Humalex platform, by immortalizing
a high number of human B-lymphocytes, makes the EBV
methodology suitable for industry level discovery research.
- 3D Screen® Platform
Based on the assumption that the tri-dimensional structure
of a protein dictates its biological activity, Vivalis has developed
an innovative drug screening platform, to identify anti-viral
molecules.
Activities
Biomanufacturing, Drug discovery, Other.
Partnership
Application fields
diseases, Infectious diseases, Autoimmune diseases, Cancer.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Vivalis proposes research and commercial licenses of its EB66
cell lines for vaccines and proteins manufacturing. Vivalis
receives upfront fees, milestone payments and royalties on its
licensees net sales.
Vivalis proposes solutions for the discovery, development
and production of therapeutic human monoclonal antibodies.
Vivalis receives upfronts, milestones payments and royalties
on its licensees net sales.
155
Company name: Voxcan
Zip code: 69280
Website: www.voxcan.fr
Turnover: 500 K € (in 2009)
Main activity: Voxcan is a CRO specialized in 3D medical
imaging services adapted to preclinical studies in a wide range
of therapeutic areas: bone and cartilage, implants, vascular
and pulmonary diseases, oncology and metabolic deseases.
Our services are designed to increase biological measurement
accuracy and to allow customers to save animal models, time
and money.
Other status: Yes
Funding
Company contacts
CEO contact detail
Last name: Chereul
Phone: +33 (0)4 78 19 52 38
l i f e
s c i e n c e s
d i r e c t o r y
Business model
Value chain
Activities
Preclinical trials.
Application fields
Animal health, Human health, Inflammatory diseases,
Infectious diseases, Metabolic diseases, Cancer, Nutrition /
Food.
Activities
Company activities
Voxcan is specialized in 3D Medical Imaging Services
(Anatomical and Functional) on animal models from mouse
to pig. Our services provide our customers with in-vivo
quantitative results to test new drugs, in a non-invasive way,
in areas such as bone-cartilage, oncology, cardiovascular, body
composition, bio distribution and pharmacokinetics… under
controlled sanitary conditions. Our activity covers standard
or made-to-order protocols for your R&D and Preclinical
projects.
Services are performed under GLP requirements on an
analysis imaging platform (X-ray Computed Tomography and
Optical Molecular imaging).Their specificities allow
to conciliate both ethical concerns and financial profits as well
as to obtain a twice shorter study time with respect to histology
analyses.
Recent news
Other contact
First name: Thomas
Last name: Chuzel
Position: Regulatory Affairs Manager
Phone: +33 (0)4 78 19 52 39
Fax: +33 (0)4 78 19 52 40
156
2 0 1 1
• 01-07-2010: PRIM-OA project is funding by Europe within the
framework of an approved Eurostars project
• 01-12-2009: Signature of a Partnership Convention between
Voxcan, Floralis anf Joseph Fourier University.
• 20-10-2009: Voxcan is supported by Rhône-Alpes Region for
its new range of innovative services.
• 15-07-2009: Voxcan is supported by the Rhône Department
Innovation Fund.
Companies
Start-up
projects
Investors
start-up projects
Start-up projects
index
158
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
A-Tech 159
Cavi-T 160
EBV Biotech 161
Kallistem 162
Smartox 164
Vet Biobank 165
Virologics 166
ViroScan3D 167
A-TECH
General INFORMATION ON PROJECT
Name of the project: A-Tech (project: UroClip)
Incubator: Crealys
Main activity planned: Prostate cancer is the most common
form of male cancer, and is increasing due to aging population
and new means of detection. Surgery is the leading treatment,
and over 24,000 operations are performed every year
in France (>250,000/year worldwide). During the surgery,
particularly difficult suturing operations are required. A-Tech
has developed a product that will dramatically simplify those
suturing operations. A-Tech offers high value added
for Patients (health benefits), Surgeons (surgical efficiency
and precision), Hospitals (financial benefits and improved
image) and insurance companies. The UroClip protocol
and device are both patent pending and have been designed
as a result of extensive interviews with urologists, A-Tech’s
Advisory Board and field studies. Having successfully entered
the manual segment of prostate removal surgery, A-Tech will
develop its technology to robot-assisted surgery, and more
generally to other surgical fields requiring particular suturing.
Nature of funding searches: A-Tech management team will
seek private investments for the tests on living animals, end
2011. Investors having connections with domains liked
to the project will clearly be preferred.
PROJECT segmentation
Business model
Value chain
Research, Other.
Activities
Medical device.
Application fields
Human health.
START-UP PROJECT
Project presentation
Currently, A-Tech is working on the UroClip’s proof of concept.
The project is incubated at Crealys and has recently signed
a partnership with VetAgro Sup (vet lab in Lyon), knowledged
in Life Sciences, tissues, biomaterials and animal surgeries.
The current objective is to perform the proof of concept
(pre-clinical trials). Tests on living animals will start end 2011.
PROJECT contactS
Project leader
First name: Arnold
Last name: Ferlin
Position: Project leader
Phone: +33 (0)6 78 06 58 61
Other contact
First name: Renaud
Last name: Marin
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
159
CAVI-T
Name of the project: CAVI-T
Incubator: CREALYS
Main activity planned: R&D, manufacturing and sales
of innovative devices based on the ultrasound cavitation
technology for the research market (cells transfection)
and the therapy market (release and/or maximization
of therapeutic products , i.e. chemotherapy) .
Business model
Service provider - Scientific, Product developer - Other health,
Value chain
Research, Manufacturing, Preclinical, Marketing / Distribution.
Activities
Instrumentation, Cell therapy, Preclinical trials,
Nanotechnology, Medical device, Drug delivery.
Application fields
Animal health, Human health, Orphan diseases, Genetic / Rare
diseases, Cancer.
PROJECT contact
Project leader
First name: Jérôme
Last name: Lavaure
Phone: +33 (0)6 87 66 17 35
START-UP PROJECT
CAVI-T project is based on a technology breakthrough that
has been recently patented by a worldwide renowned public
research laboratory (Lyon). New innovative tools able to induce
a precise, stable and reproducible mechanical stimulation
will be developed and proposed to researchers and clinicians.
The control of therapeutic ultrasound in general and the
stabilization of cavitation in particular are bringing new
horizons in cell biology, in oncology and more generally in new
generations of therapeutics.
Opportunities
For our business of cell transfection we would like to develop
collaboration with worldwide renowned research laboratories.
For the maximization of therapeutic products we would like
to develop partnership with pharmaceutical industries from
the chemotherapy field.
160
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Name of the project: EBV Biotech
Incubator: CREALYS
Main activity planned: EBV Biotech (project accompanied
by CREALYS) develop actually a kit of predictive diagnostic
of Epstein-Barr virus(EBV)-associated tumor: carcinomas and
lymphomas. Our project open a new innovative theranostic
never realized till now for EBV-associated cancers
(an immunotherapy combined with a diagnostic test).
Business model
Value chain
Activities
Diagnostics / Analysis method, Biomanufacturing, Drug
discovery.
Application fields
Human health.
START-UP PROJECT
PROJECT contact
Project leader
First name: Tadamasa
Last name: Ooka
Phone: +33 (0)4 78 77 10 78
Our project consists of establishing a specific, feasable
and predictive diagnostic test for Epstein-Barr virus-associated
cancers -an immunotherapy to treat EBV-associated cancers.
The commercialization of diagnostic test and humanized
antibody are planned for our future EBV Biotech incubated
by CREALYS incubator.
Project key features
A diagnostic test capable of detecting the patients developing
EBV-related cancers. Immunotherapy permitting to suppress
EBV-associated tumor by �inhibition
of EB- encoded protein action.
Recent news
Our project is incubated by Crealys.
Two European patents were deposited in August 2008,
then tranformed in PCT in August 2009.
Skills and know-how
Diagnostic, Immunotherapy and animal experience.
Opportunities
We are looking for industrials as subcontractors capable of
providing the poly- and monoclonal antibodies
and of commercializing Elisa diagnostic test . We are looking
for also the companies capable of humanizing mouse
monoclonal antibodies.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
161
Business model
Service provider - CRO, Service provider - Scientific, Product
Value chain
Activities
Drug discovery.
Application fields
Name of the project: Kallistem
Incubator: CREALYS
Main activity planned: Kallistem offers to industry (chemical,
pharmaceutical, food, cosmetics) its expertise
and in vitro cell models for studies of «physio-toxicology»
of spermatogenesis and the development of new treatments
of male infertility and testicular cancers.
The benefits bring by Kallistem are:
– Reduction of cost, time, number of animals used,
– Accuracy / relevance of results
– Knowledge of the mode of action of the molecules tested
(mechanistic toxicology / explanatory).
Products and services offered:
– Studies to «way»
–R&D
Website: www.kallistem.com.
Nature of funding searches: we are looking for investors,
business angels, partners.
PROJECT contactS
Project leader
Last name: Durand
Position: Research Director / President
Phone: + 33 (0)4 72 72 89 65
Mobile: +33 (0)6 80 17 58 12
Other contact
Last name: Grenet
Position: Director
Phone: +33 (0)4 99 61 02 73
Mobile: +33 (0)6 63 87 59 66
162
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Animal health, Pediatrics, Human health, Cancer,
START-UP PROJECT
We have developed innovative systems for co-culture
of germ cells and Sertoli cells (somatic cells that support
and nourish germ cells) in «bicameral» culture chambers
that allow maintaining or reforming the blood-testis barrier
(structure that isolates the most mature germ cells
from the bloodstream), which allow the different stages
of male rat gamete formation to occur in culture over a period
of 2 to 4 weeks. Thanks to the methods of analysis: cytological,
biochemical and genomic we have developed, our systems
can also be used to investigate the toxic and / or carcinogenic
effects of organic or minerals, compounds, or nanoparticles,
on male reproductive function. Our goal now is to create
a company offering services in predictive or regulatory
toxicology in the field of male reproduction to meet the needs
of pharmaceutical, cosmetic and chemical industries, but
also to enhance the fundamental knowledge on molecules
having a deleterious impact on public health, and identify
new therapeutic candidates in the context of male fertility(
traetment of infertility or male contraception) and testicular
cancers.
Increasingly, toxicology uses toxicogenomic studies on cell
lines in culture to highlight the genes whose expression is
altered by toxic substances. However, this approach is not
feasible in toxicology of spermatogenesis, because there are
no lines of germ cells differentiating in vitro that can respond
to this request. Therefore the practice is in vivo studies (that is
to say in living animals). However, toxicology in vivo tests used
for regulation are mostly irrelevant and not very informative.
The systems that we developed allow us to study precisely
the effects and mechanisms of action of toxic molecules,
substantially reduce the cost and duration of reproductive
toxicology studies on spermatogenetic function, while
dividing by 10 or 20 the number of animals required for these
evaluations. From our cultures, it is possible to study a large
number of parameters exploring the mechanisms of toxic
effects such as:
1) the alterations of the blood-testis barrier;
2) the survival and/or cell death, proliferation of Sertoli cells
and spermatogonia (stem cells of spermatogenesis);
3) the conduct of the meiotic divisions (key stage
of spermatogenesis during which genetic recombination takes
place);
4) the cytogenetic abnormalities of germ cells;
5) the expression of specific genes in germ cells or Sertoli
cells.
We can then correlate the somatic and germ disturbances,
observed in culture, to the changes in the transcriptome
and proteome of these cells (toxicogenomics) to define a panel
of genes and proteins most relevant to assess in reproductive
toxicity studies (alteration of spermatogenesis and / or cancer
genes). Using the same cell population exposed (treated group)
or not (control group) can dispense with much of the variability
between animals that are encountered in testing in vivo,
thereby maximizing the power of tests. It should be stressed
that knowledge of the mode of action of molecules studied can
also establish whether the observations made in animals are
transferable to humans, which remains a major problem in this
type of study. By contrast, in vivo methods are less informative
unlike our system, for studying the cellular and molecular
effects (or lack of effect) of a product or product cocktails.
Opportunities
We are looking for partners and clients to create a start-up
The intended customers are from chemical, pharma, cosmeto
industries government laboratories, associations for health
and environmental protection. Among some, partners may
be partners for R & D investors, «promoters» of our systems
(CRO), users.
Recent news
Analysis of spermatogenesis ex vivo: application to the analysis
of testicular toxicity Médecine / Sciences 26: 305-10.
The new challenges of testicular toxicology (editorial)
Andrologie 20: 117119 The academic work supporting
Kallistem will be one of the Award Winners of the Innovative
Techniques for Environment ADEME-Pollutec 2010.
Skills and know-how
– Cell Models:
• co-culture of germ cells of rat with Sertoli cells
in «bicameral» chambers of culture
• culture of testicular somatic cells
• purification of different types of germ cells.
– Analyses:
• light and electron microscopy
• immunocytochemistry
• cytogenetics
• flow cytometry, cell sorting
• BrdU incorporation
• survival test
• proliferation test
• test of differentiation
• study the different phases of meiosis
• cytotoxicity test.
– Test of apoptosis:
• obtaining cell extracts
• protein assay and enzyme activities
• measuring the expression of certain proteins considered
cellular biomarkers
• metabolism
• gene expression, RT-PCR, DNA chips
• mass spectrometry to monitor protein and peptide products.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
163
Name of the project: Smartox
Incubator: Grain
Main activity planned: Smartox biotech is specialized
in chemical synthesis of animal peptide toxins. Peptide toxins
are bioactive molecules that target mainly ion channels
and G protein coupled receptors. These two membrane
receptor families are implicated in several pathologies (cancer,
pain, diabetes, auto-immune diseases, etc.).Toxins are usually
used as research tools, and have also led to the discovery
of new therapeutic molecules (Byetta®, Prialt®, Captotril, etc.)
In this context, Smartox proposes a catalogue of toxins
for research activities on membrane proteins, and offers
also additional services (bespoke syntheses of peptide toxins,
toxin characterization). Smartox has the ambition to develop
its own drug discovery program based on screening
and characterization of venom compounds.
PROJECT contactS
Project leader
First name: Michel
Last name: DeWaard
Phone: +33 (0)4 56 52 05 63
Other contact
First name: Aurélien
Last name: Claeyssen
Position: Business developer
Phone: +33 (0)4 76 54 95 29
164
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Business model
Service provider - CMO, Product developer - Other health.
Value chain
Activities
Biomanufacturing.
Application fields
Animal health, Human health, Inflammatory diseases,
Autoimmune diseases, CNS related diseases, Cancer.
START-UP PROJECT
Smartox is currently a business unit of Floralis (technology
transfer office of the university of Joseph Fourier). This project
directed by Michel De Waard was born in 2008. Two R&D
and production engineers are now being employed. Smartox
is proud to count among his clients some of the most
prestigious pharmaceutical and biopharmaceutical industries.
The start-up creation is scheduled for 2011.
Business model
Name of the project: Vet Biobank
Incubator: CREALYS
Main activity planned: Cell and tissue banking activities
Nature of funding searches: Proof of concept stage is
Manufacturing, Preclinical, Marketing / Distribution, Clinical.
for veterinarians.
achieved Marketing of the first service (stem cell banking)
is due to start before the end of the first trimester 2011.
Financing resource is seaken to allow initial investment
(equipment; material, consummables stock) and to finance
the growth of working capital based on the planned ramp up
of activity.
Value chain
Activities
Diagnostics / Analysis method, Cell therapy, Biomanufacturing,
Clinical trials, Biobank, Preclinical trials.
Application fields
Animal health, Immunology, Inflammatory diseases,
Autoimmune diseases, Cancer, Other.
START-UP PROJECT
PROJECT contact
Project leader
Last name: Maddens
Phone: +33 (0)6 05 21 27 20
In first instance, Vet Biobank propose to racehorse owners
to bank their foal’s own mesenchymal stem cells contained
in the umbilical cord collected at birht. Those cells represent
a high value biological resource in order to optimize
the treatment of the future injuries they may experience
in their racing carreer. This service relies on the tissue
regenerating potentiel of those stem cells.
This service answers to an unmet medical need, since both
medical and surgical veterinary healtcare do not answer
or partially. Still today, an injury represents the cause of horse
discharge from racetracks. Partnership with the Lyon Vet
School (Vetagro Sup). Business model which optimize
the market to be captured Stong knowledge of market through
in-depth investment in market study Growing customers
portfolio.
Recent news
Market study finalized (with a strong investment on the field)
Businss model optimized.
Skills and know-how
Value chain management and know-how by the project leader
Precise knowledge of the market adressed.
Opportunities
Vet Biobank is seeking partnerships in the following fields:
– long term cell banking infrastructure
– Good manufacturing practices compliant clean rooms to host
growing activities (ISO8 à ISO5)
– financial support.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
165
VIROLOGICS
Business model
Value chain
Name of the project: Virologics
Incubator: CREALYS
Main activity planned: Virologics will develop antivirals
against targets of RNA viruses such as hepatitis, influenza…
identified through the Interactome technology .Which allows
to identify cellular functional modules that are essential
for viral replication at the time of infection. These cellular
functions are targeted by small molecules to either inhibit viral
replication or stimulate the production of virus by the cell.
PROJECT contactS
Project leader
First name: Sonia
Last name: Escaich
Position: Director
Phone: +33 (0)6 18 63 38 90
Activities
Vaccine, Drug discovery.
Application fields
Human health, Infectious diseases.
START-UP PROJECT
To create a biopharmaceutical company specialized
in the research and development of new antiviral molecules
with an original mechanism of action. This project is based
on results and technologies from the research laboratory
Inserm U851 including results of the broad mapping
of interactions between the viral proteins and cell proteins.
The company aims to discover and develop innovative
therapeutic molecules till proof of concept in man
and to license them to the pharmaceutical industry.
The interest of host proteins inhibition to develop new antivirals
is that the molecules won’t select resistance associated
with mutations in the virus targets. Inhibition of cellular
targets shared by several viruses such as the one common
to the different influenza virus, or by the hepatitis B and C
viruses will allow finding molecules that have broad-spectrum
activities. The hits are active molecules which have known
pharmacological properties. This will allow shortening
and reducing the risks associated with clinical development.
Other contact
First name: Vincent
Last name: Lotteau
Recent news
Virologics will start with a solid portfolio of therapeutic interest
targets validated by inhibitors. Active molecules have already
been identified by cell screening for the hepatitis viruses
with a molecule in clinical evaluation and several molecules
are inhibitory of influenza viruses. For influenza viruses
provirales molecules have also been identified.
Skills and know-how
Identification of targets for different viruses including human
and avian influenza, hepatitis C virus, hepatitis B virus,
the dengue virus, West Nile virus, yellow fever virus, virus
Chikungunya etc. Data mining to identify molecules hits
Virological assays for in vitro screening and validation
of molecules.
Opportunities
– Search for partners for seed funding of the startup company.
– Molecules acting on the cellular target have either antiviral
either proviral activity. These can be applied to stimulation
of virus production for production of vaccine. We are looking
for partners for this application to vaccine production.
166
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Name of the project: ViroScan3D
Incubator: CREALYS
Main activity planned: broad-spectrum pathogen
identification & pathogen discovery Discovery of new targets
for diagnostic, vaccine and therapeutics.
Business model
Value chain
Research.
Activities
Application fields
diseases.
PROJECT contactS
Project leader
First name: Catherine
Last name: Legras-Lachuer
Position: President
Phone: +33 (0)4 37 28 76 15
Mobile: +33 (0)6 63 43 24 04
Other contact
First name: Angela
Last name: Rea-Boutrois
Position: Director
Phone: +33 (0)4 37 28 76 15
Mobile: +33 (0)6 12 59 81 60
START-UP PROJECT
ViroScan3D will offer new custom services targeted towards:
the detection of a broad-spectrum of pathogens, pathogen
discovery and the identification of novel diagnostic targets.
Innovative tools and technologies of ViroScan3D include:
(i) multiplex PCR
(ii) resequencing DNA chips
(iii) panvirus arrays, for the detection of all known human
and animal viruses
(iv) next-generation sequencing, for the identification
of all pathogens
(v) microarrays for the discovery of new molecular signatures.
– The innovative tools and technologies shared by the University
of Lyon 1 and the Mérieux Foundation: syndromic, genomic,
broad-spectrum detection tools and the next-generation
sequencing technologies.
– The team, including:
(i) the experienced scientific team, anchored in the industrial
and academic environment, and who brings an unique expertise
in the fields of infectious diagnosis and genomic
(ii) the experienced strategic team anchored in the economic
and business environment.
Skills and know-how
Infectious diagnosis High throughput genomics.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
167
Companies
Start-up
projects
Investors
Investors
Investors
Index
Agcom Biotech 171
Angels Santé 172
Banque Rhône Alpes 173
Bryan Garnier & Co 174
Carvest 175
CDC Entreprises 176
CEA Investissement 177
CIC Vizille Capital Innovation 178
Crédit Agricole Private Equity 179
Eclosion 180
Edmond De Rothschild - Entreprises Patrimoniales 181
170
Edmond de Rothschild Investment Partners 182
Grenoble Angels 183
Inserm Transfert Initiative 184
Lyon Angels 185
Merck Serono Ventures 186
Mérieux Développement 187
Nyse Euronext 188
Octalfa 189
Oddo Asset Management 190
OTC Asset Management 191
Rhône-Alpes Création 192
Savoie Angels 193
Seventure Partners 194
Sham 195
SiPAREX 196
Sofimac Partners 197
Sofinnova Partners 198
Ventech 199
Viveris Management 200
ACTIVITIES
Business
General INFORMATION ON INVESTOR
Investor name: Agcom Biotech
Address: 11, rue HectorBerlioz
City: Lyon
Zip code: 69009
Creation date: 02/01/2007
AgCom biotech is an independant advisory firm in International
Business Development, founded in 2007 by several partners
with expertise in biosciences, R&D, Industry, legal affairs,
finance, business develpment and international trade.
We are strategic strategic advisors and partners
of the inovative companies, SMEs, start-ups and major
investors looking to expand their worldwide presence.
Our services are intended primarily for Environment,
Healthcare and Life Sciences Industries, Stakeholders, Private
Investors, Business Angels,Banks and Private Equity Funds.
Focus Areas
We provides assistance and personnalized solutions
in Environment, Healthcare and Life Science Industries.
– Pharmaceutical & Biotech: Drugs, vaccines, diagnostics
– Agrofood & Wellness: Functional Food, Nutrition, Cosmetic,
Biosafety
– Healthcare Technologies & Services: NTIC, Medical Devices,
Imaging, Biomaterials
– Environment & Cleantech: Waste Management, Bioremediation, Biomass, Production, Industrial effluents
treatments.
INVESTOR contact
General Manager
First name: Edwige
Last name: Morand
Position: CEO
Phone: +33 (0)4 78 47 89 14
Description of your activity
Our mission is to help all companies to transfer their
technology, and give them some operational support to market
new concept, from research to industrialization.
Agcom Biotech has positioned itself around 3 interrelated
services:
• Strategy & Corporate Finance:
- Diagnosis & Potential for Innovation, Due Diligence
– Funds Raising (from Seed Stage to Large Cap)
– M&A, Acquisitions and Divestitures Support, Special/
Distressed Situations.
• Business Development & Licensing:
– Business Development Operations
– Negotiation & Agreements
– Marketing & Sales
– Personnal skills, cultural issues & behaviour
• Technologies & Innovation
– Support to establish industry & academic partnerships
– R&D Alliance & Consortium: KOL search and selection
– Supply Agreements & Outsourcing
Our services are intended primarily for:
– Environment, Healthcare & Life Science Industry & start ups
– Stakeholders, Major & Private Investors
– Banks & Private Equity Funds.
Recent news
We would like to meet companies looking for fund raising,
strategic growth and business development support at national
and international levels.References: Danone Group, Osyris SA,
Sloning GmbH (Morphosys buy-out), Medical Device Company
(Sweden), ABA Incubator, Seventure Partners, Private Holding
(Biofarming, GMO), Olive Oil Company. More Informations:
www.agcombiotech.com.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
171
Investor name: Angels Santé
Address: 8, terrasse Bellini, La Défense 11
City: Puteaux
Zip code: 92800
ACTIVITIES
Business
Angels Santé is the first network of Business Angels
in Healthcare in France. Approved by the Ministry of Economy
of Finances and Employment in 2008, the network brings
together private investors wishing to invest in innovative
companies or with high potential of growth in the healthcare
field.
Focus Areas
Our investments are done in 4 fields:
– Drugs and Biotech
– Medical devices
– Healthcare services
– New technologies for health.
INVESTOR contact
General Manager
First name: Pierre Emmanuel
Last name: Aubert
Phone: +33 (0)6 07 57 99 16
Members of our network share a few key values: Taste
for Entrepreneurship - Willingness to support entrepreneurial
adventures - Participation in seed or early stage - Position
in regional branches throughout France - Close links with
institutions of the Health sector - Sponsorship Committee
composed of Inserm transfer, LEEM, France Biotech, Medicen
pole.
Investments
- Allied Health
- Santelog
- DNA Therapeutics
- Laboratoire Davioud
- Ekkyo
- Primadiag
- Neorphys
- Nutrivercell
- Graftys
- Alize Pharma
- Kreactive.
Recent news
Angels Santé had been awarded as « Network of the year –
Category « Espoir » at the occasion of the Congress France
Angels on October 14th, 2009 – award supported by the French
Ministry of Industry and Employment.
172
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Investor name: Banque Rhône Alpes
Address: 235, cours Lafayette
City: Lyon
Zip code: 69006
ACTIVITIES
Business
Financing markets of individuals, professionals
and businesses – Market operations – Venture capital.
Focus Areas
All sectors.
Recent news
INVESTOR contactS
General Manager
First name: Bruno
Last name: Deschamp
Position: President
Email: bruno.deschamp@banque-rhône-alpes.fr
Phone: +33 (0)4 72 75 86 86
The international branch in Lyon, located rue du Bât d’Argent,
will welcome new comers in Lyon… and the others !
For any queries you may have, please feel free contact
Catherine Schatz at +33 4 72 75 88 52
[email protected]
Other contact
First name: Patrick
Last name: Pelletier
Position: Financial Affairs Director
Phone: +33 (0)4 72 75 86 90
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
173
Investor name: Bryan Garnier & Co
Address: 26, avenue des Champs Elysées
City: PARIS
Zip code: 75008
INVESTOR contactS
ACTIVITIES
Business
Equity Research & Brokerage, Asset Management, Corporate
Finance.
Focus Areas
Technology, Media, Telecom
Healthcare
Renewables
Consumer brands & Specialty retail
Business services.
General Manager
First name: Olivier
Last name: Garnier
Position: President
Phone: +33 (0)1 56 68 75 29
Other contact
First name: Christian
Last name: Finan
Position: Director ECM
Phone: +33 (0) 1 56 68 75 30
Fax: +33 (0) 1 56 63 75 21
Bryan Garnier & Co is an independent investment banking
firm focused on fast-growing companies and growth-oriented
investors. From offices in London, Paris, Geneva and New York,
Bryan Garnier & Co offers the full range of investment banking
capabilities and institutional brokerage resources, with unique
investment ideas and personalized attention to our clients.
With a research-driven approach, Bryan Garnier & Co provides
Corporate Finance advisory, Sales & Trading and Asset
Management to a diverse range of corporate clients, private
equity firms and institutional investors. Bryan Garnier & co has
deployed its expertise for more than 10 years. It is authorized
and regulated by the Financial Services Authority (FSA) in the
United Kingdom, and is member of London Stock Exchange
and Euronext, Alternext Listing Sponsor, and is active on all
European Capital Markets.
Recent news
The news concern the operations realized by Bryan Garnier
& Co http://www.bryangarnier.com
174
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Investor name: Carvest - Crédit Agricole Création
Address: 1, rue Pierre de Truchis de Lays
City: Champagne au Mont d’Or
Zip code: 69410
ACTIVITIES
Business
Venture capital, development, transmission.
Focus Areas
Industrial or service companies, start-ups, young innovative
companies or with potential for growth.
Recent news
Several investments in 2009 in innovative start-ups (high-tech,
life Sciences).
INVESTOR contact
General Manager
First name: Olivier
Last name: Solinas
Phone: +33 (0)4 72 20 07 07
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
175
ACTIVITIES
Business
CDC Entreprises, an asset management company approved
by the AMF (Autorité des Marchés Financiers, the French
securities regulator) and a wholly-owned subsidiary of Caisse
des Dépôts, manages the group’s public interest activities,
including the FSI (the French Sovereign Fund), in the field
of private equity for SMEs. CDC Entreprises invests in private,
national and regional investment funds, and directly in SMEs.
Investor name: CDC Entreprises
Address: 137, rue de l’Université
City: 75007
Zip code: Paris
Focus Areas
CDC Entreprises covers SMEs’ entire financing chain, involving
itself directly and/or indirectly in SMEs, from seed money
for technological start-ups to small mergers and acquisitions.
It takes more risk than the traditional players, positioning
itself much more strongly in activities such as the provision
of seed money and venture capital, and targeted areas such
as biotechnology. It takes stakes in SMEs’ capital up
to a maximum of €15 million for any one company.
INVESTOR contact
General Manager
First name: Olivier
Last name: Martinez
Position: Investment Director
Phone: +33 (0)1 58 50 85 51
CDC Entreprises operates under market conditions,
and seeks levels of efficiency and profitability that will enable
it to encourage private investment. It mainly manages funds
of funds and takes minority stakes in national and regional
private equity funds. It also manages funds which invest
directly in SMEs. CDC Entreprises and its subsidiaries carry
out transactions of the following types:
– general risk capital and private equity transactions,
and small business mergers and acquisitions in all business
sectors,
– sectoral transactions in businesses: cultural and creative;
providing innovative technological products and services
in the field of healthcare; the timber industry,
– mezzanine finance in convertible bonds for businesses
not wishing to open up their capital in the short term,
– transactions aimed at bolstering equity for businesses
weakened by the crisis but having real development potential.
Investments
Close to 4,600 SMEs financed in 15 years of business. More
than 2,700 currently in the portfolios of the 189 investment
funds that are affiliated to it, including 100 directly financed
businesses. CDC Entreprises finances a new SME almost
every day.
Recent news
As part of its plans for future investment, the French
government has entrusted to CDC Entreprises
the management of the future FNA (Fonds National
d’Amorçage or National Seed Money Fund) in an amount of
€400 million. The FNA’s objective is to invest in funds which
will themselves invest in innovative, particularly technological,
businesses. The FNA’s mission is to make a significant
contribution to the success of innovative businesses bringing
competitive advantages and growth potential to the French
economy.
176
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
ACTIVITIES
Investor name: CEA Investissement
City: Grenoble
Zip code: 38054
INVESTOR contactS
General Manager
First name: Celia
Last name: Hart
Position: Manager Investment, Life Sciences
Phone: +33 (0)4 38 78 29 48
Other contact
Last name: Breniaux
Phone: +33 (0)1 69 08 41 94
l i f e
s c i e n c e s
d i r e c t o r y
Business
CEA Investment invests in the development of highly innovative
startups that work on technologies related to the fields
of activities of the CEA.
Focus Areas
CEA Investment invests in the development of highly innovative
startups that work on technologies related to the fields
of activities of the CEA. Among these fields there are:
information technologies, micro-electronic, healthcare, energy
and environment.
CEA Investment, Ltd. with capital of 27 million is
the investment branch of the CEA, a major institution
for technological research, development and innovation.
Investments
More than 20 companies – in life Sciences: Alchimedics
(MedTech) EyeTechCare (MedTech) Fluoptics (MedTech) Cytoo,
ImmunId (Diagnostic) Neorphys, Neurokin, Vaxeal, Fermentalg.
Recent news
– July 2010: EyeTechCare SA, which is developing non-invasive
therapeutic medical devices using ultrasound technology,
announces the completion of a EUR 7.5-million funding round.
The funds were provided by Lyon-based insurance company
SHAM, a first time investor, Crédit Agricole Private Equity
(CAPE), CEA Investment.
– May 2010: CEA Investment participated in the first financing
round at 750,000 euros of Fluoptics, specialised
in fluorescence imaging for cancer surgery. With this funding,
Fluoptics aims to finalise the preclinical phases
of its fluorescent tracer and develop its sales at the
international level and reinforce its managing team. Fluoptics
comes from CEA/LETI.
– July 2009: CYTOO Announces the completion of a second
fund raising of 3.2 million and the entry of AURIGA PARTNERS
in its capital. The company will use the funding to continue the
industrialization of its products and expand internationally.
– May 2009: ImmunID raised 2.4 million funds from VCI, CEA
Investment SOFIMAC. This brings to more than 5 Million euros
for its clinical development for personalized medicine kits
ImmunTraCkeR Immun’Ig .
– March 2009: Neorphys closes its second financing round.
A second financing round of 1.2 Million euros had been
achieved in 2009 with Soridec, CEA Valorisation, Fa Diese 2,
Seillans and a number of independent business angels. It will
be used to complete the regulatory preclinical development
of NEO1509.
– February 2009: the Emertec 4 fund, CEA Valorisation
Aquitaine Creation Innovation and Picoty Development
participed in the first financing round of Fermentalg company.
2 0 1 1
177
Investor name: CIC Vizille Capital Innovation
Address: 2, rue Président Carnot
City: Lyon
Zip code: 69002
General Manager
First name: Karine
Last name: Lignel
Phone: +33 (0)4 78 38 64 90
l i f e
s c i e n c e s
d i r e c t o r y
Business
Venture Capital.
Focus Areas
Technological companies: IT, Hardware, Life Sciences,
Greentech.
We invest in and follow technological companies,
on high growth market sectors, and with a huge development
capability.
INVESTOR contact
178
ACTIVITIES
2 0 1 1
Recent news
Last investments (2010):
> Nanobiotix (Life Science)
> iCosmeceuticals (Cosmetic)
> Kalistick (IT).
Investor name: Crédit Agricole Private Equity
Address: 100, bd du Montparnasse
City: Paris
Zip code: 75682
ACTIVITIES
Business
Crédit Agricole Private Equity is the Crédit Agricole group’s
private equity arm. As an AMF-accredited asset management
company, Crédit Agricole Private Equity manages 3.3 Billion
Euros. As the leading equity investor in French SMEs, Crédit
Agricole Private Equity works on a daily basis to support
160 businesses and infrastructure projects.
Focus Areas
INVESTOR contact
General Manager
First name: Alexia
Last name: Perouse
Position: Partner
Phone: +33 (0)1 43 23 95 94
Its team of 95 professionals supports companies at all stages
of their growth and expansion, from start-up right through
to sale, in a long-term relationship of mutual trust
and proximity.
Comprising 11 investment professionals, Crédit Agricole
Private Equity’s venture capital team manages more than
470M€ as of today and acquires minority stakes in young
companies with high growth potential. Its main areas
of interest are financing innovative business ventures
in the information technology and life sciences sectors.
Investments
Therapeutic: ArGEN-X, Cythéris, Poxel, Xention, Complix…
Medtech: SuperSonic Imagine, CircuLite, EOS imaging,
EyeTechCare, Spineguard, Stentys, SpineGuard…
Recent news
January 2011, sale of Biovex to Amgen for a potential amount
of 1Md$. The company develops therapeutic vaccines
for the treatment of cancer. October 2010, success
of Stentys’IPO on Euronext. This medtech company proposes
a new generation of stents for the treatment of acute
myocardial infarction End of 2009, sale of the start-up Fovea
pharmaceuticals which is specialized in the treatment
of the eye diseases to Sanofi Aventis for a potential amount
of € 370 M.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
179
Investor name: Eclosion
Address: 14, chemin des Aulx
City: Plan-les-Ouates
Zip code: 1228
ACTIVITIES
Business
Eclosion bridges the gap between academic projects
and the time when a start-up can reasonably attract venture
capital. Eclosion offers the management support, financial
investment and infrastructure solutions that allow the most
promising projects to become successful start-ups.
Focus Areas
Life Sciences.
INVESTOR contactS
General Manager
First name: Jesus
Last name: Martin-Garcia
Position: Partner
Phone: +41 22 880 10 10
Other contact
First name: Benoit
Last name: Dubuis
Position: Partner
Phone: +41 22 880 10 10
180
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Support of Proof of Concept studies emerging from academic
labs: management - financial and infrastructure solutions.
Seed investments to development capital, from discovery
to early clinical phases.
Investments
Geneuro, GenKyoTex, Arisgen, Melcure.
Investor name: Edmond De Rothschild
Entreprises Patrimoniales
Address: 55, avenue Foch
City: Lyon
Zip code: 69006
Edmond de Rothschild Entreprises Patrimoniales is a French
advisory firm specializing on small and mid-size companies.
Our mission is to help entrepreneurs throughout the process
of raising capital, merger-acquisitions, LBO/MBO/MBI/OBO
and IPO. Edmond de Rothschild Enterprises Patrimoniales
is a subsidiary of La Compagnie Financière Edmond
de Rothschild.
Investments
NA Advisory firm.
Other contact
First name: Henriette
Last name: Le Bihan
Phone: +33 (0)4 26 72 95 00
d i r e c t o r y
Funds raising, Mergers & Acquisitions, LBO/MBO/MBI/OBO,
IPO.
Medical Devices, Drug development, Biotechnology, Pharmacy,
Imaging, IT for the healthcare sector, home medical services…
General Manager
First name: David
Last name: Laurent
Position: President
Phone: +33 (0)4 26 72 95 00
s c i e n c e s
Business
Focus Areas
INVESTOR contactS
l i f e
ACTIVITIES
Recent news
Consistent track record in the healthcare sector. Recent deals:
Audacia, Provepharm, Trod Medical, ABM, Hopital&Domicile,
Medtech…
2 0 1 1
181
Investor name: Edmond de Rothschild Investment Partners
Address: 47, rue du Faubourg Saint-Honoré
City: Paris
Zip code: 75008
ACTIVITIES
Business
Investment in venture capital and development capital.
Focus Areas
Pharmacy, Biotechnologies, medical devices, molecular
diagnostics.
Investment and company development.
Recent news
INVESTOR contactS
General Manager
First name: Pierre-Michel
Last name: Passy
Position: Managing Partner
Phone: +33 (0)1 40 17 23 49
Other contact
First name: Gilles
Last name: Nobecourt
Position: Partner
Phone: +33 (0)1 40 17 25 41
182
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Partial sales of Pangenetics to Abbott (Nov 2009) - Fundraising
of BioDiscovery € 3 to 155M (May 2009).
Investor name: Grenoble Angels
Address: 1, place André Malraux - BP 297
City: Grenoble
Zip code: 38016
ACTIVITIES
Business
Business Angel, Early stage investment.
Focus Areas
NICT/Internet/E-commerce, Software/Multimedia, Electronic/
Hardware, Telecommunications/Mobile,Health Sciences,
Energy/Cleantechs, Consumer Goods/Distribution, Services,
Industry, Biotechnology.
INVESTOR contactS
General Manager
Last name: Brunet
Position: CEO
Phone: +33 (0)4 76 28 25 32
Other contact
First name: Cheikhou
Last name: Dièye
Position: General delegate
Phone: +33 (0)4 76 28 25 32
Fax: +33 (0)4 76 28 27 54
A Business Angel is an individual who invests part
of its money in an innovative company with potential
and, in addition to money, makes available to the entrepreneur,
his skills, experience, personal networks and some of his time.
Investments
Acerde
Altimet
Sas Fcg Rugby
Koffeware
La Generale de Piscine (Ex Sas O-Viva)
Made In Design
Starzik
Visio Technic
Vitamib
Widip (Ex Infomut)
Synapcell
Sweetbeam
Fluoptics
Accessurg
Picual
Ecosoftec
Abk Company.
Recent news
Grenoble Angels was named «Best Business Angels network
2009».
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
183
Investor name: Inserm Transfert Initiative
Address: 7, rue Watt
City: Paris
Zip code: 75013
General Manager
First name: Matthieu
Last name: Coutet
Position: Investissement Director
Phone: +33 (0)1 55 03 01 23
Other contact
First name: Jean-François
Last name: Rax
Position: Analyst
Phone: +33 (0)1 55 03 01 25
Fax: +33 (0)1 55 03 01 60
l i f e
s c i e n c e s
d i r e c t o r y
Business
Support for company creation and seed capital investment.
Focus Areas
Human health.
Seed investment in start-ups whose technology come
from an academic technology transfer.
Investments
INVESTOR contact
184
ACTIVITIES
2 0 1 1
Hemarina Neurokin Neorphys Sensorion DNA Therapeutics
Pharmaxon Genoscreen TxCell TCLand Expression TCL
Pharma CellVir Metagenex Vaxon Biotech.
Investor name: Lyon Angels
Address: Place de la Bourse
City: Lyon
Zip code: 69002
ACTIVITIES
Business
Business Angels Association.
Focus Areas
All field of activity but the files with come before all others are
close to Lyon.
To select and to put entrepreneurs in touch with investors who
wish to involve themselves in the enterprise. Business Angels
can bring to entrepreneurs experience, skills and network.
INVESTOR contactS
First name: Eric
Last name: Lafond
Position: Chairman
Phone: +33 (0)6 07 05 82 97
Investments
There are Business Angels who invest and not Lyon Angels
Association.
Other contact
First name: Jean-Pierre
Last name: Coutenson
Position: Vice-President
Phone: +33 (0)6 07 33 47 65
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
185
Company name: Merck Serono Ventures
Address: 9, chemin des Mines
Zip code: CH - 1211
City: Geneva 20
Founded in: 2010
INVESTOR contact
General Manager
First name: Nilesh
Last name: Kumar
Position: Associate Director Merck Serono
Ventures
Phone: + 41 22 414 32 68
186
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
ACTIVITIES
About Merck Serono:
Merck Serono is the biopharmaceutical division of Merck
KGaA, Darmstadt, Germany, a global pharmaceutical and
chemical company. Headquartered
in Geneva, Switzerland, Merck Serono discovers, develops,
manufactures and markets prescription medicines of both
chemical and biological origin in specialist indications.
In the United States and Canada, EMD Serono operates
through separately incorporated affiliates. Merck Serono
has leading brands serving patients with cancer (Erbitux®,
cetuximab), multiple sclerosis (Rebif®, interferon beta-1a),
infertility (Gonal-f®, follitropin alfa), endocrine and metabolic
disorders (Saizen® and Serostim®, somatropin), (Kuvan®,
sapropterin dihydrochloride) as well as cardiometabolic
diseases (Glucophage®, metformin), (Concor®, bisoprolol),
(Euthyrox®, levothyroxine). Not all products are available
in all markets. With an annual R&D expenditure of
over € 1bn, Merck Serono is committed to growing its
business in specialist-focused therapeutic areas including
neurodegenerative diseases, oncology, fertility and
endocrinology, as well as new areas potentially arising
out of research and development in rheumatology.
For more information, please visit www.merckserono.com
or www.merck.de
Investor name: Mérieux Développement
Address: 17, rue Bourgelat
City: Lyon
Zip code: 69002
INVESTOR contactS
General Manager
Last name: Valencony
Email: françois.valencony@merieux-
developpement.com
Phone: +33 (0)4 78 87 73 72
Other contact
First name: Aurelie
Last name: Boulleray
Email:
ACTIVITIES
Business
A healthcare investment company.
Focus Areas
New Products
Services Theranostics Medical Devices
Imaging Home care
Patient monitoring Prevention
Therapy (Vaccines - Probiotics & Nutrition)
Public Health Priorities: Cancer Alzheimer & degenerative
diseases Aging New pandemics & nosocomial infections
Well- being.
Mérieux Développement intends to be an active minority
shareholder, taking an advisory role with the management
team and having a seat on the board of directors
of the companies it invests in. The main goal of Mérieux
Développement is to pass on the new shareholders its stake
in high performing companies (across business, industrial
operations and R&D aspects).
aurelie.boulleray@merieux-developpement.
com
Phone: +33 (0)4 78 87 37 00
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
187
Investor name: Nyse Euronext
Address: 39, rue Cambon
City: PARIS
Zip code: 75001
INVESTOR contactS
General Manager
Last name: Laskart
Position: Business Development
Phone: +33 (0)1 49 27 10 31
Other contact
First name: Isabelle
Last name: Dube-Cote
Phone: +33 (0)1 49 27 11 22
ACTIVITIES
Business
NYSE Euronext (NYX) is a leading global operator of financial
markets and provider of innovative trading technologies.
With approximately 8,000 listed issues (excluding European
Structured Products), Nyse Euronext’s equities markets –
the New York Stock Exchange, Nyse Euronext, Nyse Amex,
Nyse Alternext and Nyse Arca – represent one third
of the world’s equities trading, the most liquidity of any global
exchange group.In Europe, Nyse Euronext trade equities
through its two main markets - Euronext and Alternext,
our platform dedicated to SMEs from all sectors. There are
28 Biotech companies listed on our European markets, 19 on
Euronext and 9 on Alternext, making it the largest biotech
peer group in Continental Europe.
For further information: www.euronext.com
Focus Areas
Nyse Euronext’s Business Development team is there
to support non listed companies in their reflection process,
from early on communication of information to the admission
on our market. Once a company lists on our markets, it will
benefit from a large and diverse international investor base,
a strong visibility through analyst and media coverage as well
as support in investor related efforts through the organisation
and sponsorship of events. Finally, a unique benefit for biotech
firms is our Next Biotech index. This European index serves
as a benchmark for the sector and promotes the constituent
companies. Despite extreme adverse market conditions, the
index significantly outperformed the DJ Euro Stoxx 50 and
FTSE 100 since its launch in 2008, showing the strong potential
of the sector.
Recent news
In 2010 four biotech companies realized their IPO on our
European markets: AB Science, Integragen, Neovacs
and Novagali Pharma, raising between 7 and 32 millions euros.
In addition two Medtech companies – Carmat and Stentys also
listed on our markets raising 16 and 23 millions euros.In 2010,
approximately 50% of IPOs on the European market of Nyse
Euronext and NYSE Alternext were Life Sciences companies.
188
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Investor name: Octalfa
Address: 15, chemin du Saquin, Bât G
City: Ecully
Zip code: 69130
ACTIVITIES
Business
Created in 2006 by Gilles Alberici, Octalfa is a family-owned,
independent investment company. Octalfa operates
as a holding.
Focus Areas
Life Sciences.
INVESTOR contactS
General Manager
First name: Gilles
Last name: Alberici
Position: President
Phone: +33 (0)4 37 49 87 20
Other contact
First name: Jérémy
Last name: Bastid
Position: Consultant
Phone: +33 (0)4 37 49 87 20
Fax: +33 (0)4 78 33 36 29
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
We focus on early-stage operations, striving to show an active
presence and to provide reliable and enduring support to our
partners. Octalfa also intevenes as a co-investor in later-stage
companies. Our team has entrepreneurial experience, which
we wish to pass on for the benefit of business entrepreneurs.
In parallel and consistent with its values, Octalfa established
the Dominique Alberici-Octalfa Corporate Foundation
(www.fondation-dominique-alberici.org).
Investments
Alize Pharma I Alize Pharma Ii Ipsogen, Graftys, Glycode,
Docea Power, Orega-Biotech, Antagene.
Recent news
Octalfa also supports an Investment Fund, specializing
in health and environment technologies. This Fund, named
Octalfa 360 (Health and Green Technologies) is managed
by the company 360 am (www.360-am.com) and advised
by Xenia Gestion Privée.
189
Investor name: Oddo Asset Management
Address: 12, bd de la Madeleine
City: Paris
Zip code: 75009
Creation date: 1880
INVESTOR contact
General Manager
First name: Laurent
Last name: Dumas-Crouzillac
Phone: +33 (0)1 44 51 82 72
190
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
ACTIVITIES
Business
Capital investor in growing companies in France and abroad.
Focus Areas
All sectors that have a focus on Medical devices and Cleantech.
Investments
35 participations in Life Sciences: MDW (Belgium), Airinspace
(Holland), Visiomed (France).
Investor name: OTC Asset Management
Address: 79, rue de la Boétie
City: Paris
Zip code: 75008
INVESTOR contactS
General Manager
First name: Emmanuelle
Last name: Deponge
Position: Manager in investment
Phone: +33 (0)1 53 96 52 50
ACTIVITIES
Focus Areas
All fields of activities: life sciences, ICT, environment.
Founded in 2001, OTC Asset Management is a company
of independent management for Venture Capital approved
by the AMF, which manages, through its investment funds,
315 million euros. His expertise is in financing companies
that represent the French economic activity, in all sectors.
It provides the funds necessary for their development
and their sustainability. OTC Asset Management has funded
over 80 companies that have generated a total turnover
of 1.3 billion euros and employ 7000 employees. The company
is ranked within the first French venture capital companies
(regarding the number of SMEs funded and regarding amounts
invested in 2008 according to the study published by Private
Equity Magazine in January 2009).
Other contact
First name: Michel
Last name: Gomart
Phone: +33 (0)1 53 96 52 57
Fax: +33 (0)1 53 96 52 51
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
191
Investor name: Rhône-Alpes Creation
Address: 10, rue du Château d’Eau
City: Champagne au Mont d’Or
Zip code: 69410
INVESTOR contactS
General Manager
First name: Guy
Last name: Rigaud
Position: President
Phone: +33 (0)4 72 52 39 39
Other contact
First name: Aurélie
Last name: Wirotius
Phone: +33 (0)4 72 52 39 39
192
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
ACTIVITIES
Business
Rhône-Alpes Création is a private Venture Capital Company
(RSC) wich invests in innovative start-ups based
in the Rhône-Alpes area. It is specialised in seed capital
and venture capital.
Focus Areas
Rhône-Alpes Creation mobilizes equity for young (less than
5 years) and high potentiel companies, wich are based
in the Rhône-Alpes area. The investment focus is companies
in the information technology, biotechnologies,
and environment sectors.
Rhône-Alpes Création is a French Private Equity company
with a portfolio of 52 companies and € 17,5 M under
management. Its intervention is systematically co-investment
with other seed funds, proximity venture capitalists,
or business-angels. It supports its affiliates to define strategic
guide lines and to rise new founds by mobilizing its national
and international network of investors.
Investments
52 companies.
Investor name: Business Angel (membre de Savoie Angels)
Address: 3, rue Louis Boch
City: Annecy
Zip code: 74000
INVESTOR contact
General Manager
First name: Yves
Last name: Laruaz
Position: Business Angel
Phone: +33 (0)4 50 51 51 41
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
ACTIVITIES
Focus Areas
Biotech/ICT / Leisure/tourism/hostels/fashion/.
Business Angel Consultant.
Investments
TSL: equipment, leisure; Holosfind: ICT; Sweetbeam:
services in luxury hostels; Wan Design: fashion; Allobroges
Participations; Injection 74 : plasturgy ; Marinettes Picual : fast
food for companies; Savoie Angels Invest SCR : venture capital
(council member).
193
Investor name: Seventure Partners
Address: 5-7, rue de Monttessuy
City: Paris
Zip code: 75007
ACTIVITIES
Business
An active partner of companies presenting strong growth
potential, Seventure Partners has been investing
in innovative sectors since 1997, focusing in particular
on French and European companies operating in the ITC
and life sciences industries. With some €500 million in assets
under management, Seventure Partners stands out as one
of Europe’s leading VC players.
Focus Areas
INVESTOR contact
General Manager
First name: Isabelle
Last name: de Cremoux
Position: General Partner /
Dir.of Lifesciences department
Phone: +33 (0)1 58 19 22 77
In life sciences, our four main investment sectors are
biotechnology and pharmaceutical R&D, medical equipment,
industrial chemistry and biotechnology and nutrition.
However,we also invest in diagnostics, galenic improvements,
environmental services, bio-energy, skin care, well-being
and services.
Seventure is a subsidiary of Natixis Private Equity, the asset
management of Natixis, with over €4,2bn in private equity
investments. A typical investment ranges from €500K to €10M
per round, up to €20M per company, from early to later stage.
Investments
In Lifesciences: Nutraceutics D&S, Polaris, Implanet,
Biophytis, Biancamed, Agro Biotech Accelerator, Biomatlante,
Tekka, Vivostat, Santaris Pharma, Fluxome Sciences, Noxxon
Pharma… En NTIC: Anevia, Conject, Kayentis, Talensoft, 24H00,
Mobilire, Webinterpret, Presensia, Retailo…
Recent news
Nutraceutics D&S, Polaris, Implanet, Biophytis, Biancamed,
Agro Biotech Accelerator, Biomatlante.
194
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Investor name: SHAM
Address: 18, rue Edouard Rochet
City: Lyon
Zip code: 69008
Focus Areas
Investment in public and private innovative firms evolving
in the healthcare industry (biotech, medtech, med IT…)
and satellite ones (security, food…).
General Manager
First name: Olivier
Last name: Szymkowiak
Position: Investment Manager
Phone: +33 (0)4 72 75 80 61
s c i e n c e s
d i r e c t o r y
Business
SHAM is a french mutual insurance company based in Lyon
that specializes in medical malpractice civil liability.
SHAM is one of the french leaders in its industry.
INVESTOR contact
l i f e
ACTIVITIES
2 0 1 1
SHAM manages 1.4 billion euros, invested on diversified asset
classes. 7% of this portfolio is allocated to public and private
equity investments in innovative firms.
Investments
Venture capital portfolio: Voluntis / Nokad / Laboratoires
Narval (sold on october 2009) / Ekkyo / Alize Pharma / Alize
Pharma II / Pharmaxon / Adocia / Glycode / Eyetechcare /
Orega Biotech / Biomup.
195
Investor name: Siparex - Sigefi Venture Gestion
Address: 139, rue Vendôme
City: Lyon
Zip code: 69477
INVESTOR contactS
General Manager
First name: Sébastien
Last name: Touvron
Position: Director
Phone: +33 (0)4 72 83 23 23
Other contact
First name: Gwenaël
Last name: Hamon
Phone: +33 (0)4 72 83 23 23
Fax: +33 (0)4 72 83 40 69
ACTIVITIES
Business
Siparex, founded 33 years ago, is France’s independent
middle-market private equity specialist. The Group has more
than €1 billion in assets under management, divided between
“growth capital/LBO financing” for the middle market
and “regional growth capital” and venture capital
for innovative and technology companies. Siparex also consults
on fund management in emerging markets. Siparex stresses
geographic proximity to its investee companies. It covers
all of France from its offices in Paris, Lyon, Besançon, Lille,
Nantes, and Strasbourg, and it also has a presence in Madrid
and Milan. The Group employs some 90 staff members,
including 55 investment professionals.
Focus Areas
– Life Sciences (40%): drug discovery & delivery, medical
devices (implantable or not) diagnostics, personal care
(preventive or personalized medicine)
– ICT (40%): microelectronics, software, telecoms
– Cleantech (20%): green chemistry, renewable energies,
environment.
In venture capital:
– Direct intervention in equity (equity / convertible bonds) from
€ 300 K to € 2/3 M in several financing rounds.
– Minority and temporary stakes (liquidity search
from 5 to 7 years).
– Intervention stage: ideally, for the first round of financing.
Investments
Exonhit, Genoway, Bioalliance, OPi, Novagali…
196
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Investor name: Sofimac Partners
Address: 24, avenue de l’Agriculture
City: Clermont Ferrand
Zip code: 63100
INVESTOR contactS
General Manager
First name: Pascal
Last name: Voulton
Position: Chairman and Chief Executive Officer
Phone: +33 (0)4 73 74 57 57
Other contact
Last name: Vuagnat
Phone: +33 (0)4 37 26 20 92
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
ACTIVITIES
Business
Sofimac Partners is an independant asset management
company registered under the A.M.F (French Stock Market
Authority). Sofimac Partners Group benefits from a 30 years
expertise in equity investment non quoted SMEs.
Focus Areas
Sofimac Partners manages FCPR, FCPi, FIP, SCR
management mandates, covering the whole range of regional
investment segments: seed capital, venture capital, growth
capital, leverage buy out and recovery.
In the Healthcare field the company has a highly qualified
dedicated team focused on young innovative Biotech
or Medtech companies coaching. The 4 investors team
in charge of the Fund Technologies and Sante is covering
the South-East of France and North of Italy and invests
in the following fields: Medical devices, diagnostic, medical
imaging, nuclear medicine, surgery devices.The FCPR
Technologies and Sante takes minority stakes with investments
ranging from 500 000 to 2 000 000. The company manages
today more than 180 million euros brought by regional,
national and international subscribers.
Recent news
Participation in the companies Biom’up, Dexterite Surgical
and first investment in Glomeria Therapeutics (Italy).
197
Investor name: Sofinnova Partners
Address: 17, rue de Surene
City: Paris
Zip code: 75008
INVESTOR contact
General Manager
First name: Denis
Last name: Lucquin
Position: Managing Partner
Phone: +33 (0)1 53 05 41 00
198
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
ACTIVITIES
Business
Venture Capital.
Focus Areas
Technology, Life Sciences and Cleantech.
Sofinnova Partners is an independent venture capital firm
based in Paris, France. For over 35 years, the firm has backed
nearly 500 companies at different stages of development –
pure creations, spin-offs, as well as turnaround situations –
and worked alongside Europe’s key entrepreneurs in the
technology, life sciences and cleantech sectors. With more
than €1 billion of funds under management, Sofinnova
Partners’ experienced team and hands-on approach
in nurturing and supporting portfolio companies through
to exit have created market leaders and multiplied revenues,
from landmark historical investments including Genentech
and Biogen to more recent successes such as Actelion,
Vistaprint and CoreValve. With a global mindset, the firm
has offices in Shanghai, China and a sister organization
in San Francisco, California.
Please visit www.sofinnova.fr for more information
on Sofinnova’s team and portfolio.
Investor name: Ventech
Address: 5/7, rue de Monttessuy
City: Paris Cedex 07
Zip code: 75340
Creation date: 2010
INVESTOR contactS
General Manager
First name: Laurent
Last name: Assaraf
Position: Director
Phone: + 33 1 58 19 21 50
Other contact
First name: Mounia
Last name: Chaoui
Position: General Partner
Phone: + 33 1 58 19 21 50
ACTIVITIES
Business
Since 1998, Ventech has been partnering with the best
entrepreneurs in Information Technology and Life Sciences
sectors. With more than €360m under management, Ventech
selects and finances the most ambitious European projects
and backs them to gain a global leadership position.
Thanks to its initiative in China, Ventech is able to back
investees in their development in Asia, and to invest locally
through a dedicated fund.
OUR VISION
Since its creation, Ventech has pursued an unchanged
strategy, investing in start-ups in the innovation-driven sectors
of Information Technologies and Life Sciences.
Focus Areas
LIFE SCIENCES
In the Life Sciences field, Ventech invests primarily in European
companies striving to become global leaders
in their line of business. Ventech favours a broad
and international approach covering different fields
of human health and various maturity levels in order to build
up a balanced portfolio of investments.
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
BIOTHERAPEUTICS
Currently, over half of the newly approved drugs have
been developed by biotechnology firms with development
costs more than half those of the pharmaceutical industry.
Biotechnologies therefore constitute a fertile ground of new
attractive treatments to feed the big pharma pipelines.
This creates an environment propitious for high value strategic
alliances and M&A transactions that in some instances will be
timed relatively early on.
DIAGNOSTICS
Diagnostics have also undergone a sweeping transformation.
The boom of biomarkers and personalized medicine has
contributed to the emergence of many new companies. The
sector is still young. Currently, the most significant valuations
reward companies generating revenues of several million euros,
achievable with a significant capital base.
MEDICAL EQUIPMENT/NUTRITION
Medical equipment for therapeutic use is one of the very
few human health sectors that could reach the breakeven
before the VCs’ exit. The more and more regulated nutrition
sector requires clinical trials and therefore more capital than
previously.
- Focus on identifying disruptive innovations and creating
incremental value Alongside the best entrepreneurs
and executives, Ventech backs ambitious companies driven
to grab or create a sizeable market by ushering in groundbreaking innovation (technological, business model, etc.)
and gaining global leadership. Ventech’s sector expertise
allows it to take an active role in furthering these projects
and assist companies bring new products to the markets.
The determination to take or share the lead in the investment
process stems from Ventech’s philosophy as an investor,
and reflects the very strong commitment of every team
member, who put their operating and financial expertise
at the service of the entrepreneurs. Ventech has made it a rule
to obtain board representation and therefore contributes added
value to the company’s development and strategy.
- Provide sustained support Ventech invests in the initial
phases of a project, typically in the first round of institutional
financing (Series A) as part of a streamlined, totally committed
shareholder structure. Ventech then accompanies and
assists the managers during each successive financing round
until the company’s initial public offering or M&A event. In
practice, Ventech invests on average between €5 million and
€10 million in any one company, typically between €2 million
and €5 million in the first financing round.
- Build up global leaders Ventech Capital III invests principally
in Continental Europe but will consider making significant
investment opportunities in other regions alongside first-rate
local investors. The managers of the companies can turn to
Ventech for assistance to build up local franchises and become
world leaders.
- Provide a global presence Ventech has been present in
Mainland China since 2007 both to invest locally through a
dedicated fund, Natixis Ventech China, and to assist European
companies in which Ventech has invested to develop their
business in Asia. Because of its presence in China and the
experience accumulated over time, Ventech is able to support
European and American investees in their strategic development
and facilitate their access to Asian markets and partners.
199
Investor name: Viveris Management
Address: 6, allée Turcat Mery
City: Marseille
Zip code: 13008
ACTIVITIES
Business
With 28 investment professionals dedicated to one
of the six private equity divisions, Viveris Management
is an asset management company specialized in Private Equity
for unlisted SMEs. The company supports more than 120 SMEs
and manages nearly € 400 million spread over investment
vehicles like FCPI-FIP-FCPR.
Focus Areas
INVESTOR contact
General Manager
First name: Marie-Stéphane
Last name: de Cerou
Position: Investissement Manager
Phone: +33 (0)4 91 29 41 50
200
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Targeted business sectors are: biotechnologies,
medical-health, ICT, energy, materials, environment
and electronics.
We are interested in SMEs at a early stage leading projects
innovation, to be followed up all along their development.
Investments: Portfolio of Life Sciences companies: Adocia,
Carmat, Gloster Europe, Innate Pharma, Ipsogen, Metabolic
Explorer, Trophos.
Companies
Start-up
projects
Investors
Index
Index
202
Index by kind of activities 203
Index by application fields
206
Index by R&D projects accredited
by Lyonbiopole and funded
209
Index by kind of activities
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
203
204
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
205
206
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
207
208
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
Index by R&D Projects
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
209
Index by R&D Projects
210
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
notes
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
211
notes
212
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
212
notes
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
213
notes
214
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
214
Lyonbiopole’s team
Immeuble Domilyon - 321, avenue Jean Jaurès, 69007 Lyon
T : +33 (0)4 72 76 53 30 - F : +33 (0)4 72 70 48 29
E-mail : [email protected]
Website: www.lyonbiopole.com
Philippe Archinard, President
[email protected]
Yves Laurent, General Manager
[email protected]
SCIENTIFIC DIRECTION
Bernard Mandrand, Scientific Director
[email protected]
Claudia Chagneau, Project Manager
[email protected]
Estelle Vincent, Project Management Assistant
[email protected]
Pauline Cottin, Sepsis Program Coodinator
[email protected]
For further information about R&D projects: [email protected]
ECONOMICS, INTERNATIONAL AFFAIRS AND COMMUNICATION DIRECTION
Isabelle Scarabin, Economic & International Affairs Director
[email protected]
Kevin Romani, International Project Manager
[email protected]
Emilie Roméo, Project Manager
[email protected]
Périne Michon, Communication Assistant
[email protected]
For further information: [email protected]
ADMINISTRATIVE AND ACCOUNTING SERVICE
Audrey Guilbert, Administrative and Accounting
[email protected]
Bérangère Maire, Administratve and Accounting Assistant in work-based learning
[email protected]
Corinne Peyrolles, Office Assistant
[email protected]
INFECTIOUS DISEASES CENTRE
François Martin, Director
[email protected]
Ludovic Dolt, Technician of industrial maintenance
[email protected]
Marie-Claire Gallet, Support logistics and technical laboratory
Céline Laborde, Quality Health Safety and Environment assistant in work-based learning
[email protected]
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
l i f e
s c i e n c e s
d i r e c t o r y
2 0 1 1
216
m e ta m o r p h o z 0 6 8 1 6 2 3 5 2 8
LYONBIOPOLE
Bâtiment Domilyon
321 avenue Jean Jaurès, 69007 Lyon
T : +33 (0)4 72 76 53 39 – F : +33 (0)4 72 70 48 29
[email protected] - www.lyonbiopole.com

Companies Investors Start

Transcription

Similar documents

1 Selling Innovative products

Ciencia, tecnología y valores: Axiología de la tecnociencia

ZIMA 147-CS-Brochure_r1.indd

How To Complete This Form Printed Apparel for Work

kinder 2015 16 public - Fulton County Schools

ordering instructions mail order

Learning labs_4 - Verto Solutions

Segmentation,Targeting and Positioning

#eiforum

Time: 6:00 to 8:00 PM Where: Shakey`s Pizza Parlor 12540 Valley